var title_f35_34_36384="FAST pericardial subxiphoid probe position";
var content_f35_34_36384=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F50136&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F50136&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    FAST: Pericardial subxiphoid probe position",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 334px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This photograph shows the proper probe position for obtaining a subxiphoid view of the pericardium.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Manoj Pariyadath, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_34_36384=[""].join("\n");
var outline_f35_34_36384=null;
var title_f35_34_36385="Vitiligo segmental";
var content_f35_34_36385=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F72369&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F72369&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Segmental vitiligo",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Segmental vitiligo: patches of hypopigmentation on the anterior trunk.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Stedman's Medical Dictionary. Copyright &copy;2008 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_34_36385=[""].join("\n");
var outline_f35_34_36385=null;
var title_f35_34_36386="Construction of a loop colostomy - exteriorization";
var content_f35_34_36386=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F72478&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F72478&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Construction of a loop colostomy - exteriorization",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 434px; height: 538px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This figure depicts exteriorizing a loop of colon by gently pulling the limb through the abdominal wall trephine. A penrose drain around the bowel facilitates this maneuver.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_34_36386=[""].join("\n");
var outline_f35_34_36386=null;
var title_f35_34_36387="Eosinophils in vessel wall";
var content_f35_34_36387=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F55115&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F55115&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Eosinophils within blood vessel wall in a patient with the Churg-Strauss syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 297px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEpAYwDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwBtn4gmh8RRw2k37qMhfX8DXo3iTV2j8M3FxbgJKV2kjtnvXgfxA0SXw1r1rrmjyvHa3Mm2SMMTtb/A11+ifE21tIDba3D59s42gjBP41608P7Vwq0ldLofSSakuWtH3ovUI5WmUK7knqTnrViBXeZW3EAHqTU/laVeMLvSZ5BayDcFIyB7VqabYW9zGXhuNxHYDBH1rjqKcb82p9dHFU1TTjpoZ89uDkwzAsT93JFamiadNGVkucgE8ClltUhbafmHsO9bFu0oNu2CwQfMOxqVOUvd6HDicQ1T90rarZqlyLpgzhUJGDkZHY1yt9r+owKs0BCRJw0eOa9DjktrtnV1w23/AFeAM1x2paexEgikVckg57VtTko7o58HVjN8tVG34TuZ9Vs5jc3BQkZUeop8EBtbiVJGZjnAJrltNvorXZa/aVWYHpnrW9cXqpEGWTLHhgalKW8/+AXVw/LN+y2ZsXtogRWRypccgH8jXK2V1PY+JYop8sC4wc9RV+LUT58bShiMfL6UutKGmhneApJuGx+laU2muXuc/LOiuWXU6YQvdR3UUX3HGR6g1T0rEPmQXBxtPXNP0bUFjUrcExytwD1z6VzGvXN3JqMjR5j5+buay5NddEYYalKrKVJbG1qNqLGIzwAnDAgA9aGZZbaMoxDD3qhpuq3EFs6SxI+7HLdR74qHxDLeWMmlPpFst0l5MFlUnBjB7iqirvlNq0vq6vV9Lm1qEgt5YlLb1ZAdue9ZjOxZtyFD25610B0dnYG4cqoWuU17xBouivGt/eqjFiFXrmnSk6jtFXMqdSlG7uXri6kXS3VUCLHlm5+9iuAttZ1aTVTJlhAx4Qc8Z9K6weJ9GvoGjjZTHIOCSBn3qz4e0+3ubxJLaDcwPGWyCPXjvXVH90m5RNnFQg5SR5J4l0zV7jxRc+TFLLK78KgJyK9O+Hfg46Mq3uskJdyDAt1Odo9SfWvQhZ2el+ddSICVXcgK8g+1cnqGsqnmz7y0h6KR0qHiqlePJHRHnUYxq35diz4mvIYV8qBNpIrzPQbDVdP1SRpGHks+W+bhhk119u0t0rXFwPkB4J71Wu9a022ITKl+/cCtaV4rlgrnRyqmlzPYnvNbWwjQyjzW6BS2BWOviRHmI8yPJ/hB6e1R63btqUcM1owdT2Fcxq+gywOZfLdRnJ2itKdKk/i3JnXmtnoej28p1GxZA5DY2tg8jPeuPufhzealqKQQXHlFzjzS56Vr/DoSnz5LgMEKgLnviuxt7h7eXO7jJx7VnOcqMmqbF7OVaGq1Oa03w3b+DSIxJ5931yMkA+/rV2S0n1ZZJbt2LN8o+lX9RtBd3SzMxAKhiT+tSzkmECH5UUYArlnUm9Wzuw9KlCCSXvdzi4NHbTNajaEuFPJHNdZcSJ5PmgkMBnIqbT51ju0adQy/3mGcVpXNhb3lvP8AZmUMqkjHT6UVKjqRXMrissPU8mJ4NR5IlunlYLkkiqniaRheSeT8gGSDnqK1dKmWy8PxsFy2MZI4Fcxc3U1/cT+aAqZ+TNQ78zkZYeLqYh1EtNiDQhNb6l54OBnIz1Ndpbwx2k3n4UvJhtx/kK5OOF7a2LHBYNg+1bn9pxHT7bgFlHJHrUv30m1sbY+Mqkvc66FjX9XkhiR1GF6HnpXm2ufEaG2mZIBulB7Gr3je6u7zSXRCsJOeE649a8ak0uRJ3aRWmm3fKAOtejhKELXkebOm6aUUd7beKrXxJK1lqscgMhwm0+tc3Noh0zXow8pMKvnYScsM8Vq+FtNh0fzdSvbZpbwHKxZ4iGOB7mua8VeJb2/vTKbdLeQZAKg7gK3jye09z5nTOFSGHvUW+x6R4Zv59U1KeGVPMAB+i16Vo1jFDGgMagjuK8j+D11cGUq8ZYNyzsK9ts8FuOnvXJjPdlZHDKtKcLM2IVAUADipxxTIcbRUpA/CvGe541SWohzQCe9BFHf3qTIXPaopY1Y78ZYDrT2YJ9aaZOtNGkObocV4vtFMLS4+ZT+dYGnKptvm3EgkZrovFdybmdLCzTzZXPQVLYeG737MvnIiP3AIFd1CajD3j6FV1ToxU3ZnmfiJ7a40/wCyagN0YfI9R9K808d6C2nRpdW0kclrIfl2Nzz7V7PHbI8jPe2sEsW7kyjp9KzPGPhmHUGtJFgRlQg7McY/Cu7D1lTtG/c6cZGVfm0S2IvhppFza/DxZ9QQKjs0qZPJU9BW/wCE7fal3cofk4AX3qw8vmWNpasCkKKB5Y7YpLW1TTleeznaeB1JlgAyyn2rgjeUXFvW9zdVJUaVns9PQ0JMeXu79c0b2+Xa3HsawG8R2FxdJZozpO2dqMpXP51ZkuZOoRxz/dpWlB6qxrGCqr3Xc3YHCsxYYkYcHPSq97cWmmTRR3mHNzyueOazoLh5GYKuXYdDR8WLD7T4Hi1aH5LnT3U/UZANVSSlNRfX+kcWNm8LaT7nlvxO0+5sPES6hbEiGQArtPAI7V3fhm+TXNDglibzJVXa59Gqnr9g2ueGYrmIhi8YPryRXJfDG4l0rXLmwmcbZBwueprtk/bUb9UdEE6FRcr92R69bW5jtmUtl+oJ7GpPEVzu0OCSTIa3Bdj7etUPtbxupIzjqDW34i0wap4ZuXtipia1KsffFefQfLJX2JzB8qUnuZOkyweJ/Dvn6fMj3VqSGweT7Va09vtUQkmhV5oxg54zj1rwLwFq114c8XrBK8sUUzbGAPBBPFfTOk2fkYliG+KRQSfWuzFQjT0eqPPo4iag3sck6xzySTI5ikVs7MZ/CsPxB4jS18R6NYKS94g8x9vAVewPvXp13o8TIz26jJ5ZRXKyeFdEm1u31i7R0v4vlaMtgP74rGlOCbdvka4nEfWqSj2aO2g1CLUrBTGGEzDaQR0OK8P+Kfg2e5jivLeQy3S7twx94dePevQbTxVHpl7IPscyoCV2HHNdYbew8RaVBfW6fIynC45UjqDUQnLDSvbQylSWFVpp8kup8bJbXysUMcpK9R0xX0B8BbO4isnmvpyMAiNCcnFW9Y0WzcXCtAVnXODjrWL8O0ubXU7qaSQCBPlWPPGa7ZT9tSkrm2IhGMOWldyffsdz4lupri+aOM5iB+6e5rBm3S3B89QsaHLd8jsKuzGeVJpJFIlJ3Af3hVaeJ54S6MPmAzj6VjT0VjWEVTjGK6HNeItTuJ3+z2oIj6cd6xJPDt5clWZSFPJaut0vTz50k0uCAcCrTyO7EK21BXRLEKkrI0w+DeIbkyloWnS2doY87gpyM9q6DT7i2nxBfRKQwxu7VnQXRGY27/xU1CkF0FdgFPOSax9oq2xOJwkqXuzWnRmxeWqWU2LdR5fAGOgrI1zW4tLjRrtcSuDsUfxe9YvjDXr+G7t9OsIwQwDEgZLn+gqXUdC/tp7V7xpIlRNrBep/OrVJWTqbHNDETScIrVdSXw74nfXEvIDgNFj5cdq7AJDHosc8zZdhyPQ+lYPhfwhFo0bNEXkluHzvfsvpW1r80EaLp1opm2jMjjoKzqyjKfubBCfLFQb1vcrR+XLBvjHTirMJFtZyTIcM3ArnLzVLazg2rcKzk4CrzWnpV39vsoGLoAPlDHrTdGy5kaPEOXuPU3LBHvNOjtVH74tvJ6YrJvbfyZ3ixl1IziutsLc2Nk0oJ80j5mx1rGuZM3ZOFYt94muW/O3YjCVpKo+VaGebqFbcQtERIWyZAev1FVrRQsjJIMx4OBVi5gAuTxkdjUMhJyANrYNWle7PRTilZPcLyxEkPnHDSrx07VXh0eLyzPHDF5rfxEcCrFncG3065V8PJjKHPSvNrzx1qOjeIvIu8pYYxgL+ZFXSjKteMH0InP2F21omYnjTxHrFpr8mnac5jTAXZGuSx/Ku+8PWEFxpMJ1e1gkuSNzFoxkVW02a01BTq9vCGuSOJGXlV9Aa3dMaKSBirh3J5rabapeztqjRQtOVWcrqWxraVFaQqEs4Uj7YCgZrqtPhIUZzkVz+iQHzE+XGOTXY2keB0rjryseLj6ihdRLUS7VxT26Udh61FNcRxqd7AVw6tnhayYryBTzxVKfUYo5AhYbj2rI1TVVBKpIAfY1yt69wzF0dgfXvXVToJ6yPTw+XOors6DxV4007QIh57+ZMRkItcIvxUlvpPJt7dl3HBbPIrnPGGiXN5L9ogYytjDAnmue0bSbmCfeUYvkcV6mGw1Dl97VnRUwrw+yPpHwlp6RWa37/AD3E67tx5IFdCmSKw/BhmPhq0F0rLIq7cMMHFbidK8bEN87XY8apUlOXNPc8Zv7iS1hkd3CwjLHcM9O1WtL1A6ppCS2MirKvyseorOuom8TeH5IrdxHK4xz61zngPVbrQNcm8O69AEVuUkUYz7+4r0+VKF1uv6Z9TUrxk+R9V951mnalNqGqjTrlFjvohwe0grRvNNmt2Mil0b+9gjH4jrVDxd4abVYT/ZzlbxE3wTxnDZ9PpWN8LPEGp3k0+g65LcedGW+eTJP05qJxi4ucH8jCliJ0ZqnLVbnQXF15JSW5EdxOv+rZlBK/jRbSXd2u912Bj2461PeWqLqBWQFlThT61rW7xiMLgr74rklJv3Fq+rPX5qcYqpFbkFjZrb/O2DKwxkmneJIZL/wZq2n8tI6blUDrjnin3ifMr5JXsRUUN0YJ0ywK5BINXG0GpdtTirUXioNM858D61sSLTJlYg/Lg9j2rr4PDemy36uiJDe/ejc9A3v7Vxnhuya8+I9+sbKYIJHY7eijPFdtqJntdTMcmQ+0MhHXFdeKkozfL21Fgl9Zo8r3H6zG8dwWkiEU4AEsY+6D/eX1Bq14V8QQ2sr2Vwwkt5CVZM9Aa53xrc3l1p1jc2yXAnCPGxPeuB+H8GsWWuTyahbzPE+GO7uc5zUxoKUXUk/kac6qQWGnG+rTfYu/ErwlONUhv9EikmsIzzsGWXJzXqfg691UeH7ZZmYIyDkj5gK1bFbLW7Ro7RjDdIPkTpn2rzTxX8Q28Pa9/ZM9vIzRECZlO3H0HervPEJU+qPPvRoNxl16M9Ee3u4maWG4l2MchgxGPamHUUmIW/QOwP3wOQKreG9dXVbNbrTZ1mgYchuMezCtG5s4dSt2ktFCXCg7ox0P0rnmpRdnudkHTkry27opeJrNru4ieLyWt/LAjZeuPervhu8ksLaSFEKp/AgP3ie9UtIR33RMxV04ZD0Ip11L5Dhoid8f3VNQoJ+93NqseemsM9bEWuaZ4k1WQwxxokMo+/wpApNA8D3OlRuglaV8Z+Y/xVt+F9dnZLlb2RmAOUJ6/hWtbeILbEnnbgUPJHNJ1atrR2R5VSVfDTlGK6ep89fFjWfEXhnX7G3t7uSOGJd4YdJGzyD6j2rp/CHjKPVrOETReQ5O0qeQT7V1fxJ8O6b490tGsbuNp4myrJglT7jriuKs/Dp8NiMmJrm5j5yAcfXFd9KpGcLT0ZpgYqrUc29JL8TsQyw7lI461SKY3YOVbpUkAub6wLXMLQuc4z3FLpAmhkZJ4g8YPAasatNTWm6O/D4h4SbjLVEESEuFAzj0pmsaM1zNBOrENH1A710QaGGJzHGoJ9qzJ7sJvZ+FAyc1NCE4O73NMVi1iVypaCCGJNs0kSvOi7Q+ORn3q5AHaPOMnFcwvie1ZRbJnfuzk9639IMklsZ5C0Snp71VVTi1cijCCg31J7q8uAqxBtq4yRXL+J9VZMx2Y2oEy+DyT7muxvYPt2nk2rbJo1wCx4JrgdU8PajKOSrgnnacnNXScU/fdjkqR9tpGOxx0Oo+desj5BB4Hoa9P+HFo11dpFJgxj5x6cVy2m+B7wutxPtjhZsEtyfpivWvCGlR6YSqOCAAFPf3zW2MrQ5Gos5taMHJbmzrDiKzZF4OK5m3VRKGZidgzj1rf8QzCK2kMowgHJ/wrz3xF4s07w1Zxy6izNJL9xEGWbHX6CvNw0HJaCwj5KDmytq/jzTtJ1t7ORfmB+Ysa4/xh4nuJbwyWNw0UB+6V7iq97p2k/EC9fUNKlNvfOMGCUgFiB1FaXhPwrcvp1za63AFCMPIcfMc9wR6dK9WmqdJJyVminzzad7ph4S1y6vUK3socY+VwMfnXO+MtMudR1C3aOF5sNtOF7Zr1Lwt4ShtrspOq/ZwCx2rtGKv+MLzSdC09riGEEqRjAyB9awqVI+2TpnbSxCdN4eor+fY5y4WPQdKsreONSzRgyIBgY7iszTYr+TxHG2nkx2KqHZeoPtVDTvGkGpaji/tHeNj8jMwUL/9avStKNnJDGbYIkbrkMpFayUqXvNbmNafN+65rmhYytayo0xx5gyM10UeowRw7jIK5YSp5hFyzNGp+U47VBIsktw5t8i3xxk9K4Z01Pc5qmHVT4jppvEcYDCNGZscHtWJNdXl75sgB2KOSOg/GkhtIIIhPeGSReyIv3j9axfFHiBreNIziJTwkKdB7mlCnFO0EVh6EFL92vmVdVvnswBbwtPdMeOeBXIavf8AiiONpWEaAc7dwP8A+uuv0e1guYhPeTGMsM/N1qq72STSo8M0kZPVsVupOD5Urs9mlGnNNK7PJkl8TrraSGS5lZmBPzZUA+3SvYPDM8qoz31oDIi7sZ4+tLazWNurSQoPcOgJrRh1jSp/kzJbs3UIOM1U67qx5VHb7zJ4ZYe7V2mdF4d8SoR5dyxMfY9cCuthmgkTdHKhU9wwry7ULJNMsZNQjkDW2M7gc1xKfEOOIui28vDdzjNc6w0a7bh03PFxeCpyfPB2uaGhSzQQXxto2YEEqAcc1lxXh1XVNNS4cfbFl2hmHzDHOPoRXbySQaaGCw9c4CjrXj+ivcw/EmA3asFecsoPQ9cV3b05ysabTpw3PobSt0U8aSY3kfLg8Y9Ke+gwT3T3lnGsVyDy23BYVFbxtcSIE6rlsgVJqd7d2yqnmFCADleCR9a8pJt6FVqcqk7RepHq9hJmF9oDAfMfWo4I3PysMhunHIrd0p01TTVMrB2U4JPU1amgs9Phee5dEjQZOTWXtHfRXY/rjpL2NRaoyYbGX7LKkig5Hy4Fc82nXEkrQlDuwQCexrsdG17S9YleCzk/eqM7WGCR6j1qDxLDLHZs8UhjHfHenHmUuSSsyqGMqRq+znGzZxuhaNYeHtLmgRTNqN1L5txN7+g9hW3Z6Sl1K2qaowCIuEBPGB0rnZpWEZGdz10PjK9NnpmnWQ+Vmi3uM+3/AOurcnN2v3ud0qMqLjTpvWX4HRwWljfaYjeVFIgQ8YyR+Neey6ZJp9/tCyFJGyGIOAPQGrXgXWp1eSNs+UDwP6V1+q3EVzbhpwQifNgU481OTgcbo1cFXbeqZx8NvNpdyzxuQgYMpA5Fct8UfAdx4yuE1vQpI/7QWMJPA5x5mO4PrXdWt5bXE8sl3j5+ETtioAj2M3mW0h8pjnA7V1wlKDut0aYiisTvpLozl/hV4Y1Dw5YXNvqAzdykOY/4VHpn1rrru1v7ZvOT91jkBeawdU8Yy2M/lTsXGcq4GMCr0XiqDUbZDEzu3RmzzmqlCpL3n1MKc3GagkTPe/ZtUhupQAWG1mHGao+KY/tEKzWsjIWPysf7vXaanuIvt1qyJ80y/NtJ5PrVAJcXH2azURth+PM9x61lH93P1PZpwjO019n8inY66trCYr4GNRjbKp61V0/VYNKa7JuTcxSnCybt2M/yq1r3h97W2mE7RPCTgRs36giqOhWWnWcO6KA5/iRvmU10RceW9jSrBVbunazOQj0XVtK1E3+lXkgLzby6y/KUPbFeqaJq738UwvLYSFUGXYcisnW9Fhk0Oa70USQXSDJiJypHqK4fTvFer2bmJ5IyqH5lK8tXRriY3R4tSNOh7qjZ9z1x5WGnsJEK7Sdpx1rmZPENtFKwldgV4ORV3w/4htdct44mdRMB8ynj8qr6n4ftmussoYnkr7VgkqbtNEpynK0Hch/4Suzl+SCOWRvQDg1jeK49b1CNWhtnW2A4Q8Z9/eu40dfD+nyxmazZCo+8V3c100niXQCux0cj0MdRKu6clyRMZ+22UGzwzwZ4XvL3Uohckxxo3zFvSvZNUjtEgt7OyZJHQclTwPrUur3lh9gRrBRHHLncQuDiudury2T/AEbT/nVR80nQk+1RVrSq+/JbGuDw9SrNPVE6zrEfJT5scM3pV3a0Coc74yM5x3rkJdRhs7lIGDmadsKQC4X1JArp7O+lC4IymMAkfqBUuDSu+p6leGto7rcktknu7xSylYmPCe3rXV6ckUDSbcnYOfaubsEuZbpZoVO0HOM8Vo6peCy047ubiRsEA5AFZTi37p5WLcqjVOOhV1m+j1MPBg7UfcQPQV5P8avDs+pXdhdQhVhEZjAGcZznrXpdnA8NpLMwIeTlQBniooy08XlS26TQg5MbDPNaxjy/CaU1Tg+Vq8UeCeAPD+rf8JNbpbRSRtC+5mwelfR0envMkUNsFUj/AFsvvWb4s1G08H+FZNVjsY1lf5FRBjnHevNPCvxMvbyOZbsQ29vu+bBIzmtbzrx93oFNxqS9nR09T2ZIpbIhPMMigcgDPFcP470S91WOGCzjZoHfMqg4bPb8K6PRrmO/t47i1uGlaTG1VbP1NdAGt7PzC5D3AUs3+zXM5OjK71aIleDtHd6aHm3hz4S2ysJtUlUE8+UTwPrXRXWn2umFILZ/3cY2jAwB+FU11O4OsCV5WIYnjPA9Kla0urgtcknAPc9acq85NSbujupYOUJXqPQ1LCCwcgvcqWPZxtrRSe2gtmU7DjptGRisIlmtR5scSY745auL8c+KIfD+llF+e6l4SJTjj1PtVRg6jscleinduWiO013xFDd4tYI32oeSOAa53UbIXiiS4b5gMj2ryTwvf6zq2rwW1vdTmeVsjYSQufavYDpGoW/2eK9lLN0Ynv8AhXVPDqhaz3DB1Kcl7NDdM02U/O77j2BOTV6OyADK6jB9RUqRPHMEiX7o54qWRrh2GdgHYYrirJVNWz1aU3DSJhXlgIZ/mHHaq0sFs6MQpjlUcY6GuhkZ2IEgD4/SqM6rOSFADjp61im7cr18+p2QxDdrmNY3bXem3enylvKkBeMN/eHUVyo0aKQswCEE8cZrrBayi++0L3OcAdDV0aNaTs0gkaDcc7FPAr0adRQ17nl42jaV4bM7YWEIQ7xtz3Nc7f8Ahezm1SO8ZB5sXIbvXSfalcFjgnJqobgy/wCqBPPOK54ykkcEYvqS2ZktnRsfKBjj0qTXokuPLNudx25K1Ggl6807zVBDMMAHB9RUW1uP7amt0YDTTRZSGR4cHnB61kakk2o3KteSzTRR8BTI2Cfeui1G3e3lk+TfA3zKT1WqHkiT5ojuHp3qLzp/Ae1R9jU9+UUZ2kJJZa3ZzWuU2yc49O9em+L52/4RqSeEZB25PoCea85YvEymMnI5rpvDur384WyvbRJLJ+GLZzj2rNu8lN9DDM6DqONaK+H8jmbS4je6t3c7wGHA781v+MYZNektGsABNGpRgaZ4jhsPD0LNp6K0jngddtWbm4DxWrJGV8xAxyMc1pCPLadtNSKleNacalPdHHWaXmnSlopwGX764yFNdXaatHcWcbXciHI57c1HLp1u967MuDMvP1plpZWYheG4wGBO3NXdc1onTVqRqx5qi1Ga5FFptil9afvYmO0Rg/Nk1zMXjK0jcw3yvbEnHXKn/CpPGQmt9LCR7mSN857gV5Hr1y93scLt5IYZ5zXpYWjGpG8jyK1SpQlyp3XQ9qudOh1a0O1EkRxlWH8xXGadNceGtXNvertgf7kmODW38Ilul0RvPSZoN2I/b1x+NbPivRl1OzELttdWypYd6lSVOTpvYuovrEeZK0jO0DQL3RftGrvq32q1uXDIuT8v4V0LRmfE9qwcAZrjZbTxLp2loLaB5LWJjvVcMCOxpmh6/qsF6tteW2Gk5GUKjHc5qatF1U3dMrB1/ZR5LPQ9GtbODVtPdbmIrcoeCTwfwrktF07U7e+uIpGjZA2VYjG2ultbmRWPJUN8wxUl0vnq00YbzAMtt71yw5oKz1N5cyno7RZXikea8aGWMogGN7cLWB4h8B22oSSXOn3UcMuMsrH5SfatVds+5JGO5TzQtk45jPA5zRGq6bvHQ1r4dVkk2cTYeFL3Tb2GVHSPaf4Wz+NegaxrENlpiTi3FxfRqBuH86d5O/HPWke2tzlWC578VvKp7RpzPMqYNR+GWpyWieOL/Wr0WkmmWsic5cryuKtQyT3+spDDbIEzyoPGO5NdHbaXBbZkt1WNj3A606azRI/9HkAJPzlRtLfU0pSg3eMTXBuVG8ebfzFeeJoRDAgLD5NijJyait9Pg0q0kl1aa3iHJCqctj3pJ3NkipEdrnnKiuA8eTX/ANiYKzM+ck56g9qUafO0jpopvm96y/E2tC0xrzxI1zFqaz7wQg2bcA+v0rszE4yhQM6fKQe9ea/CrTrqDde3DsqsflBr0ibVo0Je5uIkX2PNVWi78q1sZSqK3NDbz3L9leJDHhoygAxiqWqTRXM0SRDIJ5BNSpqELWQmhkjmhLYAPr702W3kAS4k2kuMjA7VglZ3ZzRlFS57WuTyCA7QMmJfU8qaWZVOXtVGezetQLDPIh8hw0ZHIPUVNHYvHBmOZ2ZvTtRdEyioq7M3XIYta02TTtWQzQHop4wfUe9eQ+IvAM0DxQ6YpMTNz83I+te04c/61tsgHr1qWW1g3JNeyER44QAAn6mrhP2cro0hJQi42vf7zlvCVo/h+ytYQ4W4QfKxHBB7GtW8vpZftLvkOwwT61HNslyNilVPynPOKYyxyJsByfQnmsaqlUfN1PRoRpwSbRSEQmiXcQAeprfsrW6v7dSjGO0QYDEct9BTbDTI7qIJIwWJfvEEZJ9K0tW1drOJLOxiBlCgAY4ApRjyLljvc5MbipVpqFLoZyJbrOsEnmHB+ZzztrlNX+FNrreuyX1/rgFpI2REi/OF9M1oP9ve6GVcyynHpmuj1uHSvDnh+TUNXf8AfRJuKhsZPoKt1HBppu+xy4yk6cUnLV9iDwt4c8L+EldtFjaW7YFfNlO9h/hVVGuG1V5LpmkbJYe1eYeE/GuueItemj0y2ghtN29iwLFV9Pqa9QW61T/llDFEemduTitZ0ZQacnds58JKMObkXzZqRiMAzRqVz13Hr+FUrtt7bioB9hVfzbuMHzkbJ6sOhqNpigLFwPY9qz5bHfRTb5r6lpNqrwgLH1rOuIhDN55Q474q1HcxzRnZIvmD3pgkEuRkZA5yetDjrfqawm4t9isWjcfuxjdzkcVPBEmw78Mc9TUDR4OcALntViLG3IBIPPWplFJaHR7S5jeD9bm1G31Dzx80Uh2kdwa7LRgktssij73PNefeCLK4stNmFxH5bSE9R1rr9Aj1G3R5BDvtc8YPI/CtKqV3buedVuqabetjonX5sYGKz9Uj2KpUhcnBNaEd7byxD5wJP7ueae+mJcJ+++YdQKwUlHc4aVdRl7xWsri01CAW8jBZ1+XB71h3mnS6fecAlD0xTLzSbi0vsQkvGeVPcfWt+3vW8mNb+2lIUY3qN1Q48rstj01U9iueDvF9Dmp1ZJCWi3bvbpWjo0jLdBCG2kdG/pW49raX0X+jTIXHIAPP5VWXTZ/MUhSHQ8EUm479TT65GrBxehj+LNkN1FHKhKuC2SOtQWupSXNukLIAIjgN3rqfEduLnS445E/eIc5xzXm99fXWk6qYri2IspANk6jIB9D6VrCUqiskPCSpzppz0aZ04kQfNIx46HrT/Mt7hcLLGrZ71mGdJ4laNgQR2NImwRuQOR3xUKdtDvdBPcsyW6i5XzAJbcjBHUA1XuPDGjzTec1lbO55ygA59xUcVwIWQlWz2Of6VtvdRXlsrRWRSUfeK9D+VaQqNPQ58TTcUrq6MjXGudL0oNYxBCBgbBgAfSvL5/F2oRzuty6kFsqrk9a9Zm1eI2Zt7mE+X0LDkrXnPjDw6kweSFQysPvoK78LOL0kjzasalKfM9ujOn8I+ILjWNMS3AFuwOCOp+oPer10qG4CW0qyXC5DeYozj09K8/8ABF3NpV75cz5RByuOSK9UttGt7u6S/wBPXdJOoDqeoqa6VOXkdVGslq2SadcxXNskMkCmXplBhRViSB4onCsT0OCfu1Wk0+eyYBf3TeZknOT+FPjdrYhp2Jkfj2Nc+nQmSUruL3ILoRtOqttQYwW6HNZ0spjniSCUGNiQf8auawRcplo2yP4lPT8KzoLCO2hSaWdmDcDI5zVJLqddO6hqzZt7uG2gkPkyzug+XHcU+G5tb47thicY4PXNXtQmMOgRzWtuvmbeCByTXl82v6g2qqihkJPTb1NVTpurqjzvapyd1qelyssDlXkUtjK45rjfEni6PS5mjAMki/eXPGavJNI20zH98wwQPWvMvGGlXcN9MzltrMXVj0Oa1w9KLlaTCrGUY86LU3xAunu23+Wi9gBnFbWkazJqwVJoEmUclzgH6V5xFYRq69C3UsTmuz8HQSmUQQIQ/c4ruq04RjojClOfMrM9ELBNN3QrsUDGD2rzzW/K3hmmkbPOCa9Pjs9mn+XO3ylcEd65q70nT7XDrD5rdFGdxzXDRmoybNqr5la4/wAGB3s0M8REbPwh9Oxrpr3VbTR5candpHG33A5wCKi0KB8jzFPkgZCivOPFsF54w8ZNHFFLHaWx2FyvYdaTSqVNdEZO60jqdbdfEXR7e5aO1k3qT8zLz+Q7102i3YvrMXUUrGFz0YY/SsTwz4Q0DSdlxHbrPOv8cgzg/SuwuI4I7EOBsRm+6grCo6asolXqQT51uN1QwQWySAqWI447VgzXLTlFb5jjj6Vb8QwuLCKRGLLyOP61g2p3MHznYRxXNq3yrY9HA0oey9puzTtYfnYyjGeM06S1jV2aRgi4zuJ/rUev6vZW8ayufKQLwg/iavHfF/iufUJpLW2nbbnARDx9PeujD4aU2TUxOl39x6RbvYpqMy22qrJIeqRPk/jW9azxBsPIwm7M3IPtXmvhLT7fSrNRNzev80jdfwrr9L0HVtem2WcbW1sfv3Mox/3yO9a1opO19F1YlThSo+1r6NnWaeyajeYQYcHBdf6Vz3xP8Fa1rmktHYH7S+8EI0mOPfNd74c8O2fhux8uGR5pDy8sh5J/pUeq60LZlVWHPTNcHtX7Rey6HiutUrzapLQ5D4eeDLLwDoJfVpEa+uDmTaM/8BWtSfxZpsTnbZTvjp0FQX082s38Yxv2jC5HA96sHw9BEAZp08w9u1VKTnLmqbs7aGDpUYqNaTv5C2XiXS9VnW3lhe3ZuAz4xms3xfbJpZLFxtIyAe4qjqunxJcOsACzLzx0arUSf8JRpT6dM2L2IZiLdx6U4OPxR6bry7m9fD/V0qtJ+718jjo7iG8nAt5fKl9M10lluGI3wCf4iOteT+KLHUPD+rhJ43hkRvlYd677Sbm+udNgkuYshl3bj8ua9GpGLpqcHdMKFb2s+RrVnSkr5bIULydAR0pYI1VCJFk3Z52nijS9LvrmEmzYI+ODn5R+Nbdv4UIiH2q/PnfxbelcdSSjuyp1qdL3ZMxUDHrhuetddol1GbfZgDHB9DXFQfukVQSXJJY+grM1bxg2lxNbWKEPn52bv9KHRlW0RhjIKcbHZeKdEZQdQ07Kyr8zAfxVF4W8Ti8XyLhdrqdprgdP+Kl2XNvLHvH3Tiuk0u6sJ3S5syIWlzlieCfeqnQlGPLUXzPNhhm01J6HfPAskqyDmrQgAHSodLJIjTcsny5LjvWmYxXnTk07HLOpKHu3Oe1Hw/a3itM8jwyj7rxttNZUenanYRfaIdUYoP4JHz0+tdm8KSKQ6gjGK53V/DslxJ5scpwP4Sc8ela0qt9JM6sLiFJ2qP8AAzYfFE8sot72GKVDx5kYxj610dlpdpeWT7xHNDMOQRkVxrxSWDSpHEN46g9ay7nULsqrxoVIJGclf5Vo6TlrHQ9mpgY1YWoOyZq3/hdNMu2W0LfZCcgA52mo1tIEBX7QrA/gRWGbm6mAEReAv1YE8/WoZtIugvmJMZCTl/mrXljPSb1OqnRr4eCUpXH+Itc07Q3Ed3vYYDBwwxn0x1NaegazFcndZuHjdQyH1Brzrxj4YsrhWuIp5xdgfMkmSv4GrNrC/h7wvaXkErAI48wAZBDds10vDU5RTjuZLEVG3GorRPSL3SZJJGkaIpvGcDkE+grnNSs7mGJ4wJYgB35rT8MeJ7nV7MXEuxEUgKUOWP1q5qmbyB5YmJ3noR1+tZKMqb13Lo17tRmrxOX0rwgPn1GeQtKg5Cr1HWu/jnWHSbRrYEFiBwuTn+lYOgX5iVork/Pk8KQeK0bCVrieSGN2EeScHjbxTnKU375z16TjJ2XuokvfGGjadeC21i6hiuMZALdf8K0baOy1iBL20kWa3PK7a8G8X+A9Zu/E9xcXO59Pkk3NKW6D0A9a9E+F1s+i6TDYB5CQSVZxjjPSqqUIxjeD1OKkqsm5xVkdPqFkYEdwG8sHvWe0FnPJF9pYqkbblb3rY1vUGtNLuLnUXjS0iUlpCK8S8da5NrkNlNpE7tbIrbkjJDBvU/hUUaUpyvt5noUa0pU2t32/U9mGtwQ6JqC30bQWloci4kI2suOoryV9btdZ1Fn0a7juHGdsZBQqccHnrziqdhdX/ib4d3mkyPJJdQOHVBkvIB2PrVH4d+C75dWe+1SFrCBFwqyfKTmuunTjSuzip+1p1lZaSIfCviLW49bmt9UjnlnZurL/AKuvTrZF1W3YXCpLkD5SO/rWhYaZp4BEd1HP32EYOPatFNOWDfsULCBkt3NTOqnqdvuUabpXu/NHLr4V0YvvkjxJnH3sCtiGxjt1K2wijX/Z4P51lX/22KZmtYVeIHcMnGBXJT+Omsr9raeFmkIwpC9DVRhOpszjdVQep6OLaT5WuvtDIeVKnIFXNPh01bqMyBsFuWZf615HD4s1U3DbZpETOQB/KuhsPGEgkKXX75TwNwwaUsNNI051UVmrHpl1qC2dw8dmsbBuNzDoPas5p1Yh3Uc9cDGaqW7Q3cHmwysuMcE4x+NW5VtorHdPcIuTyzEZFcMoSWiOyjTpU0tNSHb5bHyiTGTkHPWtWzupfs58tEZFOHJ/h96xrd4v45laMH5SDyavXd3CsCWFn8kTHdK3dzURhJS1Fi5JxSii/e3MFpos15F++hSNi6uOPfFfMV3461pr957W4EEW4lYlXgD0NfSNxf266e9k0G+BgUOPcV55pvwu0j7eZJTNMrnKRf8A6q6sO4wbcjy+WrycsXb52KdvYXnjbw9b3skrQSqNpUJlXb1FW/Cfwza1ulub5GnlPIBGFUeuK9W0Xw9cWFvHFC0cESDCxoM4FdBZQx28bKGDMeuetRVx3LdU9jKrX9nFJ+80YWj+ENKtJluZIhNOOcnoK6fesa4UBEHTFVZ7iOI5LKPWuX1rVpJCY0bEecEg9a8/36z94540a+Mlds2NVvwAyqw9+a5Z0XULos5+SLvUFs000rKvIxwSavI8VjBudl3gZIzyTXQoKmro9mjh1h48sdytY30djPK0p4Ix7ipJdftnVhJGQD0z1rKsIBc3kkt0Sqcsa05bHTJbbCkiXGQWPeh2VtOnzOuVOnz3ndspXTeaouofmGcde1QQM1nfR3ULMCDuOO1S2zLC/kPzGeMioLuNllZcFk7EUnKyUoHRGCadKWzO4u9A0nxL9k1G9iErbQQD0zWT4ufT7KzZJofLiUbMx8H6CuWs9R1KyJhgucW5OfLbt7g1LqFp/adpmd87ec7jyaThytXfuHkUstq0JuXNr0/Q0tGsLpNJkvbGaVkUEqpPJqxbauZYQ0r/ALzoee9cudaay0n7LI/lRjqd3auafxpYwyNHCskyqcb16ZrSom5Oyuuh6EMNaPPimrnrF7o9xMCtthBnkiuL8SeBtSnnjaCPzAx+Y56V5Zpfju/s7tIrae4Ry+M7iRnPpX0L8O/Ekmo6U66sxE8ZADsMbx/U1cqs6FnF3PLr0Z+ydWnJSS3PLV8A3y3p2QsM9TXo/h/wakFnHFcbhjk81232i2OChVs9MYqe3mgkJCsAV6g8YrKtjKs1seZ9YqxWiMOLw2YCzWN5LCSOx71YtBrVjlbkpex9QR8rAVp/2hYo21ruAMBnG8Zpltq+n3O8R3S4Q4OeK53KbXvIz56tTeN/kNh1a2Zgsu+F+mHH9auTSxiAsGyMdazLrV9L/wBWJFmc/wAKjNZdxeRIWmLMsePlQ55ojS5tbWLjhHPVJoZqlqb65EtvJluh2im22kSSttnClfYYP41DYXz20K/Y4QwLZYM3Kg9a1rXV3kuBHHFuJ68VvNyitD071qMeWK2OW1+G6tLuO3tNOd1c8uo+UD1zWS8zQzENuRx2r0g3zXbvbFUi2/xE5z7V574yEVo2b1WKg/IQvNVSjGpo1Z+R2YTHya5auhUvpI3KC4gVtw703WrWyvfB+qQwttcwsVTuGAyKraWsGo2pMMx+RsDee9aK6TghZpD5PR0HAYe9aNqlNcz2PRrKNag1Ddnm/hG8k0zUFgt5fMCRAS5BK5PWu3s9aN3cFICWhHYDFdAtpolraPHBbRyO3zEKMnH1qxo2mWhiFzBEsYxggjvXTUrxn71jyaalCPv9DMIIh3RxgFjkA9fzq/p1pIjBlJWQ8+1WNQMUAMUcePUjmjRpSQRICdhwG9awcro3k5ShfoTS31xbBknWN4Rz8y81VtZIryaRrcbeOB6GreoWwvwse4qzHHHb60unaabOQAPx7U00l5nnzTb00M/XNJu9Q8Jalp14wMdxGdrE/dYHIrwPStG1Wy1EWqxMcnbyOPrX015K3NwYpJJNg5GemaztSNnZShIoBJIxxuIq6VZxvFGuHqxpVPaS+LyOV8G+G7nSyJ2jIkC7lDdCfesTxfaeILvWFLPtt+vycACvW7SylSxeR22gjIB4xUZtIr6H9y6SFeDsIODUxr2k2XVxSr1OeXTseLto+sxarazWxcLuHJbAr1uwtUdUNzNwq/MN3FXDo6YVrradpwDV/S9OgmldhGfLGAM9GqatdSj6GOIxSm5VLmVd21qMJAEyRgAd6w7fwPprXUs1xa+dcP8AdwuMfjXX6vqGh+Ht899LGpUZ2jqP8Kw7L4p+FrmUpFcordAGYAn8KyhUqtXppnJOUpRTS0Me48AjzWZYowOowKnt/AlorpLcorP6YrtbTX9Jvhm3uQeOR3FTQX1lcyeXFKpk7DvSeJrLdCdaqvsnIaxoaJbRJbstvAp+YltoNcde2OhTXD20mvI8iAhoxJnp9O9dh8XNK1DUfDuzTGxOD0zjcPTNfMsy3GhXTi5ixdn7qtzg+tdOGtUi5t69j0sLiqrgne0Vu7H0Hb2mi6LZJNLcBYXAAkkbP5CpbPVNCvGmitb5Wl25UMMHPtXlljoviXWfD6NfRyxqzZjEikHbjjiuq8K/DPUfI8662gnoG71vKnTim5z1Oepi18UXoduhtI02SASu4wPmxzVuG+s7NHFzP5bBeSg4QfWuA8T6Lf2zLFZxSLLjaZAx4wO3tXD6x4a8fNbiTynkt/vBYnyR+dYeyhNayOvERjThGp0fY9Qfxppel3TSLfXMsmDgnJGPxrobDxJDqcCSQ3SsGGdycZr5ktbHVZpntbiG4EzA5DoQR9a6r4T3pttUey1LzUjjJ6g9R2qo4WPKwlUoVZxUY7+l7/I9zvg6QoFkZ945rNdFZ413EZ9fWrLzWt5cPcW3mxsqgFG6Y9qZqVuyOjqAFBx1rlb0WhvQj7OXK9GJAAk5CucDqc1n6jcR/PcXBCQg4B9aszSxiCQBsvjLY9KyJYWvJI2uVKQofkj7D/69FOktHLoaVKrhPlitWalpOsvlsgPkt8vvWzqMFklrCqFhKFG7J4rnbaQrMkUYzgjgDpUuqa7p8E72txOftSjI2pkD8aFTUkrL/MnEc8ais9v61LBgWQgFXDdmAp6jzYirHDDgg07T79Z7NJ4GOGHcdaSKeG/V5FJWRW2ntSlTcbpDVZv4tiKJreC4LXERY46k5FF3c2UVnO7yAIQcIuakMN2SY0RJh2BGTSLpE0ww9uwZu23AqXNpWsW3SvzSlb5nl0PhjVfEerM892ttYs3yoz9R7CvRdG0HS9Ks/skemx3QRuZZACWPFR6hpV7aOjC1l2qcjaM81o6cJ5LfeY5Bk9xiuhYh1EuXREToU7c0pc1zJ0jRNBtZi8Gj2ccpz+8dd7A+xNbSWU0ixoqhIhkZGOT7ela0WjZkQkYA5xWqunW/2ZxMSoxnIPSuV1ebVnNUxNKlpT+ZysFjeec1vaoZlX5ip4ZfoaS4Z7QmSa4mhcAgxyHjH51dtb+HTLyVoWPPy7jzkVxXjmGfW7K8FuR5hORGW5PriuqlT55+9ojOded3aN1YrXvi/QrW+Ecl4JpIxgRwJwD6E9Kk0zxPpOqTS+RbygpwYxwee9eWN4Q1N1DR2jjB7jA/Wuu8HeEtS0uZrrU/3MjLgAHJArunQpQV09RUa1erNRe3krI3/Fj6xDpx/wCEekbznPzKCDIq+1eard+NItSjUyas0vXBLbT/AEr2a2g3RuLeLcwXPzHlqdp8F1JclpIisa4DZGMfSs41oxi7IuWAlVlzTnqYXhLU/FFzeSNrsEa2u35NoVX3fgf510Ws+Kb/AEGxM9pp812WJU+WQCMeteffELxPc2Ovta2c8iW6LghBtOfr3rK8N+MpbzUk0y8Z5LaQ43n7wP1qZU4tqUl8jWNODgqfPa7trqz03wx470XxiRpwFzZ6q2SFfjkc9RXQ6nZrfW/9n64JBgbVnXkn/GuFt/AUEWpS6ppEsyXykud2DtPtXb6Vqt5JaeTq8CCWM4Uqc5FYTioPmp7ficyoz1hPUp+HvCkWmSSLbyy3UMp/iXGD2rQv7DDG3KsJHAAGc4rd028ilhH2bG/0PGKbdSWGjL9q1KbzJXbbhecVi6spS13JhVqUnyfcFrp8NnZCOCIMxXBOOv41RUGyzHIgw3OAOAa6DT9TsdR2/YyefUYNYnjbxHo3huFX1F98zHCxJyf/AK1ZwlKUuVLU544iUZuNVPXcpXMcVo0dxfTokMjAbpDjnsK6CC1gEIbKhTyPTNeYw+ONC8WXCaddWs0duDvy3Rueh9K9Ftb3S7m3ZoplSGEHceARita1OcEuZNMuVadRXj8KKy28VvA1zcTEBpMHPTrV4W8kkw2j5e1eFeNviQsfiE2tgxe3VtrMTxgHHSvVNC8X20GgW1/e3KOs/wBwI2efr6VrUoVIx5t7g5qa/du8jtILHYmZMEY5rPlOntdGMohkQ9W65rmtT8Y3Gp2Mn9nJ5MedpbPzCsK0nl3r50rdcknmsYUZvWTNKGW1ZRc6rsdD4h8R+dfDTLixmitT96RX4P1/wrR0O20yK2dLK48mRxyhOCT61yeqXO/bHDli3A3nGT7ZpzWPlpG/Bb+L2ro9kuWy0OqeGgqShB2Z2M0F7aWMsl3Ms9tkZwecU3VfEbQQRw6ZFsThdxHb2rnXuZFtPJ8+QQ/xKTVc3SKA8RXcOGVuhFZ+zV/f1MoYD2mstThPihaz/Y7mWcyOj/MWB5z71534N8J3/iDVI3jzBZqctcSDj8PU19D3NzY6giRy28ZRV5U/MCa4vxBcarHcldNhFvABtQgbQB7V2UnpZLUvEL23IpK3Lpp1OZ+JUFz4f/sy70a4mEcPySSI2PmGMZH513ngvWL3WPDdvqFxEIb7qsqH7+DwT6GuB8RxapB4UubrWp0dZMJEoxljmur8IXDaL8OLd7lgZGRpck8KD0FVOH7uzd3c5pzTxPMlo1qv8z1rRNTi16xMV2oW6T5ZFHRvcUQ+CtB+3Lezadbz3KnKySIGKn1FeHeCfG88mqI6HO5ihb2z3Fd9428b3llZyvpW6RgoG0DJGe9cFXCVITtDS5z1KMpXjRl7j1PTTBBLkAx4Xr04pHubG1cRT3cCORkKzgGvle68TeIcPNPcGMt8xGcA1qeGfE0F/ldQKJc5wMEncPxpyy2cVdyuVRy6FVqMp2vtofS629vK+8eW5656055oYAS8kaj6ivHHudVkthDpU915j4AwThR61dutMvNP04Xeu3bKpHWRgDXOsJprL/MmtlypzUHUueky3mlyv5j+Q7464BOKxtR0rw7KweezgG9t/wAowWPrXkF9400vTfljnlmk6gJyPzrX0zV38UQW0sXmq8bcgdPrXQsFOC5ruw6eEhCokpnZta2lvdiS2ceV2jzyfasu5u3uWfJ2qWPeqHjK5i06JZJJtsoGCy1h6Vqtrd2xkNwqBThi7YzTjSc4vqkezQgopTlLVnTWR+zyySFVKMMcjrUWoP8A6QjsQU4wBWda6laX0wgtr2F3xwCamuDFGwV2MhxyQeBUyi+dJnRDkd5p3Zt+H1hbUArAANzz61wesadPp/iO9vr0M9tHIXcevPAH1rN8W3GtRRQpa3Trb7+WjBBH1IqlrHinUL61S0v5mkWFFTbjG4eprqp4eSkpwfked7aVOtKM1dMv+Fdd1G/8WJLC8ptpXwIc/Iidhtr09lRpS0YjDA7XVSP5V5D4Y1Sx0+VzYQMk7qVaVjnAx2roPBNnfX+q3E7yv5MQ3tIT972rWvST30SRnFuzm9NbHoJWaIb4GZXHYnofapIfEGoD91lZSTwHH9a4vxV8SLbw/bCEEzztnaoHIx79q81i+Jms3GpK5igMJb/VKpyB9eua5KWHdV2OetVhB2qK7PoSTxLqFmyiWyVyeg3Coh4onkLM1jboc9DXH6TrUWoad58tvIsgHJ3dPwrzq/8AHN/LfXH2VlihVyqrjPA71P1Zczg1qdEfYqmqrVr6H0/YOzDY49qyvGF6LeBLRAQ7jcSPSt12hsYJLi4YLGnJNcLqEx1WeW4V98B5TnkfWuTDxXNzPZHBh4e3q80VojmZrkyu0QD4H8Q6VPptvBcRhIZ1e7z8wY5NZvxRstRsfBkFxpSPtdj5zx8lR/SvJvh0+pS+I43gklBOVdi2AQa9NWlT50dzxUZVvYU1rtc928YWmo6To63FkiyXC4O3bnA7mvKrrXvEurS7RMUXOP3Qx+FexWDyQWjQ3Mu9T23biKrXr6YzlLKBWuW6kLU4fER5dVe3Uc6NaNTkbumcf4T0a/SUSS3E0jDl2LHA9hW74l1ebTDbxiTiXIPqMV5H4x17UbfV7u18+4hjjbEaKxAHv71b8I+KLjZ5OpFrqFSD+85K/Q10zotvmepeHxNNVVGOiN/xTolx4rsla3eMXy8qOzj0Jrn9K0aTwvcw3uqxKbpPuxE5BPbpXpml2yRyi7hZmilGU2+nvWL4/wBOS4SG8RizKNrRkc/UVnSalUUZbHVmKpwl7elu9P8Ag+pX0rxvKl5GJ5DvkODjgCvT2+SCOZhGwlAYse9fMwina9CxROSWAXg+te4Wthd+ILbSojdSWjwRCMox2jI6k5q8TRgmraHlwxElra50w+y3OcEo6g/KvQ1mySWYlxLGZMtghz2ot9PuLMyyecWiEhXJHX6V4h4x1u9t/ElwyzOY1lIHPGM9KwpUVNvXY6qmJVKPNHr+B71pSy2QZdNbaDltzEEgfWvLviZoPiK/1L+01imurB/+WiAsFI7Gt3wT4gF7fQsuSjR5Yeteuafqul6fpQgEwVDzhuSfaiUpYed0rtnJipznFOK1PnnwNpXmamojT5Qwedz7fwiu919xprMSgR51KK27GFPt61vXLWc19NeQiCCEckgBd1cv4mtBq8gWBzMpO9fm4H09q19r7Sd5aI66NJunZb9TyfxD4T1Kxhk1AoskMjFsKcso65PtWdFqNwbSyglMqwJ/qkB45PJ/OvU9etJdKiNq4Z4Z4htI+YZI5AqlpRsdH02OfVLOCV4WJhjdfmGf5V2c2l7HnqlyzvCR1Hhe1mtrUmZi8EqAnb2NdroWkl5g10vy4B59+lec+D/iCmueIItJ+wpBDLndIpzgDmvS9PuxZ3LK7NJbv9189AK82qpRv3PQxGLlXTcOhl+M/BNxq/7+2uGheAHbxkEf570uj2dxp9hH/asr3DFcBm6tWnruv/Y7SaWzn84MMYUfdHeuD0Pxo93qaW8qAx55yeRV0o1Zws9kedCbj70zuxb2l9AiKmwj5SD1qK40NrZJZJkRLdVyHJ61zF54qjt9Y8pItqM2PTFdWbmeaEJNIWiYBtvr6VE4Sha+x2QrTWtJ6eZmaVe2dvqxWWJGTacDHcV4L438U6/e+I7uWSeWCBZGEMUY2oi544r2++0orqxmlPkxD593b8q5fVfCUWpSXF94fuINTt8kyQxEM8THqCvpUKbh7yVz0K1HDV3G9Tlb6+Zy+lzLr/gGX+1HYyW1xlWB6jFb/hHV4dVgOlTRiRAu1d4yMehqtq3hbVNI8P8AnNYSRxzOd6J/CAOMjtVHwzbzaJDLq01u8MSqVUMPvk9hXoR5ZQb/AKueXUapzspcz2v3NPWb7w74Mn2GzZrp/mAiH9TVvwn440PU7gJNbvbuSPlkYc+3HWuS1OG88b6lDFOiwMQVgk28KPc+nvUmgfDe9g1+2M97bC0tnEksqk9Aeg9amUEl+8epz+2qpvkWnkdR8XbJbiS1lhiWG3IwAq7c968s0G1u73xBBDbwuAZNu7HCj1NfRfiSey1RI7eMRzQoAoOM5NeYeJPHX9gT/ZLHTI5Xi43zcKD7KOv41hQk2tjvq1owoQa0kvxPRtJ1GDw5Zwi4nUuseAWYDmuJ+JN1deJxC1nfxyRx/ehM2OfUVH4XuB4/0C9uNSSO0vLFtyTRjarD0I6VkXWqeHIZBbvFK0qjDXCn5c/Srp01z8z+JHDLExqtz5dyh4c8CX+sXObl4YbdT8xEgcke2K9l8O6RZ6bElrZgkquOe5FcN4JjijvTdrNtilyiBTnIz1r0LXrmx8M2UM6xy3F1NyoDYz70sVVlzKBtTjFv3b8zMH4k2Nu2gsT5pmJwiKMktXlvh7wxe3cjSXBdtp+6OVH49K9i0jxFaa45gkiEcin7hPStK/vrLRbKSW5gBQkhXJwPyrOnWlQXLbVmk4TlaM9kcFoFklvrENvEpO0g7gmQR3FekySeGtM8x72KBX2GQgjr61zOj+OdIE5hsVh+0ScBimOa2b2XSr1AdUtRIdpyUJHXrmsa7nKyldCrv27/AHaslbZnD6R40s9Qvpvs9uhhIO2IDP8AOvPtZivk1Gee4spUEp43AgY7V6Long7QtN1ifU7C4mFtEhdhKw2xin3PxI8JGN4pLX7SY84kkBwfp3NdEJqm17NNuxVWtzW5o2sU/Cfh8jTo7ueONQVOVI7e9cr4s8YXOkXRTRZPJt04CY4P1rpx8T7HU0Niln5NvzjbjAHqfSvHfFuorqOrSPaqBbKcL6t71b55Tbmt9jknUSpOzNDTNKvvGN3cXFxNs2qXL44X2rf8LaDpmlXpW8uPtN83EYGAq/h1rU+HVuD4OvZlYRuSwdjxnA4rhra2uRqS3Eu/5XyWzz/9etef99KnFWSS1Lw+GjUpRrSvKTf4Lue1aZY/ZrJ2+WWORsZXqox0rEi+GlpOXlhe4KOxPA6Vu+FLuKLSJ7y8lcwKu4qw5+grnP8AhZt6ksqwW6rEHIUAngVzp1HUahudGNio+49UmfQOtw/bdLniADHGQDXn0t0lv/o4wrKckA/oa9KuE3W8y8D5TzXkls1jZalLHcyg+Yx6nOSa87DK8H5HNlU7Np7Gg+pTpayW6kPFKNrxsMqRWVpOkWyJKYo40KtuJAArL8X682h30Ufko0DjIfdjd9K2dIvbe5sXuU+aGeE7fr/+ut3GdJLs2eyvYzjOVJe+kcB4l8cS2HiX7Np7JLBC+2ZV5B9RXa6FrenIRdsp8zjKehNeS3el2Efiyb7PewzHeWKZ6N6ZrvZPD1/PoU0tkyCaQBlGRyP8a2rxi6ippaWKwcpPDSr4h9dkX/Enhqz167a600W8kkpLNDKcHPt61ztp4IvpLswtaCzt0OZJHGFA/qaoadpXiJZlLyPG6ccmvSdPmv5dPS31GZpBjhfetfa1aPutprucbwUJR9pRdl2ZVuHGmeHpn04mdbePaMdfriua8H3cd/rAOsNJJHJ8oizn8a7RI7W3kcSL8pHzA8gisXw/NpFpe3CWMwaV3xt6lfaiM0oPTXuRUo1XK3QsX2l6PoF1LfyRsYU+YSA849APWuM8R/EEXmpwnSGeG1ACmJ1Hz/U12/j6CfUdLgSyT95EfnU9GFeb2Xg+5vr9ZJbbEKNmTHGK1oqMo803qcc6tSLSirWPS5PEWn2fh2y+2XKxCQfIznk5/wAK8v8AGPhmXU7j+0tHdbq0flijZw1XvidpF062j2tuzWEEexSgyFPfNWfgzp95d2WrQ+ViE7djSHaCx6gE1MUqceZdSvaxrVPY1NFcwNNvp/DBt42AIf75B5A9Aa2ZpNYk1W0urV3lsZMblPIUe4rcn+Gzm5Mt7IHiDH5Q4xk1uQeHzpCNH542kfcU/drR1YfM3r0VzWpbdOpwvjvWbvTIoUK/vJxn2wKx/A/jW6sNUjjvGMttIdpB6r9D6V3PizRLTW9OR5psS24OyRTnA968jhhUaxFEkuQJAocjHfrVwcZwsctVVqM+Zs+n7BkuYY47W3jeRxvy4B2/T0rzPxjp88ct5LKodWzgeldrqGq2Xh+1he4kYMY1C7Op4rxPU/GmrX2p3EyXGIg5C25UbdvasMNGXNdbGtWvCDSa3Og+E1pBbXuoXksZeVYSqY7EnmvVvDvn3HmMWBWUY2NXL/Dhv7f8OXc0FusEsL7JEiA+c46/yqn4C0bxX/wm0d3fx3cUCv8AMHB2Bf5U6tpuTbtYI4inSo8sNbnbag1pb2kpnAxEP3nPb1rjfD7+EZ/EQ+x3jSXJOViKkKT6A969K8X+Fv7Qt702s4iM8TKwI4GRXz2PDV/4buy1yyC6LERbHzj3owklUi7S1MK9SNTl5Pmewa74csdQma5tpFGwgso7Gt2wKWtvaZBYBeh615T4GvnsdXL6zqPkpMNojJyWNes2ANxbtLaAzuDhT2FZ104+63c1p3jByktDz74wazrjxLDpcDxQyKfMmXqB0x7ZrlPg5oWs2niD7alx9iRFw0Rb55s9tvp9ayPG+k+I7jxPcR3FveyO8h2YBwfTFd/8FPAev6VrM+qaki28SxFVjc5Z2IyM+lXJQp0rnBUq807vW3Q7bUfGFvozNb6td2wDHiKT5ufp1rL1wQa3DbGSWE27nKBPuYNeCeNYryPxNfRX6v8Aa1mbcT7mvW/CSPbeGNO+0pyTlQykHBqPYqnFTTO/CuNerytb9jrItJt7K1RYoI4ogo3EdSPrXH+M/FFsIhaWS/ZyDtdzj8q6ubxJp0F3Y6SrH7TcA4THQ4/i9M14l49tGsNXuxKGTzZDIBjjr0qaabneZ2QcFTmrbeZ7L8M4rddHAupYvNkcsjk53DtXCfFfQrO11xpZWYeeAxAxVv4ba1CumWlhOCGZt3Jzj0rpvH3hhvEl2jQSxx3CLgGV9q4x0NVfkrXk9DOdN04prW6uec6brMdp4dfTbYLDFM2CFHzEe/vWbqfhxpEQ2gZ0fkMBXpPhT4YxWdqZ9fuUkG4lUh+bI+tbmsWll5cUVkyRojbVAORgetbvE01K1PV9Tlw9KVS6UdDE+F/hqac2ofkRfez2rY8fGS41sWtsrSrEuzGOAe+K2NO1ax8P6bNJPcrAZjhN3XOOcUmj3Ol38rXb3ltuGWG2QAsfp1rjqVJSqe0a0RpBujOU72scn4T0SfTtXluZkba5CqG9fatD4uWepS+FL2WONktbTa+4kZbPpUviK4azC3qhUMr7kQHtWdB4rh1EjSdXkMiXeY2iPQiplKVSScd0dkqNSpRdfRLU8c8PrdPLJcMzqUXIY123j/xQ1rpVhZWMgF1dwh5pOhUen41s65oWheC5mNywmjk5SFX5P1rhfG1vBrCrrEDmI7QohI+XA6YrsnVp12uXZP8ApHJToYhU+aC1t87Gkx1K48BxWWmuzyzOWmRTyVzwM+lcSNDv/tCWLW+y6dgAGNdR4UvZbfSjDFPsaQnvyAKpaLo93e639tubkwxxS72ck7jg9qrmjGrJNebY3gp1MPCpFNt3SS/M0Nb0/S/CFhLpt6k11qk0Y3vEwCxjrgVzfhTSrTXNRW1LvGzHIJ54Hauo8Z6fcarO94m0zZwBkZYdvxrP+HtpqcWv+bFpbzwqDHcZUjaD159ayo1JTTlLV2/4YMbgpYSUYNe7p8+5n6rdamLo6dpxnitIGKpFHxn3OOproNBFxq8MVvfKGni43kc49DW9deHdQ/tTdbQSrGwyjbT09zWrBqmkeGEWC5QS3Z+aRhzg1FObcPeXvfqep7Klgpc9OfNfS3ZFLxLK2geHYMYId8kEcH2riLW+sJxJIYCSzknH0Fen6ZqNl45eewurMm2wWiIPIqiPhxa27ukUuF3Zwc8VrRqKk2qujPDxVX28m4nvGqbhpt3sxu2HGa8I0jWoJdZuNM1CJDcxZZZSAAeele9zruV1J+VgRXz18T7O10jUPOjjYl22Ox4x9K87L7SUodScvmqabbLvjzRm1vQVihx5sDF1b1B7UzR7HUtK+H7+RD5l6qMUQjPBNS+A9SGq2ZtJSWaM7c56qelP8f8Aiq48NfZrS3RNuPlJ610U+eTVFrWLud1dwoSlWjL41b0PGdFsLx9fjW4gnDs5JAUg5r33whbz2mimO4yGJLKDmuL8T+NDaQafeCwjYzoGZl+U59BjvVrwd4u/ti6wxKtu6E9q1rU+b37GmEqwhTeGTu7nVGXzWLOwyTg5pt08lrYyTqfmA+X3qvLIsLTGdlVF5JPAFRvNDqOmt9nuEkC54BzUW112N5NuNluYC6rd/aljkmO1z8+4ZHNWtO8KJDrKalDOTETuO3oc1kXDJPcQhN3ms20ofWu5FybWzijQrwoXA6mtKra0j1M8PK697oa086KRnG4jmki8t9xQgseo9ao2dvPcKZJRkk9ewFX2g2oCcAk4BHpXNaw5uMtCJNsRbkeW3VGGQa5fW/FVnpjrFIfKhjfAiiQLx64HWul/dqz+awQINxauZ1LS7DxTpF9LYDdc2wJdB95l+lbUuVv3tjjr2p+/1KniLxbHFBZS6VP5kUvzH1H4VyPifxfeXreVE/7snLgHAY98msq5jh3xW0aOZFOwAkkn1r0Hw54K06zj87UwJrkj5ARkCuzlpUUm9yUqtW/IM8AzR3mnT2tyjl7kEk5yFGOBXMap4G1GK9LWKrLAr53Z5WvQGjtPDkEt1HGx3cHHYVJZ65pvlNJJOhikwc56CsPayjJyitGdCw6nTcZP3kctrFjPfwxi7EhaJVUEnpgdM1yh8IX16lzcx2UyCJSS5XAP419A2i6LfxpcMxEIG7CDIb8a5vxF4p0r7UtjNeQ20WdiQhvX1pxxVvdSOOdB1HZ6Lued/CQ6houtySq5ELrsaME4J+lew6P47vUdobrT5BAG2rK39a838RXdvpSNHY7o5FOXZePwq54M1+71y4lgvHV0SLKfLgk+ppVqUaic2tBxw8U1TbPRfEuuMdPujp8sYZl4LHBXP9a8G8Uai6XPlRz/AOkld5bdn6DNXtcjvWvZraa4cANnJbGaTSvCn/CQ2jpDIIryL7sr52kehrahSjQjds5JaaRRxeo6rHdywCbcHUjcR696+itO8SLo3wxm1O1jDm0gDY6kngc/nXmumfB7VLy0cXcflSxyZSVDuVlr1rwr4aS00SbSdSKtFLH5ZjBz2rlxLg9L3O6FR1aU5Tavpb/hjyDwb4+8Rax4lDajeCeCQb2TYAqemPStHSPH+saZ40uhd3Ly2zTGJ4mPCjOBgdqqeLtGXwdMVtREgD8GPq31rE8GW0OpeIbifUS4iGbiRvpyc11RpU5Q5raWOLk5YqJe+KHiWY626xWsMcjDd5zRgsR2xmquj+K9dl043MkxbyztVigO7A9Ksapa2njrW1XT5GtzbHY2/lWjz1Hoa9BXw9pKWsFuiGMIoUBTwQP61KlGEUpI0hCcqjlS2R4ZZ3eq6jqz3UJmmvC/mM6jJBzn8K9et7R/EOmP/aKwm82YR2AO1zXQaL4Z063M0sbohwRgL/OudvtT0rwnfxxXReXzM/Mozwe59qznUU2lHoejgFGjCp7XqHhXwm2hSyX2oXURAB5zwvuaveIdetr/AEqO5066+0BCfN2nHTmn+KIW13QHtdMfCSKHyp4Ydh9K848KeHtWttcl+0QyQWoUrKT0I9vWo9n7WLcnYqGL9lXp2V4/5nTeHviIdRnOizRSRRzAxxyq+Sj9jWNJd33hbUcXRd7Viej79x65AzXV6J4R0fTb4aoJPMmB3KhbgN64rM+KusWcWl6bHPBHLO5Zvk44B71UHGErJb7mNSVWEpVJPZ6WKXjvXIb3wpZ39u4eUS7NhGCMjqa4DTdbvIrpZeHx0BFXbDxREtq1jcabDLp8jZkXJ3/UHsa3fDfh/wAPavczfZpr1BEN+xwPnHs1b07Ru0/dOGpUlWmrHVpfLf8AhqC5uD5UgBIRuh+grzjRpLi/8WwyRTiMLMDudsYGegNPubg6h4sSKRWSCOVYY4x/CucYqbVtCOhayRcSq1qr7gR1I61NGlGM/ad+h1V8TOrRWGS0j26nVfE7QdV1K8tb2NWlgaMKAvJBB5rgLmx1N9RawhEzmI7dgzgV7HpmtvrvhO71OBGji09GACclQATmua+HXi+TUtaNvqaWzAj93I6AHd2BPf8AGsqXu3hbbUidWE4xm5NN6P5HM+IbKXQLGISKUlYAZxxnGaqaRdT21rNdTSO0bnaBngn1r6Kv9V097SS216wtWtyMuzxgj/61c1r/AIX8LeIdMjOmXbW2w4UQIHB+o4rmdRTUufqejDETpzjK3wrRLq+54oviKaGf5QSoOQua9Y8GaoLvS7abb9nd8g5OM1VtPhxocJQX7y3G0ZDR5Ut9R2rN8aQy6bpezTYmht4iEXg/KKpuCjyR1uzow9avObdeV42v53O91b7Y2lSpDKSxXG5e1eNaha3N5fG3VZeGwf8AaNd98M9Xv73SJI7iUN5ZwGcZzUPiHVJdN1ELa2MLTDl5CvetqMXRqONrnBWqqpG9rGOv27wZpU2oRuIrh8JGP51zdv45164Msz3r5dycDoOBXZywSeMNImguJQsqncp29D6Vg6R4Cv47VlngZn3nlfStoa1G6tjzcVHnivZLTr6n05PO7wBkO0jqCeleP/Eq2bV1kt2UZVshwOc167ebLR5Wk+4/T2Nct/ZltrNteKXaORyenXH+FeThZxpPmZpRhGdF+6eDWepah4c/dQIqncNzHqcV2/jazh1/whZX0kJW6bvjvS3vhCygvjDLLnkuSx6gelaNr4v06bR7nRYLQkqNsbkdCO9epOa54zprbcispziovXscpbaK1/4S8i8GGhB8st2rC8H6fNaazvbcExzjvXReItTuNMtY7ZUJWRQSal8KywStGspHmk4/Wru1TbezO6EYuqmt0bOvbZtImiyN7KHA7YFeXW2o3OnX5aCVo3Q9B39q921Dw+2o6dJHbFUlKnBPp6V5Hc+DtVg1MxPbMd3AY9D+NLDTg4NNnPiKz9te51ugxW9/5N+yhXkXdjHQ11MVkrEY5z0rO0HQHsNPggcncow2OldZpmms8iBQcCuOrOzep3zrQjDsamnabmzwBjIqndaZMu1SpwvcV2NnF5UIU9qlaNXB4rz1iWmeC8dKM2zyXxDZ77SVeSuDuAPIHrXmOk6lN4e1E31pM5kBKMD/ABp6GvXvGOj3Ntevc224ow5HauSsNIttUaWKSLy5Rztr1aE48muzO5V44lJPchTTNKvruPVLAlhJ8xj28K3cVtWcVzc3T4TKJ2x1Na/h3wslmgWNMgnJ9q9C0nSbe1jB8sFzWFbEqO7ubzxkMNT5Yo4aDw7d6ioS4hUW7DkNzmsbWfgwt2kn9n3htQ3IXqAa9l2jjAGKdXEsdUj8Gh41XGzqu54foXw58Q6BGYW1OO4t8YKBTXjPjjwrq+g6rLLdxSPHI+5JQM5PpX2o0YNUL/SLTUEVbuFHCnI3LmuinmLv76B4nmgoy6Hzeuiz6j4Ri1PXJhDMVwoIPIHQketZngaeCz1tPLmdwQU+7gGvoHxXoFrNpjRFVVMY6V4xa6FDaeI4maVVVX4wOPpXoUMRGrBnXRrXkpbnVXelafqEyy3ceG6ZHFWbaCKzzBZpFGmM7Qwyff3pmuzJp9v5rKWAGQo715fd+IY31cySymN3IIH90CphCVRb6Hp1JUoS50k2z2W21a7ggNsJWCEdCeKxfEniE6dYv5RZbkDKuegrK0/xtpM1zDF58TTNhehxn61PrF7ZnK3arJu6A9KzjRSl7yKlyyTcLLuc3qOqWviW1X+22MTjpNHzz70WeiINK1C209syTR7PNPDY9hSzWtpLJsghCox7Dmul0yzisbTYj75mGSemOOldUmoRtH7jmVBTev3nNeHLC38GacbjUpo/tNx7dq6nTNQi1CBZ4zuXOB9K858Z6XquoajJMFacIAFVewrNsNb1bT0S2to5IznkrHn9CKbpOoubqONSNB8m0fxZ61qur2+lW/mSSFEPX1wK8X8ca6utavJcW+fs4+VAwwcetda9pqWpWDXF9GzPjGHwMj1wKfpPgm0Maz3JYyMMhCeFpQhCnrJ6k1VWre7TWhwnhrVdVg16we2mnYqyoIwxwy+mPSvQPiH4h1e2uGt7fNvEykBwOWz1GauWTaH4Z8y4hkgkvVBG3AY/h6VG/wASLIRSRajpyTjOVDKDj/69S0m7qN0jKnSnRi7ys2cx4IutXnvltWFw1nKMMZAcKfUE1Y+J2lG0sbWS4ZvNViqknO4da7rw54ki8WXCwWiC3aMcF8YUfhUPi3w1/bUYtrm5DMjfI6+tKUveSasUoxdNxlK7PNPh7punXt/Imoy4JACJ/er1jTtEstLyLCERbsbiTmsfSvBVtoUUdzPcMSh+7sGTXVGEXNuwhdd7DIbt+NKtU6Qeh0YOEYxtNanNa3o2nPcC8t0jj1GFtwMfAkPXmuIunN/fsNV3vcZOV2n/APVXoltp93DcSLcwiSNv4lYVswWGmRBZRY+Zcj+JjwKI1lTWuoqtOVR2irDfAOnWNlps2nrA0VvfxFXQ8kFhivP7T4Vaxaay/wBpmt7WzjlykxkBZlB6hRzXpXnRrG7ZZGIypU9DXAfELX73TbuCTzXeQqGRT0x6msISn7Ryju+5FbCwjFa2S/E9D1j7BqNp9jw0gCBC7dX461mWNhDo2nSiANK4BYsepwOleVaf8RNVilZ5jG467dgAr0Pwn4oTxEjh4xFKgzmM8GnKhUjB226m9KrQbil02MzQfG7S6mVut8UbnaCDnBrT1HxF/pjafdWYuLZ+Ax6ipLjwdp1zfG8IeJnbcVU4Ut64rW/sxQplCLLt7jrTbpKzSJUJNvmdvMNItLOys2NvDs3dqy9QgttUncRyIJ14ZSea2HVZkaFcp8uPxrxLxlFqOmaxMIZLhFByHUkZpU05TbvqXXqKML2uj2HQdFGmBpEIYMM4qxBrgKti0LAMRkmuA+HPiLVZlWO7V54s7d5HNem22n2ciF9rZY5OKdaDjL94YUqkZU70lY7bWUlmhlVVzjOPeuBt7iayu1lLMjo53DrkZ5FejyOost4zzya891ARzXcxQsZkYsR6j2rzKb5oWNsrdlKElojzz4s661n40gkt32qkasAOmD6128OkaVd6Pbayw+ys652FcE/hXBeN9M/trxvo4APkTYVsex5ruvjpElr4ZitNOdovKUBtnAx6V6V25U6adm0efObptpq9m7GN4oit7u1iVGQkfdYc5FYng3T5LjWtoZR5LjcPamfDS2aTwuskzl1eRwu45wAQKn8BTvJ8QJbdB+7ZmXHsuOa052qUl2PRqKNoVduY9107TyFDZwcdu9Pu9O3nOAa14ECIoA7VLtBrw/bO90fPyxEue5ziaUXccDb9K27S0SBAAozVlUCjIpw+lTOq5GdXETqaMTGO1OUEiinDjisjC5FdW0dxGUkUEdOaxIvDFpHdeei7W9u9dCPTnNLn860jVlFWTHGbjqivb2qQcKBxVnoPekPHTk0tQ5N7hKblqxSR64oHWkHencY75pCEJI70ZpCQDxQf1oApaxa/arR0HUjivMr3w1PJOQYsMpyGr1o1GYkY8gE+tdNHEulsaQqcp57PookskFzGW2gA1wHiT4VNqM/nabtibBxnoK+gRChBDKKxdau4rWEfZ3RpGO0KOa6qONmn7p6FGf1iXJY+ZdI+GOunWYobkRJGrf6wP8uK9fufAumi3SO4vGeQAD5FztrvItMhewR3QeY43MwHesi6tXtwSOVHY1vLGSqO0dLHVh4QbcYyZw48GomoQyWs0hgjPKMetddZaDDKrbEXeBzkc02GYkZOV9KsJdSRkMjEEd6VSrOSOueHmo2gzC8SeG5rWzklsYt02MAAV5nH4d8Y3N+gEsixs3QDgc17qur3LADCN9Vpsl9dP91kj/3Vop4icFZq5zSo4mWjf4lDQvBX+ixPqz+ZPtGQOB+VWr/wNYXcbKGeMFSvynsaYst3FOJ/Pd2B5DHg1tWutQOAJsxv3B6Vy1KlZPmTM61HEw1jK54D4o+GGp6bLL9j2zW+SVyuc156+hahBcFZrZ1APIwWBr7Ke7tJUw0sZHuayLxNGVi5t45X7BRmuujmcrWnG5zQ9s9OU8C8O2Er6WptYGt5Ax3EDBIHeur0y2vIIECr58me7Zr0aYxXGR9jiii7AAVGlrCjbkjVT7VpLFc920ehCk7LnWpz9roUt4RLrNwVT+GKMfzNXptDsfKItp5N3oRwK1SvHIpNgKnAAPrWDqN+RryO97nJa1aX+l2Mtxb4n2/pXAavPq0tuZ/7RMY6sqjG2vbCm+IpIAVYYI9a5bVfB9hfMSzyIjfeQd61o1op+8iKntX8LPKdE1HVy80S3C3ADAljyea9RtNM0/U9Ntm12zEzquAWHQH3q5pXhfTdMXFrAoUHPrk1tlm2bCFxjHSqr4iLfuKxnGjVmrTOYu/DXhSGxeG10iNpX6NjkVW0nwwbaN/7Ot0h80/NXWCFQdxAzVr7VBYWoklHJ6KKw9vKKd22axw6pfAtTHt9AmhGZZN59M5pfsJQFIjs55J71oW3iC3nmWOSPy9/3Tuz+lSXwCyBlPBqeeT3NYxk3yz0Znx6JJcKcX8SseAu2s+/8KX8r/vIFmx0O0HNarNjBHWrUOsXMC7eGA6Gk5zi7oUqFZfw5X9Tl7Twpq0bMRbRW0Q7mpY9EnjBUX44PYVvXeq3d2Nkj7U9FqCA/IfrT9tNq8kVTw1Vr95L7i5o+oLqXhiC4jcksCCR35rKsLdU1WOdt2zcyso6cDvVDwGLnTvC0VrIodFJOe4ya2PPWK3CwcysSW9qwhBxjyMcXyqTit3+ZnWFnZz+I7QTWyCIs6oT/CcZFVfjRpmoX3hpm0m3kuLgMElSIbm+uPpUimVLxGc8xvuL+lM1Pxdf2V2rW5jcngnPFdEHUVRTSvYwxGAlWko0Wlocn4G0a90fw5axanFJb3MjvIIpBhlB6ZHbpV/4WeH5Lj4h6nqZXbDCuxfdm6/yqa51a61CV7q8kDyIhOQMAd6d8HPE8cmp3kEn3pnJHvWlVyVGckty8XTdKhCnL4lc9sHpTh0po5HFOA4rxj5Zjs4HXpSqc9DWVrd21vBhDhjxn0pPDYlNo7zOzbjxmr9m1HmOr6q1Q9u38jYB54pR60gGccUfhWZyDh0zS/lUbNtWqC6oouDFKjDJ4OKai3sa06M6ibgr2NPt70UgYYBHQ0o780jIUUoJpBjjFFACjmg+lGc0nWgAI/Kq11ew22PNkVfqasHpXnXjfTNUudTjayDPERzz0rWjTVSVm7G1GEZStI72K5gvYHWKQMpGCVNY40W3hZQNxA55pfCWnS6fY/6R/rH6j0reZAcHv61Un7KTUWbxrfV5tU3oRQoRCqDnA4qpKitKUkADdeehrRUACory3W5hKE4cAlSOuazjLXUzpVbTv3Me+s7ZocylVAPBHFZ32FGi3QMJB2INc+mrFZJGv3IWLI2+p9MVp+A5ri8a/kkUrblgUU9j/wDqrrg5crfY+lnhamGo+0cr7ehMYXRdzIVI9KRJBnB4b0roZIcggiqNzYo2Gxgj0qo1Uznp4uMtJGeDxSMgbqBQ8bQHrlT3NKSK0ub+aITAuc4GKl8tFHygCjeAf8KA+DRcrUbIcLng06Jtygnoe9V7g5Q+1Zramlts81tsbHFS5JbmtPDyqLTc2JNysQmGHrSgkDnmobGaO8iaS1lVwnUZ5qYH2oTMpwcHyvdDjnGO9RsvAPcU/PFDEYpkDMD/AOtTWHPrTsYHFBx2pXKRGcHtVS/t/tEQXOCDxVz61G+ByRwKasaJ2ZiRaGh1GO8kYhl/h7GtqeTzWz0AFMMgDAdzSSc9/wBKqTcrX6F2vLme5G4/KosEipiOOelRuTgYxSNY3I/yzU8XCkEd6iyBx3qSIjafrTdrFvYr20gFs8iAqy5DL7VhR6kLaWR5AWQHcR1NaOnanazWN2kzmOTDbMjrXmOrX76dO8r72jB3AE9a2p0+dNPocuFim5X0O+1PVIZdP8y2EqrK2CHHf8KzrvTVuYYSkypIozJGO9M0v4gaLH4dSa/tdzhtoiABJbuadD4htLjTr7VbIfK67cMOfpinTUl0a1MnV99wS21vcS0ubK4tLhIJBJ5eVYjt7VxfwxSU+OSIQdnm8fStTwYhltb2Oddvmylj6jNegeEdP0fRNX32y5mk4JJzirqyUITgYY2cpwhV7pnqsQwi/Sql9qdvZzxwyt879BVtG/d7hzxkVzUmjNqGoSXN3I+4N8ozwB7V4cYqSbvY8fB0qVSbdZ+6iXxxfx6fpIl2h5pDiMH+dO8DTX1xphkvc7SflBGOKt3+ix38tp9oO6O3HQ96140SJdqKFUdMVUpJwUTpliqUMH7Bayb37Ik/CkIxSZ70A+1YnjjhgjFRNBGzDK8jmpOD+FKOaabWxUZuOzFUYGAKVeTim8A5p8fU0mJasy7/AF7T7C6WC5kYN3wM4+tUrbxjpk14LaQSwFjhXkHyn8e1cX4qgmXxPfpKDiQAp78dq6ax8MCfRIUuxtn2A8jmut0acV7z3R9KsvwVPDxqVZO8jom1O3Gomz58zGc9jV4EGuG1SxutOnsViZpMLtLd+vArsrTd5CeZ97HNY1IKNrM8vF4WnTpRqU3e/wDVyY9RTSoPand89qQmszzvMPpQMY70e1AHFAheD2qtMg89JQPmX0q1TCoPXFBcJcruc5qXh7RtRvDcynyps5cA4DGtSzitrSAQ2kapGOgHf3pNQtVkPTn2qO2tGAALEYroc3KNnLQ9P2qlSV5u3YsuuQcVE0ZKnPWp0Vl9SKiuH2jBByayTsznhJ3tEx72EvlVqg1vMGCqQx9DXRW8HmOcn86ivNMDSIYnYAnnFdSqpaHp0sWoP2bZl2qPG5WSP5h1IGasXEcUgA4V/wC8Olbi2yJEEUcYrnvFMDWunm5iyPmCtjsD3qVWUpWQqNeOIqqN7NmRqUMkUqxLIMP39Ky9SsUmtmhl3Iw5IxkH3rXstGvbi282SUuPvKCf5VHO/mrmOUw3KcHPIatk++571OqoNRg7tbnO6BBFZ36jzmRXO1vQiurumWG5KRnch5U1z7200rvIyqXB5ZOlW0Z9iBskqOtL338Tub4mnGtP2l9epsK3HrS/yqnC5LDnirYPHWrPLnHlYHryKZkFjikZlB9DUQZjI27G0dPekkJIlNNYdaYzjg5oJO0cYppdS0rbibcPkjNMfjPXGacWxUbPmmaJMa3rTG7+lObkimsSH2sMGi5ohmOTzU0X3TjHWonIp8Qyp+tJ6op7HNRT6TJplzdtNvjg5YqvWm6TL4Y8UWbxeXGXUYO8YYfX/GqdnqVrY6zPoUVoDBljuY7i57g1saTpGiLdGWyt1iuGyCQentitqj9nq5NO+no+55MZTrq1rxa+aOH1/wCHoiuVjtJoUgBJDk9j1rRutItdP8Nm0092kCAsztwWP0rpNfXyUSIkbh0qmLJxbyLtysmSOegrf20pJOTM6NP3rLqjkvCSJHbTyhmZm+/u61pabeM3iFVVyfmGKZplmbK/mgfpKMiuy8A6BaXt9LcyD/SLdsEfyNFecYqUpdS66aw0Wuh6dp277JDv67RVnjr3pqAKox24pe4rwGfOSd3cf1oNJSg0iBfwqGa7ht8eY4GeOtOnkCRMzMAB3PauRMR1zWIhBuFlCw3Pn75rSnT502zuwmFjVvKbskdr29jRxjFBx/D0HSk6DPesziYtMnmNtbySgAsoyB70/tUF6jSWkqoMvjgUKzaTLpJOa5tjznUNYubfxlp1xrsMZti2EYDAweAfwJr1OY7uR0rw7xV/aWpaxDbzwSCKE7idpwFHvXqnhLVjqml/OMSxHaT611YqOkdLH0mb4VOhGtTaajo7dDXZFfG9c46Z7U7PPAopABziuU+YbewDr6ij1pB1ozQIUelKOD0pueMmjJyOKAHA80GmqaJpFihaSVgkaDJY0DSctEIybutLt244FNtp4rq2Se2kWSJxlXHQinnqM0eRTuvdYe9MKA9BT/pRQJO2xRuJ1tI2cqzYHQda5ix8YebeNHLAwTdhT6V2ZUdSAcisu60a0uphKIVRwfvKMZrSnyfbPWwVfDRTVeF79SzaXRlJJQqDSX8cOoWc9qHQlhjGe9TLEfLxGVZQMcVydpb3TXjCDd5gJyacYczvHoOjQhVm5xfLy7DrPV30uCayu4n3xZCHHUVL4b+z6gJFmhVi/wA3I5FU7kXtxdNFKwLDjJrQ8J2yxW88oObgMVb2raWic9ro9XExhChKW0nbVFTULFLS8KwgBD2qvhEYqVwPWr2p2VytwLl2BjZvyNVTJtuCLhcr2IrSE3yq46U3KC96+gpjC/dAx61E0y5x1NDuyBhHzEay7m52EgZB7mnKXKrs6aFJ1WWbuXbMCOBt6djVKS+YfMBmoCYpl5ldZM9+lQTxSBiDklepFZSlLSx6dHDQWkjWtPOumG0rntzUwkxO8EpMcq9j0rBt5Jo5A0TFSKuW1yt5q8YueUPyu2atTbaRNXDct5fZSIfFF9d6fYJNaQGdt2Dj0p3h29uL6wWa5hMLkkbT/Ot7TrERrcJchjbkExM3Y1XtbSe5ysYwAe/FaRmrW5ddzzXy8z97RDWPXNMPrnJqW4tri3x5qYHrVctTTuaxaavFjiOOaWOQKCM9/Wo5G+SqJyWYj1rKrNxVkdFKkqm4nh+DT7lGvLuPy7+UEF+v/wCqpDp/2aVposFckgqetclo9zPLEyzZWdcgr0yK1dEvzKZbeaVkkQ8AmuqUJxTT1R4tGMIzTpvRm5FCk3mXl6m9UX5EA7+lcJdeOFt9VMepjajnaqRr8sfNekaU7CcJMysMZGRjNc74v8DWGoTjULWIOxbcYweAfX6VFKUJ3p1NH0N1L2dS8Unfv0KoNndMssE8TzjnarAkA1q+H9ROj61FcN/qHGyT3U9/wrgtI0Gey8TNd+YY4lJITu57jFd4LQXtm0lsDJGPvBeqGtakFbkk7pmtVJxcZqyf9XPVBcQmATrKphIzuBzVGw1T7ddOI4WSBOA78bvpXBeHNZbRnNvfuGsT90t/DXolqsFxbJLbMGiYZBU8V5k6ap+7Lc8CthIYe/NrfZl0HPpSj0pkSBFABp/p3rA8tpJ6GNryT3ey0hyEY/Ow9PSr+mWa2VuqKAMDoO1W9oByO/enAdwK0dT3VFHRLEydJUo6IBwaeAT1NNHJGOtZHiu8ns7NRakLJIcA+lRGLnLlRnQoOtNQXU2iARw1IBivNND8T6rBraWl9++iZtp45Hvmu+1jUEsLQSt95vu1VSlKm/eO2vllWjUjT35tixdwJcWs0RQHzFIrK8K6U+k2lwspBaV88dhXFQ+JtWhv5Zo5Hkt0fLK/K4/pXV+HPFMmvahJCtiY4UXcX3Zx7Gr5ZqNrafoduJy7F4WhJXTg7N6nR5oA54pfWkIrE+fsLim+1O5IpAKAsJj9aDgDmnCmEZXBNAW7iqe45FYHjz7U/huRLRGYlxvC8nbW+BtHFOU4B4/CmrX1N8PV9hVjUWttThPhzeSWiDTLjOxssgYfdPtXdEYrF8V3EWlacb+C2ja73AIxH3feqvhrxG2pRhbkoWP8SjFa1Pf99HqYqhLHJ4yjGy6rzOkHv3pc7aKQ4IIrA8Wxlz6kwuPJhgdjn73YVZvdh0+f7RKYIzGQ7KcFeO1WRGqnIH6Vm+JbaW70iWG3BLEgkDuKt22ijupSpTqQilyq+rPNLS/On3Mp0/VpYY9x+QAsWHrtruNM0mXUtKS5fULgSTDzEIUIVNQ+DfCltbRG8v4d05JARxwPfFdcSuNsYAA6ADFb1KqWkbX9D1s1x9Pm5MP066annyTXmm6r5WpfMwPEmOHHrWjBqSWOuvsObSYDdjscVvX5trgMs0SyhRy2Olc7PNZPa+VFBtYcZNONpF0q6xcbVIdLO35mrrF/BNZhLeRZCTng9KwpJhIu1xz2IqGFEiHFI5BJbvW1OlyKxtRwsaK5IMmV/wB3t7Dnms6+Ecd4k8iAoRyoNXVYqy8cGuisNItJrYSTRB3b1oqPlVy54qOEfPPW/Y5GS9tZ4xHGiIR0GOTVj7TBL5ckUSpsXbImcgn1pNZsIdG1VJAubV+SMZ2mkt7ddQuZpLLGe6DuamMm1dO7O29GcFVjdR7+oXtosoxbxhC43fLyKyY7GSIZA+cGtdxdWG3dwG45qzpls1xP5ivgLT0v5lQxEqNNu94lW81ud7aK3EYSQdT3rLS9vLSQS+Y2SeVNX9djMerqz4UkYJHSoL9op0RUI8zPWsko2cutzegqahG0dJbnU3Fwt34ZllAUuuPqK5g5Azg4qK0vN0Eto4bjowao2d45MBjiqVoPm6M58PgXRlOPd3JpZAFLHpXN6l4ksbC7eCcSeYME7Rmt0HzlkTdgkZFeb+JX1GLVpEW13qAMNtzmtVS9tY2qS9hFs96l8P2Yld1hXJ7gVxviXwyqTfaIi0co/jWvUm6NWLrn/Hm/0qKFefNZs+IwtZxfL0PPred1jWOd8uByw9K0t5ltpI4ZlDspAY9qzp/9c9Taf981rVgl7yPp4S546kek2iafGov9s8wyPNbsK09HnSxunlTaYZMqwHPBqG8/491pdN/1bfShSdRXfUzrxTjZmd4z8PSahpzm1k3xbtwArlfAPi298K6y+malK8lgx2rnnyzXqkP/ACD3+leO65/yGbn/AHq6aSjXpulNHDVV7N69PkfRthdxXdukkLAowyDVod65/wAEf8gGy/65iuhrxpRs7HiV4KnNxQmRSj2NO9KUVBkVb6/trBFM7gOxAVe7H2FYXimKa7sWYnymAJjBPLcdKZ4q/wCRgsvoP507xP8Adsv96umlHklFrqe3l9CKcZrc5DwIBcasn2xhviY4Xqc16XrOmQapbpFKzJtOQyHmvOfDH/I2P9TXqq9BWmMXJNOJecYmcqkZrRpHK6/oKQaEINO8uOIMWmkkPJAFYvgHXoLW+k03yEWJ+fN/iJ9/aux8T/8AIAuPpXl3hf8A5GKP/drOMnUg0zvy6P1rA1FWd9TsvEni2bR/EiQbY3swqlh3IPcGujh1ewubT7TDOhXGSM8j8K838d/8h9f+uSf1qLQvvP8A7lZypacy6JFvKMPVw1OVrPuup6C/iKwVh5kmwE4BPetgcgEDg143cf8AIYt/98V7QOifSs0rx5jx84wNLBuCp9UR8Uh6mnnvS+tI8UjpaUf1oHQ0WBFTVbGHVLB7WckI3O4dQa5W08J32mais1pJFLCeGydpx7iu3qQ/c/CtYV5U1yrY7MPjKtCLjB6MrHhRzyBzTFlXeEJAYjIHrU/f8Kpy/wDH5D9TUJcxhBKe5aB7VDJPFETvmjUjqCwqdu1ecap/yF7n/eNJK7sduBwccS2m7WOwm1uEMdrLIB6GsPUtduJ5QlsRFH696yoPuGpW7V1woR3Z7lHAUKL5krslnv5Ft9m7k9T3NWrK0Nxbqy8s3HFULj7ldN4a/wBUtaS9xtoMU1Roc0FZ3OcuEMM7Rsy7x1ANMjilnDeVE7gdcCo9R/5Ge6+tdhoH/Hm/+9U+0fJzMdTEOlTjJK7Zy2nnzma2k+SZPuhuOK39EupEj8uTlM4ye1ZWq/8AIeH0rY0f/Vt9aJ2lC7McbadO7W5k+PCptISrZfd0HpWBopnhvhNbMAznG0d62fFf+sk/3RWdo3/H5bf7wrOjZL1PRwS5MDy76MdrTXUV1i8JcNzjH8qdb6l5LJ5EeI2ODk1q+Kv9an41gjp+NEZWj6l0FGtQi5I0NTgV7qN7jGxwKxbxLeG5/wBGLSD0x0rU1D/XQ/7tVbT/AJCEn0qqSVR8trbm1BunBSv02M3TzlXIUGQk5B6j3qVlkfmQbdvb1qY/8f351MelROotNP6R1ufvXKakDAX7x9O1WYfK2nzQrNnqaIv9c30oHVvrVe2ktY6MUoqWjP/Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This biopsy demonstrates the presence of eosinophils within the blood vessel wall of a patient with the Churg-Strauss syndrome. Although eosinophils are the hallmark of Churg-Strauss syndrome, this biopsy does not show fibrinoid necrosis of the blood vessel wall and, hence, is not diagnostic of vasculitis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_34_36387=[""].join("\n");
var outline_f35_34_36387=null;
var title_f35_34_36388="VSD closure device 2D";
var content_f35_34_36388=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1181px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/81090/VSD_closure_device_movie.mp4?title=VSD+closure+device+2D\" style=\"width:496px;height:400px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 565px\">",
"   <div class=\"ttl\">",
"    VSD closure device 2D",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 545px; height: 345px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This&nbsp;is&nbsp;a movie&nbsp;clip from mid esophageal apical four chamber&nbsp;view obtained during intraoperative transesophageal echocardiography.&nbsp; Still on cardiopulmonary bypass, the VSD device has now been deployed and is stably seated on the muscular septum occluding the large defect. Note that the delivery cable has now been removed in the real time image.",
"    <div class=\"footnotes\">",
"     RA: right atrium; LA: left atrium; IVS: intraventricular septum; RV: right ventricle; LV: left ventricle; small arrows: Amplatzer VSD occluder device; large arrow: delivery cable.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_34_36388=[""].join("\n");
var outline_f35_34_36388=null;
var title_f35_34_36389="Etanercept: Patient drug information";
var content_f35_34_36389=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Etanercept: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/31/28151?source=see_link\">",
"     see \"Etanercept: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/1/32790?source=see_link\">",
"     see \"Etanercept: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F167887\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Enbrel&reg;;",
"     </li>",
"     <li>",
"      Enbrel&reg; SureClick&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F167888\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Enbrel&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10025914\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700828",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       TB (tuberculosis) has been seen in patients started on this drug. These patients were exposed to TB in the past, but never got the infection. You will be tested to see if you have been exposed to TB before starting this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700912",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may add to your chance of getting lymphoma or other cancers.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700487",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad infections have happened in patients who take this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10025916\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691734",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat arthritis. The arthritis is most often moderate to very active and may not have been helped with other kinds of care.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691726",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat ankylosing spondylitis.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692062",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat very bad psoriasis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10025915\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702070",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to etanercept or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702364",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to latex, talk with your doctor. Some products are found in latex.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703161",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an infection.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10025920\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696985",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hepatitis B testing may be done. A hepatitis B infection may get worse during care.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad infections have been reported with use of this drug. If you have any infection, are taking antibiotics now or in the recent past, or have many infections, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697613",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before getting any vaccines. Use with this drug may either raise the chance of an infection or make the vaccine not work as well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697206",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), talk with your doctor. You may be more likely to get infections.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697311",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have MS (multiple sclerosis) or other nerve disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10025921\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698189",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Irritation where the shot is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698315",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may have more chance of getting an infection. Wash hands often. Stay away from people with infections, colds, or flu.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3796283",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Damage to the nerves. This can be long-lasting.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10025923\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699024",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699094",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling in your legs or belly.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698988",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Numbness or tingling in your hands or feet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10025918\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696001",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into the fatty part of the skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696360",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Your doctor may teach you how to give the shot.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Move the site where you give the shot with each shot.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Throw syringe away after use. Do not use more than one time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694881",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow how to give closely if you or a family member is giving the shot at home.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696118",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Throw away needles in a needle/sharp disposal box and take the box back to your doctor when it is full.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10025919\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696565",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it. Wait 3 to 4 days between each shot.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10025924\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699391",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a refrigerator. Do not freeze.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699161",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not shake.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10025925\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12442 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-189.41.172.26-C9598D4138-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_34_36389=[""].join("\n");
var outline_f35_34_36389=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167887\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167888\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025914\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025916\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025915\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025920\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025921\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025923\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025918\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025919\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025924\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025925\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?27/31/28151?source=related_link\">",
"      Etanercept: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/1/32790?source=related_link\">",
"      Etanercept: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_34_36390="Cetirizine: Drug information";
var content_f35_34_36390=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Cetirizine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?27/28/28100?source=see_link\">",
"    see \"Cetirizine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?18/7/18549?source=see_link\">",
"    see \"Cetirizine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F148795\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      All Day Allergy [OTC];",
"     </li>",
"     <li>",
"      ZyrTEC&reg; Allergy [OTC];",
"     </li>",
"     <li>",
"      ZyrTEC&reg; Children's Allergy [OTC];",
"     </li>",
"     <li>",
"      ZyrTEC&reg; Children's Hives Relief [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F148796\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Aller-Relief [OTC];",
"     </li>",
"     <li>",
"      Apo-Cetirizine&reg; [OTC];",
"     </li>",
"     <li>",
"      Extra Strength Allergy Relief [OTC];",
"     </li>",
"     <li>",
"      PMS-Cetirizine;",
"     </li>",
"     <li>",
"      Reactine [OTC];",
"     </li>",
"     <li>",
"      Reactine&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F148840\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Histamine H;",
"      <sub>",
"       1",
"      </sub>",
"      Antagonist",
"     </li>",
"     <li>",
"      Histamine H;",
"      <sub>",
"       1",
"      </sub>",
"      Antagonist, Second Generation",
"     </li>",
"     <li>",
"      Piperazine Derivative",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F148799\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Perennial or seasonal allergic rhinitis, chronic urticaria: Oral: 5-10 mg once daily, depending upon symptom severity",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F148818\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?18/7/18549?source=see_link\">",
"      see \"Cetirizine: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Perennial allergic rhinitis, chronic urticaria:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     6-12 months: 2.5 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     12 months to &lt;2 years: 2.5 mg once daily; may increase to 2.5 mg every 12 hours if needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Perennial or seasonal allergic rhinitis, chronic urticaria:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2-5 years: Initial: 2.5 mg once daily; may be increased to 2.5 mg every 12 hours",
"     <b>",
"      or",
"     </b>",
"     5 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &ge;6 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F148800\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Initial: 5 mg once daily; may increase to 10 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Manufacturer recommends 5 mg/day in patients &ge;77 years of age.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F148801\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &lt;6 years: Cetirizine use not recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children 6-11 years: &lt;2.5 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &ge;12 and Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     11-31 mL/minute or hemodialysis: Administer 5 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;11 mL/minute, not on dialysis: Cetirizine use not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F148802\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &lt;6 years: Cetirizine use not recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children 6-11 years: &lt;2.5 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &ge;12 and Adults: Administer 5 mg once daily",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F148773\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, liquid gel, oral, as hydrochloride:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     ZyrTEC&reg; Allergy: 10 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral, as hydrochloride: 5 mg/5 mL (5 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Syrup, oral, as hydrochloride: 5 mg/5 mL (5 mL, 118 mL, 120 mL, 473 mL, 480 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     ZyrTEC&reg; Children's Allergy: 5 mg/5 mL (118 mL) [contains propylene glycol; grape flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     ZyrTEC&reg; Children's Allergy: 5 mg/5 mL (118 mL) [dye free, sugar free; contains propylene glycol, sodium benzoate; bubblegum flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     ZyrTEC&reg; Children's Hives Relief: 5 mg/5 mL (118 mL) [contains propylene glycol; grape flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as hydrochloride: 5 mg, 10 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     All Day Allergy: 10 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     ZyrTEC&reg; Allergy: 10 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, chewable, oral, as hydrochloride: 5 mg, 10 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     All Day Allergy: 5 mg, 10 mg [fruit flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     ZyrTEC&reg; Children's Allergy: 5 mg, 10 mg [grape flavor]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F148758\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes liquid gel capsule",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F148776\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be administered with or without food.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F148775\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Perennial and seasonal allergic rhinitis and other allergic symptoms including urticaria; chronic idiopathic urticaria",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F148846\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       ZyrTEC&reg; may be confused with Lipitor&reg;, Serax, Xanax&reg;, Zantac&reg;, Zerit&reg;, Zocor&reg;, ZyPREXA&reg;, ZyrTEC-D&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       ZyrTEC&reg; (cetirizine) may be confused with ZyrTEC&reg; Itchy Eye (ketotifen)",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F148838\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%: Central nervous system: Headache (children 11% to 14%, placebo 12%), somnolence (adults 14%, children 2% to 4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     2% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Insomnia (children 9%, adults &lt;2%), fatigue (adults 6%), malaise (4%), dizziness (adults 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain (children 4% to 6%), dry mouth (adults 5%), diarrhea (children 2% to 3%), nausea (children 2% to 3%, placebo 2%), vomiting (children 2% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Epistaxis (children 2% to 4%, placebo 3%), pharyngitis (children 3% to 6%, placebo 3%), bronchospasm (children 2% to 3%, placebo 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;2% (Limited to important or life-threatening; as reported in adults and/or children): Aggressive reaction, anaphylaxis, angioedema, ataxia, chest pain, confusion, convulsions, depersonalization, depression, edema, fussiness, hallucinations, hemolytic anemia, hepatitis, hypertension, hypotension (severe), irritability, liver function abnormal, nervousness, ototoxicity, palpitation, paralysis, paresthesia, photosensitivity, rash, suicidal ideation, suicide, taste perversion, tongue discoloration, tongue edema, tremor, visual field defect, weakness",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F148779\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to cetirizine, hydroxyzine, or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F148762\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment; dosage adjustment recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; dosage adjustment recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sedatives: Effects may be potentiated when used with other sedative drugs or ethanol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly; may be more sensitive to adverse effects.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F148834\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (minor), P-glycoprotein;",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F148767\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): Anticholinergics may diminish the therapeutic effect of Acetylcholinesterase Inhibitors (Central). Acetylcholinesterase Inhibitors (Central) may diminish the therapeutic effect of Anticholinergics. If the anticholinergic action is a side effect of the agent, the result may be beneficial.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: May diminish the sedative effect of Antihistamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzylpenicilloyl Polylysine: Antihistamines may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Suspend systemic H1 antagonists for benzylpenicilloyl-polylysine skin testing and delay testing until systemic antihistaminic effects have dissipated. A histamine skin test may be used to assess persistent antihistaminic effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Betahistine: Antihistamines may diminish the therapeutic effect of Betahistine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Antihistamines may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving antihistamines (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F148792\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     Ethanol: May increase CNS depression; monitor for increased effects with coadministration. Caution patients about effects.",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F148782\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Maternal use of cetirizine has not been associated with an increased risk of major malformations. The use of antihistamines for the treatment of rhinitis during pregnancy is generally considered to be safe at recommended doses. Although safety data is limited, cetirizine may be a preferred second generation antihistamine for the treatment of rhinitis during pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F12889211\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Cetirizine is excreted into breast milk.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F148783\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken with or without food.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F148781\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (ZyrTEC Allergy Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (25): $18.78",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chewable",
"     </b>",
"     (Cetirizine HCl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (30): $160.92",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (30): $160.92",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chewable",
"     </b>",
"     (ZyrTEC Childrens Allergy Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (5): $6.12",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (12): $10.80",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (KLS Aller-Tec Childrens Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg/mL (240 mL): $9.79",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Wal-Zyr All Day Allergy Child Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg/5 mL (120 mL): $9.99",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Syrup",
"     </b>",
"     (Cetirizine HCl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg/mL (120 mL): $36.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Syrup",
"     </b>",
"     (ZyrTEC Childrens Allergy Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg/mL (118 mL): $9.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg/5 mL (5 mL): $1.09",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Syrup",
"     </b>",
"     (ZyrTEC Childrens Hives Relief Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg/mL (118 mL): $10.87",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, orally-disintegrating",
"     </b>",
"     (ZyrTEC Allergy Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (66): $34.02",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Cetirizine HCl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (100): $249.40",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (100): $249.40",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Wal-Zyr Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (45): $22.99",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (ZyrTEC Allergy Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (30): $18.72",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (ZyrTEC Hives Relief Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (14): $13.08",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F148771\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Relief of symptoms, sedation and anticholinergic effects",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F148784\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Aceterin (EE);",
"     </li>",
"     <li>",
"      Adezio (HK, SG);",
"     </li>",
"     <li>",
"      Agelmin (GR, SG);",
"     </li>",
"     <li>",
"      Alatrol (MY);",
"     </li>",
"     <li>",
"      Alercet (EC, GT, PA, PE, SV);",
"     </li>",
"     <li>",
"      Alerest (TH);",
"     </li>",
"     <li>",
"      Alergone (PH);",
"     </li>",
"     <li>",
"      Alerid (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Alertop (CN, PY);",
"     </li>",
"     <li>",
"      Alerviden (CO);",
"     </li>",
"     <li>",
"      Aletir (BR);",
"     </li>",
"     <li>",
"      Allergy-Care (IL);",
"     </li>",
"     <li>",
"      Allerkid (PH);",
"     </li>",
"     <li>",
"      Allertec (SG);",
"     </li>",
"     <li>",
"      Altirin (KP);",
"     </li>",
"     <li>",
"      Alzene (AU);",
"     </li>",
"     <li>",
"      Alzytec (SG);",
"     </li>",
"     <li>",
"      Azurex (TH);",
"     </li>",
"     <li>",
"      Cabal (AR);",
"     </li>",
"     <li>",
"      Cerini (ID);",
"     </li>",
"     <li>",
"      Ceritec (MY, SG);",
"     </li>",
"     <li>",
"      Cetalerg (DE);",
"     </li>",
"     <li>",
"      Cethis (HK, TH);",
"     </li>",
"     <li>",
"      Cetihis (MY);",
"     </li>",
"     <li>",
"      Cetirax (CO);",
"     </li>",
"     <li>",
"      Cetirin (HK);",
"     </li>",
"     <li>",
"      Cetitev (MX);",
"     </li>",
"     <li>",
"      Cetrimed (TH);",
"     </li>",
"     <li>",
"      Cetrine (CL, CO, EC);",
"     </li>",
"     <li>",
"      Cetrizin (TH);",
"     </li>",
"     <li>",
"      Cety (TW);",
"     </li>",
"     <li>",
"      Cistamine (TH);",
"     </li>",
"     <li>",
"      Deallergy (TW);",
"     </li>",
"     <li>",
"      Estin (ID);",
"     </li>",
"     <li>",
"      Falergi (ID);",
"     </li>",
"     <li>",
"      Finallerg (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      H-One (PH);",
"     </li>",
"     <li>",
"      Hismazine (MY);",
"     </li>",
"     <li>",
"      Histatec (CH);",
"     </li>",
"     <li>",
"      Histazine (IL);",
"     </li>",
"     <li>",
"      Histrine (ID);",
"     </li>",
"     <li>",
"      Incidal-OD (ID);",
"     </li>",
"     <li>",
"      Lergium (PE);",
"     </li>",
"     <li>",
"      Nosemin (KP);",
"     </li>",
"     <li>",
"      Ozen (ID);",
"     </li>",
"     <li>",
"      Prixlae (PH);",
"     </li>",
"     <li>",
"      Razene (NZ);",
"     </li>",
"     <li>",
"      Reactine (FR, MX);",
"     </li>",
"     <li>",
"      Recozin (PH);",
"     </li>",
"     <li>",
"      Ryvel (ID);",
"     </li>",
"     <li>",
"      Sancotec (KP);",
"     </li>",
"     <li>",
"      Setin (TH);",
"     </li>",
"     <li>",
"      Simtec (MY);",
"     </li>",
"     <li>",
"      Sunizine (SG);",
"     </li>",
"     <li>",
"      Sutac (TH);",
"     </li>",
"     <li>",
"      Symitec (TW);",
"     </li>",
"     <li>",
"      Terizin (SG);",
"     </li>",
"     <li>",
"      Texzine (PH);",
"     </li>",
"     <li>",
"      Tirizine (HK);",
"     </li>",
"     <li>",
"      Tolmex (EC);",
"     </li>",
"     <li>",
"      Tradaxin (MX);",
"     </li>",
"     <li>",
"      Triz (IN);",
"     </li>",
"     <li>",
"      Virlix (BF, BJ, CI, ES, ET, FR, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, PH, PT, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);",
"     </li>",
"     <li>",
"      Zanlan (GT, HN, NI, PA, SV);",
"     </li>",
"     <li>",
"      Zenriz (ID);",
"     </li>",
"     <li>",
"      Zensil (TH);",
"     </li>",
"     <li>",
"      Zeran (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);",
"     </li>",
"     <li>",
"      Zertine (HK, TH);",
"     </li>",
"     <li>",
"      Zetaler (PE);",
"     </li>",
"     <li>",
"      Zetop (NZ);",
"     </li>",
"     <li>",
"      Zetrix (PH);",
"     </li>",
"     <li>",
"      Zilarex (AU);",
"     </li>",
"     <li>",
"      Zinex (PH);",
"     </li>",
"     <li>",
"      Zirtec (IT);",
"     </li>",
"     <li>",
"      Zirtek (GB, IE);",
"     </li>",
"     <li>",
"      Zirtraler (DO, GT, HN, NI, PA, SV);",
"     </li>",
"     <li>",
"      Zyllergy (IL);",
"     </li>",
"     <li>",
"      Zymed (TH);",
"     </li>",
"     <li>",
"      Zyrac (TH);",
"     </li>",
"     <li>",
"      Zyrlex (SE);",
"     </li>",
"     <li>",
"      Zyrtec (AT, AU, BE, BG, BR, CH, CN, CO, CR, CZ, DE, DK, DO, EE, ES, FI, FR, GT, HK, HN, HU, IN, KP, LU, MT, MY, NL, NO, NZ, PA, PE, PH, PK, PL, PT, RU, SK, SV, TH, TR, TW, UY, VE, ZA)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F148761\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Competes with histamine for H",
"     <sub>",
"      1",
"     </sub>",
"     -receptor sites on effector cells in the gastrointestinal tract, blood vessels, and respiratory tract",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F148778\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Suppression of skin wheal and flare: 0.7 hours (Simons, 1999)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration of action: Suppression of skin wheal and flare: &ge;24 hours (Simons, 1999)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Rapid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: 0.56 L/kg (Simons, 1999)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding, plasma: Mean: 93%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Limited hepatic",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: 1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (70%); feces (10%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Allegra L, Paupe J, Wieseman HG, et al, &ldquo;Cetirizine for Seasonal Allergic Rhinitis in Children Aged 2-6 Years. A Double-Blind Comparison With Placebo,&rdquo;",
"      <i>",
"       Pediatr Allergy Immunol",
"      </i>",
"      , 1993; 4:157-61.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Barnes CL, McKenzie CA, Webster KD, et al, &ldquo;Cetirizine: A New, Nonsedating Antihistamine,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 1993; 27:464-70.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dasgupta A, Wells A, and Datta P, &ldquo;False-Positive Serum Tricyclic Antidepressant Concentrations Using Fluorescence Polarization Immunoassay due to the Presence of Hydroxyzine and Cetirizine,&rdquo;",
"      <i>",
"       Ther Drug Monit",
"      </i>",
"      , 2007, 29(1):134-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/34/36390/abstract-text/17333576/pubmed\" id=\"17333576\" target=\"_blank\">",
"        17333576",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kaiser HB, &ldquo;Cetirizine in Allergic Rhinitis,&rdquo;",
"      <i>",
"       Pediatr Allergy Immunol",
"      </i>",
"      , 1993; 4(Suppl):44-6.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ramaekers JG, Uiterwijk MM, and O'Hanlon J, &ldquo;Effects of Loratadine and Cetirizine on Actual Driving and Psychometric Test Performance, and EEG During Driving,&rdquo;",
"      <i>",
"       Eur J Clin Pharmacol",
"      </i>",
"      , 1992; 42:363-9.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9236 Version 44.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-218.28.111.102-8C7B610DBC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_34_36390=[""].join("\n");
var outline_f35_34_36390=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148795\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148796\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148840\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148799\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148818\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148800\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148801\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148802\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148773\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148758\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148776\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148775\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148846\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148838\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148779\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148762\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148834\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148767\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148792\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148782\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12889211\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148783\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148781\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148771\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148784\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148761\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148778\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9236\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9236|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?27/28/28100?source=related_link\">",
"      Cetirizine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?18/7/18549?source=related_link\">",
"      Cetirizine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_34_36391="Procainamide: Drug information";
var content_f35_34_36391=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Procainamide: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?4/45/4820?source=see_link\">",
"    see \"Procainamide: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/18/38182?source=see_link\">",
"    see \"Procainamide: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709347\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F213545\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Procainamide&reg;;",
"     </li>",
"     <li>",
"      Procainamide Hydrochloride Injection, USP;",
"     </li>",
"     <li>",
"      Procan SR&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F213582\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antiarrhythmic Agent, Class Ia",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F213547\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dose must be titrated to patient's response.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Antiarrhythmic:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      I.M.:",
"     </i>",
"     50 mg/kg/day divided every 3-6 hours",
"     <b>",
"      or",
"     </b>",
"     0.5-1 g every 4-8 hours (Koch-Weser, 1971)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      I.V.:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Loading dose: 15-18 mg/kg administered as slow infusion over 25-30 minutes",
"     <b>",
"      or",
"     </b>",
"     100 mg/dose at a rate not to exceed 50 mg/minute repeated every 5 minutes as needed to a total dose of 1 g.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Hemodynamically stable monomorphic VT or pre-excited atrial fibrillation (ACLS, 2010): Loading dose: Infuse 20-50 mg/minute",
"     <b>",
"      or",
"     </b>",
"     100 mg every 5 minutes until arrhythmia controlled, hypotension occurs, QRS complex widens by 50% of its original width, or total of 17 mg/kg is given. Follow with a continuous infusion of 1-4 mg/minute.",
"     <b>",
"      Note:",
"     </b>",
"     Not recommended for use in ongoing ventricular fibrillation (VF) or pulseless ventricular tachycardia (VT) due to prolonged administration time and uncertain efficacy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Maintenance dose: 1-4 mg/minute by continuous infusion. Maintenance infusions should be reduced by one-third in patients with moderate renal or cardiac impairment and by two-thirds in patients with severe renal or cardiac impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Oral (not available in the U.S.; Canadian labeling):",
"     </i>",
"     Sustained release formulation (Procan SR&reg;): Maintenance: 50 mg/kg/24 hours given in divided doses every 6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Suggested Procan SR&reg; maintenance dose:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &lt;55 kg: 500 mg every 6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     55-91 kg: 750 mg every 6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &gt;91 kg: 1000 mg every 6 hours",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F213566\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/18/38182?source=see_link\">",
"      see \"Procainamide: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Must be titrated to patient's response:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Arrhythmias:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      I.M.:",
"     </i>",
"     20-30 mg/kg/day divided every 4-6 hours; maximum: 4 g/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      I.V.:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Load: 3-6 mg/kg/dose over 5 minutes not to exceed 100 mg/dose; may repeat every 5-10 minutes to maximum of 15 mg/kg/load",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Maintenance as continuous I.V. infusion: 20-80 mcg/kg/minute; maximum: 2 g/24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Possible VT (PALS, 2010): I.V.; I.O.: 15 mg/kg over 30-60 minutes",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F213548\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing. Initiate doses at lower end of dosage range.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F213549\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-4em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-50 mL/minute: Administer every 6-12 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: Administer every 8-24 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Loading dose: Reduce dose to 12 mg/kg in severe renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Maintenance infusion: Reduce dose by one-third in patients with mild renal impairment. Reduce dose by two-thirds in patients with severe renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dialysis:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Procainamide: Moderately hemodialyzable (20% to 50%): Monitor procainamide/N-acetylprocainamide (NAPA) concentrations; supplementation may be necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     NAPA: Not dialyzable (0% to 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Procainamide/NAPA: Not peritoneal dialyzable (0% to 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Procainamide/NAPA: Replace according to blood concentration monitoring during continuous arteriovenous or venovenous hemofiltration.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F213550\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reduce dose by 50%.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F213516\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as hydrochloride: 100 mg/mL (10 mL); 500 mg/mL (2 mL)",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F10076332\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, sustained release, oral, as hydrochloride:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Procan SR&reg;: 250 mg, 500 mg, 750 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F213501\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F213521\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: Do",
"     <b>",
"      not",
"     </b>",
"     crush or chew sustained release drug products (not available in the U.S.).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.V.: Must dilute prior to I.V. administration. Dilute loading dose to a maximum concentration of 20 mg/mL; administer loading dose at a maximum rate of 50 mg/minute",
"    </p>",
"   </div>",
"   <div class=\"block uica drugH1Div\" id=\"F14473099\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Usual Infusion Concentrations: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      I.V. infusion:",
"     </b>",
"     1000 mg in 500 mL (concentration: 2 mg/mL), 1000 mg in 250 mL (concentration: 4 mg/mL),",
"     <b>",
"      or",
"     </b>",
"     2000 mg in 250 mL (concentration: 8 mg/mL) of D",
"     <sub>",
"      5",
"     </sub>",
"     W or NS",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F213589\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, NS, sterile water for injection;",
"     <b>",
"      variable stability (consult detailed reference)",
"     </b>",
"     in D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W.",
"     <b>",
"      Note:",
"     </b>",
"     Some information indicates that procainamide may be subject to greater decomposition in D",
"     <sub>",
"      5",
"     </sub>",
"     W unless the admixture is refrigerated or the pH is adjusted. Procainamide is believed to form an association complex with dextrose - the bioavailability of procainamide in this complex is not known and the complex formation is reversible (Raymond, 1988).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Amiodarone, bivalirudin, cisatracurium, dexmedetomidine, famotidine, fenoldopam, heparin, hetastarch in lactate electrolyte injection (Hextend&reg;), hydrocortisone sodium succinate, metoprolol, nitroprusside, pancuronium, pantoprazole, potassium chloride, ranitidine, remifentanil, vasopressin, vitamin B complex with C.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Milrinone.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Diltiazem, inamrinone, nesiritide.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Pantoprazole.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F213520\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Intravenous: Treatment of life-threatening ventricular arrhythmias",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Oral (Canadian labeling; not available in U.S.): Treatment of supraventricular arrhythmias.",
"     <b>",
"      Note:",
"     </b>",
"     In the treatment of atrial fibrillation, use only when preferred treatment is ineffective or cannot be used. Use in paroxysmal atrial tachycardia when reflex stimulation or other measures are ineffective.",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F213578\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paroxysmal supraventricular tachycardia (PSVT); prevent recurrence of ventricular tachycardia; symptomatic premature ventricular contractions",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACLS guidelines: I.V.: Treatment of the following arrhythmias in patients with preserved left ventricular function: Stable monomorphic VT; pre-excited atrial fibrillation; stable wide complex regular tachycardia (likely VT)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PALS guidelines: I.V.: Tachycardia with pulses and poor perfusion (probable SVT [unresponsive to vagal maneuvers and adenosine or synchronized cardioversion]; probable VT [unresponsive to synchronized cardioversion or adenosine])",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F213591\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Procanbid may be confused with probenecid, Procan SR&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Pronestyl may be confused with Ponstel&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - high; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Administration issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Procainamide hydrochloride is available in 10 mL vials of 100 mg/mL and in 2 mL vials with 500 mg/mL. Note that",
"       <b>",
"        BOTH",
"       </b>",
"       vials contain 1 gram of drug; confusing the strengths can lead to massive overdoses or underdoses.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       PCA is an error-prone abbreviation (mistaken as patient controlled analgesia)",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F213580\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;1%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Hypotension (I.V. up to 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea (oral: 3% to 4%), nausea (oral: 3% to 4%), taste disorder (oral: 3% to 4%), vomiting (oral: 3% to 4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Positive ANA (&le;50%), SLE-like syndrome (&le;30%, increased incidence with long-term therapy or slow acetylators; syndrome may include abdominal pain, arthralgia, arthritis, chills, fever, hepatomegaly, myalgia, pericarditis, pleural effusion, pulmonary infiltrates, rash)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Agranulocytosis, alkaline phosphatase increased, angioedema, anorexia, aplastic anemia, arrhythmia exacerbated, arthralgia, asystole, bone marrow suppression, cerebellar ataxia, confusion, demyelinating polyradiculoneuropathy, disorientation, dizziness, drug fever, fever, first degree heart block, flushing, granulomatous hepatitis, hallucinations, hemolytic anemia, hepatic failure, hyperbilirubinemia, hypoplastic anemia, intrahepatic cholestasis, leukopenia, lightheadedness, maculopapular rash, mania, mental depression, myasthenia gravis worsened, myocardial contractility depressed, myocarditis, myopathy, neuromuscular blockade, neutropenia, pancreatitis, pancytopenia, paradoxical increase in ventricular rate in atrial fibrillation/flutter, peripheral/polyneuropathy, pleural effusion, positive Coombs' test, proarrhythmia, pseudo-obstruction, psychosis, pulmonary embolism,  QT",
"     <sub>",
"      c",
"     </sub>",
"     -interval prolongation, pruritus, rash, respiratory failure due to myopathy, second-degree heart block, tachycardia, thrombocytopenia, torsade de pointes, transaminases increased, urticaria, vasculitis, ventricular fibrillation, weakness",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F213525\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to procainamide, procaine, other ester-type local anesthetics, or any component of the formulation; complete heart block; second-degree AV block or various types of hemiblock (without a functional artificial pacemaker); SLE; torsade de pointes",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F213505\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Blood dyscrasias:",
"     <b>",
"      [U.S. Boxed Warning]: Potentially fatal blood dyscrasias (eg, agranulocytosis) have occurred with therapeutic doses;",
"     </b>",
"     weekly monitoring is recommended during the first 3 months of therapy and periodically thereafter. Discontinue procainamide if this occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Conduction disturbances: Reduce dose if first-degree heart block occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Drug-induced lupus erythematosus-like syndrome:",
"     <b>",
"      [U.S. Boxed Warning]: Long-term administration leads to the development of a positive antinuclear antibody (ANA) test in 50% of patients which may result in a drug-induced lupus erythematosus-like syndrome (in 20% to 30% of patients);",
"     </b>",
"     discontinue procainamide with rising ANA titers or with SLE symptoms and choose an alternative agent.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Proarrhythmic effects: Watch for proarrhythmic effects; monitor and adjust dose to prevent QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation. Avoid use in patients with QT prolongation (ACLS, 2010).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Atrial fibrillation/flutter: May increase ventricular response rate in patients with atrial fibrillation or flutter; control AV conduction before initiating.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Electrolyte imbalance: Correct electrolyte disturbances, especially hypokalemia or hypomagnesemia, prior to use and throughout therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Heart failure (HF): Use with caution or avoid (ACLS, 2010) in patients with HF; may precipitate or exacerbate condition due to negative inotropic actions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myasthenia gravis: Avoid use in myasthenia gravis; may worsen condition.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; dosage reduction recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Antiarrhythmics: Use caution with concurrent use of other antiarrhythmics; may exacerbate or increase the risk of conduction disturbances.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Drugs with QT prolongation potential: Avoid concurrent use with other drugs known to prolong QT",
"     <sub>",
"      c",
"     </sub>",
"     interval.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sodium metabisulfite: This product contains sodium metabisulfite which may cause allergic-type reactions, including anaphylactic symptoms and life-threatening asthmatic episodes in susceptible people; this is seen more frequently in asthmatics.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use caution and dose cautiously; renal clearance of procainamide/NAPA declines in patients &ge;50 years of age (independent of creatinine clearance reductions) and in the presence of concomitant renal impairment. In the treatment of atrial fibrillation, avoid antiarrhythmics as first-line treatment. In older adults, data suggests rate control may provide more benefits than risks compared to rhythm control for most patients (Beers Criteria).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CAST trial:",
"     <b>",
"      [U.S. Boxed Warning] In the Cardiac Arrhythmia Suppression Trial (CAST), recent (&gt;6 days but &lt;2 years ago) myocardial infarction patients with asymptomatic, non-life-threatening ventricular arrhythmias did not benefit and may have been harmed by attempts to suppress the arrhythmia with flecainide or encainide.",
"     </b>",
"     An increased mortality or nonfatal cardiac arrest rate (7.7%) was seen in the active treatment group compared with patients in the placebo group (3%). The applicability of the CAST results to other populations is unknown. Procainamide should be reserved for patients with life-threatening ventricular arrhythmias.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F213576\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2D6 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F213510\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates. Management: Avoid concurrent use of abiraterone with CYP2D6 substrates that have a narrow therapeutic index whenever possible.  When concurrent use is not avoidable, monitor patients closely for signs/symptoms of toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amiodarone: May enhance the QTc-prolonging effect of Antiarrhythmic Agents (Class Ia). Amiodarone may increase the serum concentration of Antiarrhythmic Agents (Class Ia). Management: Risk of QTc prolongation and Torsades de Pointes may be increased; consider alternative therapy when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cimetidine: May decrease the excretion of Procainamide.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Moderate): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Strong): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Darunavir: May increase the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     EriBULin: May enhance the QTc-prolonging effect of Antiarrhythmic Agents (Class Ia).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fingolimod: May enhance the arrhythmogenic effect of Antiarrhythmic Agents (Class Ia).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: May enhance the QTc-prolonging effect of other Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     LamoTRIgine: May increase the serum concentration of Procainamide. Management: Consider monitoring for increased procainamide concentrations and/or systemic effects in patients receiving procainamide with lamotrigine.  The lamotrigine Canadian product monograph states that coadministration of these agents is not recommended.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lurasidone: May enhance the QTc-prolonging effect of Procainamide. Management: Consider alternatives to procainamide in patients with acute lurasidone overdose.  If procainamide treatment cannot be avoided, monitor for excessive QTc interval prolongation.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular-Blocking Agents: Procainamide may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: May enhance the arrhythmogenic effect of Antiarrhythmic Agents (Class Ia). Management: Concurrent use of propafenone with quinidine, amiodarone, or other class IA or class III antiarrhythmics should be avoided.  Treatment with such agents should be withheld for at least 5 half-lives prior to initiation of propafenone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents. Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranitidine: May increase the serum concentration of Procainamide. Ranitidine may also increase the concentration of the active N-acetyl-procainamide (NAPA) metabolite.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trimethoprim: May increase serum concentrations of the active metabolite(s) of Procainamide. Trimethoprim may increase the serum concentration of Procainamide.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F213541\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Avoid ethanol (acute ethanol administration reduces procainamide serum concentrations).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Avoid ephedra (may worsen arrhythmia).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F213512\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F10950407\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted. Procainamide crosses the placenta; procainamide and its active metabolite (N-acetyl procainamide) can be detected in the cord blood and neonatal serum.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F213555\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended (AAP rates \"compatible\"; AAP 2001 update pending)",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F213528\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Procainamide and its metabolite are found in breast milk and concentrations may be higher than in the maternal serum. In a case report, procainamide was used throughout pregnancy with a dose of 2 g/day prior to delivery. After birth (39 weeks gestation) milk and maternal serum concentrations were obtained over 15 hours of a dosing interval. Mean maternal serum concentrations were procainamide 1.1 mcg/mL and N-acetyl procainamide 1.6 mcg/mL. Mean milk concentrations were procainamide 5.4 mcg/mL and N-acetyl procainamide 3.5 mcg/mL. Due to the potential for adverse events in the nursing infant, breast-feeding is not recommended by the manufacturer.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323724\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Procainamide HCl Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg/mL (10 mL): $28.36",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg/mL (2 mL): $23.52",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F213514\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     ECG, blood pressure, renal function; with prolonged use monitor CBC with differential, platelet count; procainamide and NAPA blood concentrations in patients with hepatic impairment, renal impairment, or receiving constant infusion &gt;3 mg/minute for longer than 24 hours; ANA titers",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F213517\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Timing of serum samples: Draw 6-12 hours after I.V. infusion has started; half-life is 2.5-5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Therapeutic concentrations: Procainamide: 4-10 mcg/mL; NAPA 15-25 mcg/mL; Combined: 10-30 mcg/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Toxic concentration: Procainamide: &gt;10-12 mcg/mL",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038779\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Biocoryl (ES);",
"     </li>",
"     <li>",
"      Cardiorytmin (FI);",
"     </li>",
"     <li>",
"      Gima (ID);",
"     </li>",
"     <li>",
"      Medaject[inj.] (DE);",
"     </li>",
"     <li>",
"      Pasconeural-Injektopas (DE);",
"     </li>",
"     <li>",
"      Procainamid (PL);",
"     </li>",
"     <li>",
"      Procainamid Duriles (DE);",
"     </li>",
"     <li>",
"      Procainamide Cloridrato (IT);",
"     </li>",
"     <li>",
"      Procainamide Durules (NZ);",
"     </li>",
"     <li>",
"      Procainamidum (PL);",
"     </li>",
"     <li>",
"      Procamid depot (FI);",
"     </li>",
"     <li>",
"      Procamide (BR, IT);",
"     </li>",
"     <li>",
"      Pronestyl (AU, BE, CH, CL, ET, GB, IE, IN, KE, LU, MY, NL, NO, SG, TW, TZ, UG, ZA)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F213504\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Decreases myocardial excitability and conduction velocity and may depress myocardial contractility, by increasing the electrical stimulation threshold of ventricle, His-Purkinje system and through direct cardiac effects",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F213524\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: I.M. 10-30 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : Children: 2.2 L/kg; Adults: 2 L/kg; decreased with congestive heart failure or shock",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 15% to 20%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic via acetylation to produce N-acetyl procainamide (NAPA) (active metabolite)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Procainamide (hepatic acetylator, phenotype, cardiac and renal function dependent): Children: 1.7 hours; Adults: 2.5-4.7 hours; Anephric: 11 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     NAPA (dependent upon renal function): Children: 6 hours; Adults: 6-8 hours; Anephric: 42 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: I.M.: 15-60 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (30% to 60% unchanged procainamide; 6% to 52% as NAPA); feces (&lt;5% unchanged procainamide.",
"     <b>",
"      Note:",
"     </b>",
"     &gt;80% of formed NAPA is renally eliminated in contrast to procainamide which is ~50% renally eliminated (Gibson, 1977).",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Transfer of Drugs and Other Chemicals Into Human Milk,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/34/36391/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/34/36391/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Coyle JD and Lima JJ, &ldquo;Procainamide&rdquo; in",
"      <i>",
"       Applied Pharmacokinetics: Principles of Therapeutic Drug Monitoring",
"      </i>",
"      , 3rd Ed. Evans WE, Schentag JJ, and Jusko W (eds). Applied Therapeutics, Inc: Spokane, WA, 1992, 22-1-33.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dumesic DA, Silverman NH, Tobias S, et al, \"Transplacental Cardioversion of Fetal Supraventricular Tachycardia With Procainamide,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1982, 307(18):1128-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/34/36391/abstract-text/7121530/pubmed\" id=\"7121530\" target=\"_blank\">",
"        7121530",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Echt DS, Liebson PR, Mitchell LB, et al, &ldquo;Mortality and Morbidity in Patients Receiving Encainide, Flecainide, or Placebo: The Cardiac Arrhythmia Suppression Trial,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1991, 324(12):781-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/34/36391/abstract-text/1900101/pubmed\" id=\"1900101\" target=\"_blank\">",
"        1900101",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Field JM, Hazinski MF, Sayre MR, et al, &ldquo;Part 1: Executive Summary: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2010, 122 (18 Suppl 3):640-56.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/34/36391/abstract-text/20956217/pubmed\" id=\"20956217\" target=\"_blank\">",
"        20956217",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Flaker GC, Blackshear JL, McBride R, et al, &ldquo;Antiarrhythmic Drug Therapy and Cardiac Mortality in Atrial Fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 1992, 20:527-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/34/36391/abstract-text/1512329/pubmed\" id=\"1512329\" target=\"_blank\">",
"        1512329",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fuster V, Ryden LE, Cannom DS, et al, &ldquo;ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation-Executive Summary. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2006, 48(4):854-906.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/34/36391/abstract-text/16904574 /pubmed\" id=\"16904574 \" target=\"_blank\">",
"        16904574",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gibson TP, Atkinson AJ Jr, Matusik E, et al, &ldquo;Kinetics of Procainamide and N-Acetylprocainamide in Renal Failure,&rdquo;",
"      <i>",
"       Kidney Int",
"      </i>",
"      , 1977, 12(6):422-9",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/34/36391/abstract-text/609192/pubmed\" id=\"609192\" target=\"_blank\">",
"        609192",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kleinman ME, Chameides L, Schexnayder SM, et al, &ldquo;Part 14: Pediatric Advanced Life Support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2010, 122(18 Suppl 3):876-908.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/34/36391/abstract-text/20956230/pubmed\" id=\"20956230\" target=\"_blank\">",
"        20956230",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Koch-Weser J, &ldquo;Antiarrhythmic Prophylaxis in Ambulatory Patients With Coronary Heart Disease,&rdquo;",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 1972, 129(5):763-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/34/36391/abstract-text/4554558/pubmed\" id=\"4554558\" target=\"_blank\">",
"        4554558",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Koch-Weser J and Klein SW, &ldquo;Procainamide Dosage Schedules, Plasma Concentrations, and Clinical Effects,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1971, 215(9):1454-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/34/36391/abstract-text/5107621/pubmed\" id=\"5107621\" target=\"_blank\">",
"        5107621",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Neumar RW, Otto CW, Link MS, et al, &ldquo;Part 8: Adult Advanced Cardiovascular Life Support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2010, 122(18 Suppl 3):729-67.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Oudijk MA, Ruskamp JM, Ambachtsheer BE, et al, \"Drug Treatment of Fetal Tachycardias,\"",
"      <i>",
"       Paediatr Drugs",
"      </i>",
"      , 2002, 4(1):49-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/34/36391/abstract-text/11817986/pubmed\" id=\"11817986\" target=\"_blank\">",
"        11817986",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pittard WB III and Glazier H, \"Procainamide Excretion in Human Milk,\"",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1983, 102(4):631-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/34/36391/abstract-text/6187910/pubmed\" id=\"6187910\" target=\"_blank\">",
"        6187910",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Raymond GG, Reed MT, Teagarden JR, et al, &ldquo;Stability of Procainamide Hydrochloride in Neutralized 5% Dextrose Injection,&rdquo;",
"      <i>",
"       Am J Hosp Pharm",
"      </i>",
"      , 1988, 45(12):2513-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/34/36391/abstract-text/3228104/pubmed\" id=\"3228104\" target=\"_blank\">",
"        3228104",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wann SL, Curtis AB, January CT, et al, &ldquo;2011 ACCF/AHA/HRS Focused Update on the Management of Patients With Atrial Fibrillation (Updating the 2006 Guideline): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 123 (1):104-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/34/36391/abstract-text/21173346/pubmed\" id=\"21173346\" target=\"_blank\">",
"        21173346",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9813 Version 40.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-88.81.100.162-2094B74F85-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_34_36391=[""].join("\n");
var outline_f35_34_36391=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709347\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213545\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213582\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213547\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213566\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213548\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213549\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213550\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213516\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10076332\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213501\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213521\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14473099\">",
"      Usual Infusion Concentrations: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213589\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213520\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213578\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213591\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213580\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213525\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213505\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213576\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213510\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213541\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213512\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10950407\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213555\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213528\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323724\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213514\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213517\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038779\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213504\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213524\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9813\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9813|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?4/45/4820?source=related_link\">",
"      Procainamide: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/18/38182?source=related_link\">",
"      Procainamide: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_34_36392="Disseminated intravascular coagulation";
var content_f35_34_36392=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F61719%7EDERM%2F74453&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F61719%7EDERM%2F74453&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Retiform purpura in disseminated intravascular coagulation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAF6AfgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDb02Y4ZCcMKvXK+bbZxkjmshBsuQRxmteGT5D6dK74nKJEVkQFWw2ORTbiBZoyjD5vWq8PG7B5U1ficSJ0wwpiMe23212F3HnitONh9oWQcZ+Vl9DTL+ATRGSMYZeR61E2XS3uU4z8sg9x3piNedd8RB6VyssIS8YHG1hj611ed0BIrnr5CGLehzWbRSdjyL4leD/Nle9sI9soBLqB94V57pybXw3DDqPSvpTVEV1STAIZcEV5f4r8J+Xcm608YV+WXHesKkbGkTEsJAAK0Gb5ODWRHHNbOUmUq3uOKvK+UGa57amzegrHmopxxT889qjn+6aGTEzZzg8EUzPy0s5ycGo/4aEUtyq+fNxmtK0HQZ5rNfHmjPAPpWhZcgUDN224SpT1NRW33BU2eTWbNobEchqBXAY1NL0NQIgLMSM00S/iJ2lxjtRuLAntUMq/NipLfjINKxo9ivLkNU1u3rSzqCeKWJSowat7HOviFm5quO9SynnrTMcVmbvYqyfeq1Afl+lVZf8AWYqxEcAitDK2pbgOCc1bjG4VSh5PHerkbcYpFwLdvxmur8LD92T71yVsSetdj4WGLcH3q4EVDcuT+6PsK8m8XsTfyYr1e94iP0ryHxQ+6/mxTqbEQ3OG1I/vD9aqW3+sHrmp9SOZqjsgDKB0qEXU2Oz0UYRa2SOlZWkLhAa1n5/CpRUCvLUduPmp8wptty1OJNQvwjmotQ5jNTRDp71VvnBBUEH8aJNCgjDgTN2T710EY+Uc1lwW0nm79vGfWtNY53OB8v0FZSkjojBsJQcdaqxkbyeo9q1IdML8ybmJ9a0rfTVWPdsVc9Kh1V0NPYt7mD87j5I2qK4sZJ1+dSK6iK0O7GOKsm1RwMLk1m6jNFRXU5C10kwruXPPYmphaOGB28+tdaLIZ4AH0okswRnHHvR7SQ/ZROTdZBnKH6g03zUCYOVPuK6OWzXBXHSqEtpg42hqtVWiJUF0OWveX9qmtRjbWvLpoIOBg1ReJ7c5ZMqO4FaRqp7mFSk+hchHy1n6q/DfSr0M0cifI3OOh61j6i33hmtL3MuWxTsF3TDPrXV2uFjGfSua0wZlxj3roeQopiSuxmoPtQ4x0rktVwx7V0t4dyfNXM6meeKEhy2ILOBGGCtFS2nAoqiIp2PoG6+SaNux5FacGAv61l3mGt4yTyhIzV22ffbI+R0wa70chIhxOwPdaljOyRSOcmqk7hbmJvbH1qZXHHY1a1EXZBh9wOUPB9qqwKV+0W56ffWrcDBoCDziq5G3UYyp4dDmqEX7M+Zbrn8azLuIbnz68VoWLYjZemCRioruLK5xWbdxmGymSIqw5U/pVCeESxshGfStSZdkjds1U2YPJ61DKOd1HTYrxPs80ah8ZRgOvtXE6npU1mW2ISo+8P7teovCJHG4YYH5cdaj1fSHaAXcI354kT1qJQuWpHkCMM49KJ2+Wuq1PQo51aS2yki9Vrk7+KSBysy7SOPrXPKNjSJmzH5qOdpxSMdzH2pxGB7VJUdyk+N341oWHUfWqEoG4Y9avWBOBQwZvW/3BUpqO3xsGBUmRms2b0yOTpUaMBT5jgY7Go0XJo6CfxCswpyA8nHFIYjuqdEwKLlvYgLetSxgbarzHa9TRP8AJVvYwjqyGb71M7cU+Xqajzhahbm72K8h+enK+0HmmPgucdqa/arMka2nHfitFYDzWfpI4H0rejtJ5o8wRll70gvylaLCg/Suy8NLi1SuU+xTR/fjYV2Hh91aEKOGHUVpFWM5O7NDUDiA1494ib/S5iOua9e1RsQPnsM143rrZnmJ/vGlU2HBanF6jgynFP01SZBmlnt5ricrDE7n2FaumaNcRuHuNsQ+uTWfMjSUXLY39LBWOtJjjkkAd6oWscoG2A8f3iKmNoxYb5C3rWbqJGsKbElcP905HrTUYpynX6VfWKNY+O1MhUlySuB71Dqs1VBPci2SOPmZsEdBVy1sUbkirMUeMEru+laFui7goYc81nKTZpGnFbDLfToyoOCMVow2I42gfjUybAAMiplbAyBwDUO5aRA8Sx4C44680pYITk4B6ZqZtgywI9hmqckhaTgZOeTSGOmnjVePvelNgmV3wDg4qnPbTN/9aprK3ZTmTOe2aZdtDSXkgCpGAxtP1psR4ORxQ3PsRQiLleRDzjFU2jJHzLnnIIq7I23pnmq/mKWPb2PeqFe5FLAHHBIPas+a1GSBzWlknBzgelQzZYEBTx0OKFoJps568tkV8qMH1FZN/AzA4GG7e9dTKiMdp69dxrPuLcYOfu/StIysYzjcxNLjYSYcEGt4qAnvWWQ8L715TPerYuQ6Y+63pnrW6lc5+SxXvW4NcvqB/emuhumO01zt4SZcVS1ImS2qkoPpRU1mMCihuwobHv0yq1rcADocik0t90G08elELErOcfKag0s7SeO55r0epxlm9PzxYwCDT4mYEgj8ag1DmWMDP3qfJ8vY1cSWaNqxAYE04kPqMIHZearWBLsMg1PajdqRPotWIuWhG9iD3NWZlGxiPSqdjktJt9TxVsnMbDviosMwLpSZCe1VrlOEOOnpV+6jPzVVdQYxmoKKsoKlXHQdau2NwRJsP+rkHNRyRYtwx5LDpVW23MGBP3aEIZqelxs7tENrHn61yGuaMJ4ys6/N2OK9JKiWxSRiNwG1s+tUzZRXSFJQCp6EdRWco3NE7Hgup6XNYOcjdGejVVdfk/lXrOt6MIVZZVDRHj6GvP8AWtGltN0kQLxA847VzzhY0gzmJvlYHpVywJ44qtK3zZzn2q1ZdealrQq+pvW/CA09jzTLf7lONZM3gRSnHt3psT88ClmINRxEA8nFPoLqWwwFO3ZXNZ11eJGDgjIrMl1pQCFPb1pIvkkzWuWUMSTxVdr1Il5YAVgXOqtJkIKz5J3kPzMapvQIUrPU6KXVkDHHIqF9WBHX8KwQ3FKDUXOpQizV/tFiw5x3pRqDM4GeM1lZ44pVOCM+tNSG6UUjv9FbcgIPFeg+HhixGe5rzrQGC2qknjGa66y16C0sQiRPJIPwFWpJPU8+UW3odZwcZUNUEVxb213I88kcKAdWOK4y78Q6hcnEW2EHsg/rWRPFLNIGuWZyefmOaHVXQI0JPc7TWPFFi6vFZ77h+m5Rha4qS0E8jPKB8xPGasW6hFyVB5qaNS7DGOeOKwnVbOmFBIorCE+WFQPWnPb4PJznrWtBbguN2APWpJrUEBUXJ7msuY3UDKX5WCpg047WbBya14tNJQZwKlg03Y2GBPvSujVJIzrZ02kbeamkXawwoIPerg0tmbKKR6kmhrU8ZyOcc96RVkR2snlt8/3RUskySOAFC57UrRsEwdox6d6heNQ2FPzHuaaCxINwOQSCOoJrTtl3bSXZiePYVmQREyqBkt3rct7dYznq3akxN2GLbY3FWO76dahWNk+Uod571roCME8egps64Ibk9+OuaklMgjhKoN5x3waQRg52j86mALcPg55z6U0sM7Tkj2oGhmPm6/SoZMkkg5WpyM4wMD3pDFk89MUA0UJC7EheQB1pIYs8SHPer0cAAJwMHqKJYSpBUDNMm3QYERIiwUHjFZvmSSEqY8KK10XsT+NMkg5y2MnrQLYxHi+YDZ8p71BNAy7v5VtMiFhjg1RuRk4HfqRVITVznJhtJBQ+1VpIgOvBPet6a0ywbGcVVmtc5YLx/KrTIlC5iyR7lIJOPWsa806cSboxvT2611DwmMcocGoXVQckhSPeqU7GM6Vzn7dSvDZB9KK2XiV89D9RRV89zH2Ulsev2zAQznqO3NRaYcq56HJrlLLWJ7aNkJDRnsRXQaLewTRhVkxJ1wa9KNRSOOUHEvag/wA8fruqwmS2cdRWdfODdQLnjPIq/DIGTHT0raJlJGhbLty3alsTiSWUgY6CmSN5VkeecdKZExg03c/DYJqmJFmwlbznZSOvStR8OOnPtXNaDOJIi/PU1vxSAnJ7+lShlG4AZ2zwO1UAjO+3rzWjfDD8DI96Zaw5beR9KllFfU1EaxgDtzWda43Sjp3FX78lpG3HOOlVLQYmYdSVpAW7LJtrkHsabYEbwCMKe9UZpZbcnyWzn7ynvVYasIBiWI5B6qaQ+hr69aGSJgAMHoK4+4t4yxTG3s6nnNb934rsioV4Zz2ztqpIsV3KZYeEYZ54NKSGnY888T+FGVftdkoOTygrlLUFJNjDBHBB7GvYJo5YH2SNmIniuc8Q+GDcn7TaD5++B1rGUblpmBAcRg0SOFyTQYJ7RSJomGPQZrD1bUQikKea5nE66WuhYvr9IweelYk2qyEnyz+dZ087zNljzTRyeals6I0le5PLPLIf3jflVZzUjH5agcndSRpUaSshT0pFJpRjvVq2065uj+5hcj1PAoMrN6oq5p6ZJwASfQc10Fh4XMjD7RPx3Ef+NdRYaXZWg2wxgN6nkmpuio3Rxtjod5dFSyeTGedzd/wroLDw3bxnLjzWHd+n5V0i2uRzyKtw2wwPSocytXuZ0NmqBcAfhVn7MDgNwK0UhUDntUggJxuUkVnzAolFIlwcDn2pjWTSHPQdq1hGiqQFx7VG0iKu1eo9KOYtRMY2hUsAcgc1YsbZjKpK4BFWnjfIzwCc5FXcrHEGyMjoBSuWoleS1UHLHjtirVnCGTBGD3pYIxP98kknJGelasaRxx8Y4FJjehDBAOgGakEA4HTino6fwyLu+oqxHtdhlhgUibkKwbhyMg1m6mmwL2J6d63iPLQlhtHvWdqKRuByMAcYPJpoqJhlmwVAyo9qEhRgSxK+3erqoSQscZ2DqatQ2qsuRG5Pb0qmVcyEjZD+7x+FbFhvbIbp6561chsl2hmUj14qZYowp2Y29hikJtDfL5BGQfeniHeeBijAHGPrg1NE4C4wfypE2KzxNnC/d70bRnJ5WrIcMCxA9OOtAK7CMbaRSK/lBiOMCjyQWBBNWAvyijGzDZ5HagTKsoCrhQTjvVSR3Zdi/eHSrlzKu3Bxgnmo8KT8u3BFMRDHGxTJPNOEZLEsM54oI2jPH507eWxgUIGrFeWHLk4wKpyQblPStZ4wVznr1qFo07jiqRBiyxuAQcAVCiqUI7D1rauowVHOcdhWfJGJTtDBSOo9aEMxbhAZNoOR9aa1oskWFXn+dX2txHI7beenHFNkLxg4B+vrTBxuZD2bIvIoq87/ACE7TnuaKZPKMXIyMZFOVymCCQR0NTOucAVCY8HGetbxkcrjcvWuqOJYzcgyKvGe9ddpVzFeOphIKjqO4rgSCvQ9e9S2dzPazb4XKuOhHeuuliLaM5qlFPVHo144klSFOQev0qtr0+21ZFPGAKytE1hLm4P2g7JSMDPGaj1ebzr+KIZIzk4rqU01ocji1ubGisIY1VDkY5roYH6ccZrlNOk23RUAqD6108DZXPpzTT6AS3a7jinQjZGAetSMNyhiOTTH4xmkMyLs5mYHv3qC0Uhnz6VamjLSb+3pUcAzK2RSAzr9yi57msi4G/Z+dbGpjCMD17Vjg7pVUjpSBoc8W6FDjkHNdDaWkF/bIsw2kd14JrJC5jAGK1dGcqcflVqzJJZPD8QU+XK/tu5qBdHmjdUec7D2ArpYm3jaetQXgIYEZO0U+VBdnMXOjxqxUgMhPORXgHjy0Fh4lu7eMbY87lHsa+mkkU/LIQDnOTXzz8Q7W61LxletbQkxqQofPFc9eKUTqwsnzHGL1z6U/kccfnW5a+HHyDdThB/dUVqW+kWdvjbGHY935rz2z0lKxycVrcXJAghdz7Dite28LXEuGupViHcDk119rGI1Coo9OBViZCY8dMVPMDXMc7a6LaW7DZGZWH8T81uw2OYxu4UdgKmsrTedzDatacUTsAirgd881Dkx8pUhtcDCKBUkNoyMGYfTNaqQrGg4/GoLmZd21QTjrUtspIakDMeuBVqKLGOBt9TSWu6QHC8Dua0EtQFwpy3WoZdrFJ1UDOefXHFSwtvGR0xzRPZyuc7sKO1Ma2dFBB/KgpRH3KgJgEfUVnrHglgcnpjNWo7aZzgH3Oas21ukDh3BJPXjNBSSQkVq0qhnH4VXuYNnQnrxz0rejAPA5PXFZNzFuuGDH73v0oQlqT6PbpJC7yNznhB29zV6C12vIJQZI2GQW6D2FU1UpNYwoT8yksQcZ56e9beBitUc9RuL9SE2yBTgAE/3VFZ0A8rVJfmPljhQe+K13OxHcckAmsK0SS5lnkAI384wePzqZIqjqncnurkzPtjb65pqhQwBzjuaha2aGRTyc9fataxhzErMB6DJqDo0SILMqzhEQj1J4wK0vJUKdpwD1rOniJmOxipB7VoW7OwC/MR0zVbiaJAuYsBST0pHUdPlBx0HanLHtOeMeuaq3Csz4Vt3rgUhJXBlznaC1OUHI+TqKWJQMfeHHPpUjMM5PakOxHsK8kqR7VGSM4xmpmy2Sw4+tQO4jHC9ehqkgJQSFzkVEz7s889sU2Ny2cn8KtqFKAEYOKTEzMCbmbd19TSyA9iOBV4RKVyMe9NMHIOOKQyhFFIwO9Tnse1WEQ8Kq4xVtYwqk44qFco56sD0xVWM3cTZtjO7GBVG9xsbaOvoavE7m2tn6UnlI54GfrTGlbU58GRiQ4K8cHNCREtuAIde1bctqoJO0E9qRYQTyBnHWpK03MG4Xc25utU5lLHIBwOMVv31jviJXhgOtU7CDKkPtzVXDoZKxs5ICFh3GMUV0IiVSd2PoKKDO5gmMKuMYFRFQRjuKuMm5fY9KgYbcgjOO5rQxsVWQdRUMmQSccVbddxGDxULggHNNSJcSuGIYEHB6g+lbGhXiR34N2+cjAJrIkUjkYqINjriuinV5Wc1SlzHc6jMsd3G8LcFc5rf0G9W4Qgn5hwc153pl6fNCTtmNuMk9K6Xw9I0ep7FOU/nXbGSlqjklDl3O7I+XGahlGRgU4NlQc803d3zk1pYgrSxkjg1WCEEkdK0GXfUDfKMAcVIzn9XYqvPWsu3+abcFGB1rY1mPg7u/GayAy2+8OwXjgk9ahuw0WxxCSKvaZnAIrmbvWYIY9kYMjei9qzn1jUJ08uF/JjH90c1LrRiXGjKZ6PJqtvZgtczpEB6msXUfHdlEGFpA9xIRjJ4FcK1vJIxeWRnY/3jmljtV65INYzxXY6IYVdSfVtf1C/JLy+Sh6JHxxWG+XyDyfc1euIyr8KTnuafbWHmFWJ79K5Z1HLc64UlFaFIWRdclifpTVtNpyMmuiaBVTavy/SpLKzRcsQWxWXMapGJFFKinEZ3Y64p8MbSsMjJP6Vq3Lea5jiOFHWrFrDEiZGMii5aRFHb+XGCcZHbFIsnksSWyPQU6/vQi7UHzHt6VQj3P25PrSsNInnui+QpP1xUcaMGDE5z39alt4Azlcna3TNaYsAFj2twP88Um7F6IsWsYEQyeeKtjHIHUVUYvBGoBDYNL50xAwnA6+9QLluXEUMhUge2aaYA7bV+UCo4ZWWTbMCB2OKkadYizMPw9aB8rJFiOOmBjn3psqqqdRj06VLFcLIi7gFLDgVVuojJIABwOcUAo9xbWSWRyIxlfWrRsV2lmGTUun2+1ASQPatDYDnoOKBT8jkUZotTkkz+8iT7xOQB6CtqBnZFaSXcGGcBcVQ8QxLAm6FAvmfKx7ZqQXUiooVsBQACBWkTGs9Eaind2P8AKktBJcbmmQow4UZzx61Dp4mmfc7Ep71rxId1KTFSjZXMye3ZnChc++KsRwqkahlzj9KsSZBAC5HrSck8nA71Jv0K7xA/dBGD1HemsWQYAwR0xV9FGSCKd5QD5ZVINNDKSM5UAjpUioNxAwD396kaP5jsG1TSLH82WpMQiRknp8vf3phgJJO3A9KupgAY59qjf7wLH5aBXKrRhsYH1qOaEN2yKuB13ECqd5dKq7EHzetO47u5VVMNnGSDirgB24H51nW7PJcnkYFaagLHT3GOEOMdxS/LgqQaRW+fjkegqcDA7UrE3KcpCLs24z3qCYMq8d+9XJlyCTjr3piJ5gIxkY79qbArQwuF3Mcg9KfFCVc9MVb8kcAcKBTnQ4+7z6mpuO9ys0WfmXoKckQIyw5HTFPKnaQfSngYXABDU7CZTuItw4HPeqLWwj+YDHPp0rXZSpO7G7sBVW8jLx4QkHvmmJGWkbNIWY5zxn2oq1FatCO5J560UDsjnc4UnrUb4bOOeKl4PccdajAALc8HvVpmNirhiCKaUyvzVZO1CTjOaibOcmgRTljIB9B0NUZQQwyvBrWkG5dp4PrVG4hJXr09adyOWxWDjgdu9dd4GmMly6SvmSP7v0rjHwhKjpU+k6m2m6rDNn5D8rD1FdVCpbQ5a1O+p7T5w24NSxkBc4wDXBy+N7VMGGFnYf3jVSXxxduD5cMa56Hriuv2sTmVKTPR5ZQq4HU96zr7VrCxiJuLlFb+6Dk15nea9qF3nfcOB6LxWaMuSXJLHuTWUsSlsaRw76nWaz4rWfK2MPQ/ff8AwrmLy7nun3yysxPOAOKi8td2S2PpV23jXavQ1yzrNnVCjGJBaxCTkjI9MVqRoF5AxSQxYxjA9qtKuCAf5VhKRvZEQTOKjkUJn1q6FEaksMCqcrbyfl696SdylEh8vzyOxFXoISincRkiqkTLFkE81ZjmLDnBPpQy+UsGMeWCRjFQeVKSx3cepp6XKq33cikmlaYFNnyngBe1SUlYgVBGpYHJJzjNRG4KE+YSVA6Ad6lkgKAKxNU7gEyEFs46YqkWxFbzpcsM/wBK1iY44gUjznvWbaRbplLAlfWukjsUKqFztAoZOl9TLjnZZQSgx1xWhC5lOU+UdQaX7Egl3D+H1pqypDM3AwB1qJFqz2JY4ndjv4UHitCKJB0XPuahjUSASA5z0FSO+3KHhjxwOKkXkVr8g/Khww6cVHYWW475AWbryanjs2MoZ5Px9a0kTbuG3AxwBQXdJWRCbVV2lcAegpuw+dn7varbBs4OOlRCPDknkUEk9ugXAPOO9TBTkkjI9KYBtGBzn9KmiBUdOKBEVxbRzxhZkDLnI9jUMelwn5zknPQmrx5cEDj+dSKMn0pp2IkrkIiWPCjge1KvyHHr+lOuPkw3UfWqKXoaUqQRnuaRUY3Rak5YAce9BGPvcj1NOiUEZPNNVtpYE5BoKSJVYFdzL16Uoztx074A5pplwMgEemaWJwWycZ6g1SCwvlk4GT+VDxhSO9Wd+MHGSepz1pjIOex9KZJCgKD5z16GiVlAxjcO5pSpA4XPuaYQQDgcDtUjsihO5jAwcufaqM0M3mALnceTxWy8RAUkY5zg81C+RJwBluMmhDTsU4EWLO/rTmuRuO4fSpZIWMnqMjntSXCRiLexHH86sVk2MspiZd3UdeB0rQCNJyOgqlYJhSwXhjWzBGFjBx160hSM6aN2IUfKO/FMgTY5Bzg1eu8lSwGB2qpbMZpRkEYpk9C4ATkk546U5kbHQCnqATxy3vT3TgZ5HqaHEVyo6DcecZpFTIOGy3rViaD5Cy4/CgqFHA6CgCARYTJwW7VRuXVMA8HuK0SG7ZH1qvLAsp2uvyjkGiwFF5U3/eGP5UVVvgUZgqDHT1oosaKFzmnRskEc9aZ83QHj0q2ykklu3SmFMrtP6UXMLkLKpyO4OKY0YK09sA4oGD15x6UXArOgUHNVp+nXirsu09SaoyZC8+tMTRl3i/NuArJvch4QD1et64UFDXN6nIPtNvHnkviqUiJJM2rSNSnAHuatJbA4waq2RyF6hcYrWhXoalzY1BES2xweaYbdhyOa0lTPejao+9S57hyGYkWWwy+1XrWJlxgYFSbFzVmIALz+HvScirDUj+YEZH1q9HECOef6VQlkdXI24WpLSZ1lCg7ge1LUuxcnT93gAscdKxpGaNiGHFad7I7EKCV45IrKnVfMwr7hiriNIQSBpMkfSrkUiblx94+naqzQbGxnOeRirEFupBZSQw5plxLENoZJ8lsL3rTjgWOPAA4796pW16qKAFyQa1IW3r90kk5FSKRnXcJkjPrn8qq/2ST8zMvTNdEFTHzYAHqKq3LKyEqfu0XsgTbM/TrI7x8o+tbyxYXntVbTW3RHK421oKMKMdTzUXHIyr0Ss5RMkHj0qgbZ4yflLDv7V0TxbgSwyf5VX8kbQRnjqD3obuXB2KcFx5MYBU+4q3bnzmzwB71KLQMPnGCe9NuIjBCdnOe9Kw9HsXBGAACAcdDipggUAkjJqlY7jHlizH1z0q2rbUIzuz1OP0oFYciDbz8xoKBSp/SkgI3Yz+FWQvZOp5yTQBC6EpkAA0+M4i/eckcU+eRY129fes5ppN7c8elAWuX9wQZY4NHnq/G7tisn7SZH8sLx3PQVbtrR+SXDZ5wKB8vcuTkNEecVlpCTKWAwB61qmJmHbI60w27BG3Hg0DjoRRTqE2u3B64qTzEb5YyM/wA6iNg28Bc8+/FSW1p5U+5STz36UByotxQgJ843E9vSkEHUg/KKuLwSMf8A16VU9wtNGd9SghZTgkY/pVlSXAIxj0qB49pwvr3q1GowDkg07lOw1k+U8478Ugh24zUuGC5754pY1ycHIA5PaiwiAqozzkfSs+WDfKSykbeR71buH2vz0JyB7VE/MpZX7Z5/pSQLQjlC7FJOAByKzrq6QyGOMA7epNW7ssYSSrEg4wKzIYVeUAgjJx9K0sNLqaunhTEGHQmtaMEg+g5rGguolGFOQDggVdW7CyKuRg9DSsZy1JrtAE+YHHNZQnEM23bjI5961ZX8xcY+Wsa5gBmU7vrTFHszV09zJHuPXtmrnmBsr0ArLsWVVIDZOfWrhkAIxy3p60rgyWTDDnjnqelIxGCrLgY4I71G5LEKoGeuM1MCAPmwQR0HagRGQSegC9qjkILhQ2DnkUtzOgB2kgdKoRNJM5dfuA800OxFc25knJA+ntRWnGox169aKdx8zRwMnA6VFu6jHNTyoOpJ/Cq+0iTgjNZ3MxGGCCMcetQk4GFzzVl1GMmq8jYH0p3ArszYPHNVnJO7ceBUssnzcdaoXtysSMXOCBk/SmJuxXvZBGpJPFcc16JtaCoQQgIyfU0/xBq5k/c2zZeTv6VhizdFJy/mDkleg+taRj3MXLWyPSLEhQFLZJ5BrTibJz6V55purXVqVhmkHykYDjqPY12WnXfnowbaSOQQaxcWjaEkzaWQqSpbIPTipxa7m3Bsj0JqDT4zIwPORWrFGVGXHOaV7F2IBEOMDp6U/wAvGMVZZFB9KaxVeSR6fSkLlKZjGQoNXIbYhVIxuB61VkQMAWBDE9RV+xVvL2g4A9ady7Ed+uyEAc5/Ss5UK5aRRgcDFbstuJoyO4qrNbCLOGX1pqRS2MkZeUhhjNa9igMJBTa2MHiobmBWiSVc7sdO9S2t04H7wEnGOBVNjtoUnjMJYtGACcDFaNhPGYF5IZT3p97a+dGrc9OneqFxG0CjIOWGMDtSHZM0rqcKm4EHPGM1TtpcyIuDnuKjij3kK2Qp5A96AvkXBJbA6gUAo6nRQgMq5wAOtTFMgbeT6VThkBtwFIJYZzU9qxChSfmHeoE0PZmLYx8p4NCx/wAJyfarBGM4B/xpkYym7ofekCHqoUAseOlRybFJBXOevepcjb06dRSgZXOetABGoCgR8L6U1lC8epp6EAbSMH+dJcRs6Dnae1Mdg24+YqQT0qZeEALcj2qq9wIo/vHjrmlidnwyZ2tQU42JChbIYdajitjk78+4qx1PGePWpCxVd0a/L3J70CMu7tQg3DkelW9NY8J0HrVkw+YgLEn6VEmYpcqm3PBoGndWLoGCRnn6UgBZuFx606NTnnqalMRC8cj0oJIyoPHOetOjUZwOtIkTFsMTU+1Qeew7UCbFXggZ+alZCUyD360wldwx1FBfqG6UElaVlywbsevrTkIRBg5z3PWqGrsI1Ds3XjHWq1lNLLMEPTqTTNeXS5tSP8gDnBXv3IqC3vBLMyfwIcZ9ae6+YBuO0d8UsIRBtUDA6nH86LkEkkQfJZQPrUckcScKRz1qV5E6L0FV5mxk9Tn0polkT+X5LKTjA/KsiVfKGI8sWPrzVjUJ1P7uMEljziqbKS4CA7hWgJMpwZFwQvVjz6V0NvGmxSAW2jHNZUVqVlVgSGPtWpakqu0nOKVxy8ixKcL8vAxWfcIZOD/DyKuFgwIbIx6VVYhnbipbMwjUIAV9OasRMQgYnj3qqrjIOenBqQNuI54qSmy9E/OcYJqVX4wTnis8zHfgcDpTpZCCNvXuKsQl2rHao4HtUdrG21gz/L+QFLLcRpDJI/CRgu30AqC3uribR2uYrJfNb5lt2k+8n19SO1FgcjWhUFVKMro4yGU5B+hoqtpM8Mmm28lmgSBkykYGNo9PzzRRYRxcjDZ9arSYIBHcYqzLgIVGMdOlVnBCrkYx1rMBN5AAwCKrzOMHb+dLI2zJBzVK6l2hiDtAGOashuxRvLzYjKSBx2NcB4g1eaeZ44txHTGeRV/xNq29PsqHMhPJ6YFYEUEjBJmIUKeWPetYRtqzCU76F3TrYvGrSMBL2zzVy8hlLRkkYPyllHBPvViws0kjV2cl35ynFDQsJXjjmdlJ4LnPNDdy0rGTe2riAknlTjHpW/4MuTKyxzOAw4APUiqc6s0OzjeDgj+8PrWdC0thdxtkoC+d3T8M0PVWGtHc9iskCqCvI9jWihEgwo9voa5vSL4T28WWKFhnOetdLbjy1B5JPX3rneh0LUfLBlTtJ3VTkgkQncuS3HXtW3GoIyR2pHiyMgcdqLjMYQ4AMjHjoM1YsZRlufrTruFu3frVa3jaKZj/AAZ596ANSCTefT+tQ32MqeM9CPQU6Vv3W5PwIqgyFpN0pbHU4oLjHqaBhRrYFOVHOaW0QM+cYAOPwpliWaBkJBC9+hwalt/lyF5UNtoCxbeNlRsDJ7Gs25i847gfbFaz/OmDwcdQelRQRKSf4lAzn3ouC01MvUlMSIEB7c+lVmiMhBbJ966G+gWaAocYxmsq1AMhRkwc5zTHF31Lun2rmA4HB6VfgthCcseas2kSpHgdqnaLcpzjmkRzdCIrkDtTWTaxyvBqZN3Q4xSSbh3yKBleRQBnpTrdicAjIxQ21gd/GODimtKickEdutBSLQU53Z5HamSqXQrnae1OgYSfMCR65poLeeATlaAKz2mSC3UDpVu1h8qIDjjmpCGc8dvWpFUDAPJoC7egxgoHyjqaa0YYYLFRjp61K6MqZHPoKdHGGGTgep70CJLVCI9uBnFIYgh3AcfTNPXcMd1pWYEbRwaBFdXLZJIBBxUqPxznb3NRPgkAkDnPSm7iY9ozj1p2GyaWTDcEVGku/g9BzVG4f5yc8qegp8NyrZyQG6EDtQFi4WKv8w4oEuWHp71CJfl+UjPvUbyjJwRwKQtCK+RJFDSHG3nNR2Dxu7FABnoTRMouYtrE+nHeookSEAAEYpl9DTLEHG7ikTru3Z7Gqc9zGkW4kgd6Yl4jJkttT1xSIsXRkk+lVru5aOBiv3icYqpb6ms0jAMcDj61LK6EKXPUcCmhbFEtIQ0uQxz+Bp6M5Xdj5s9BUu2PgKvHpUiqnOenpVg2CN+6BXOf60kJYN8xxSNJn5QMU2eUIRz+NAizJIFUfNWfLdbTtBOSaqahfpbozMwGOTk4GPWufh1lZ5W8o+YT0x0pWuZ3R1MUg34/h/rWjCoI9u1cvb3wXG9eWrVivwVIB+buewoSsUzT81I2wpBbtVS4uTA+GOS3eqcjsSSD16kVnzXJfau4kg9xVjUbmukkUjPGzAwspDZ9COayUvo4ITb2/iGL7OvyAmEtIq+gbp+NVpQZbeaMljuUghOvSjTtVksrGCH+yrnKKFO1VxxQkKaOktJY49Kthp7AwKoEZ7sPWisyO7adI3VGiLfN5bdV+tFBSirFF2LOcgdKrO/ycct7ipZc7uWOapXU4QMm7msERJlS8m8tWY/e9K43X9UbLQQ5ec+/StHWtScv5NuC87cAZ6e9Zlpo5iiMkrAyvkkLzn8a1joZtGTZaS7yF7lgZG5x1Jq9dW5SDyoiruOAjcVpQQ+VEFdSc8Ak4Oac9q+6MkjAPGPWq5iVAS1sHMCsUjULyQCRVO5tyHPk5IY7hntjtWtGxaPy2I3HjAqhdWcqLuWVgAcgA8UIpoo3E0TxldoMgPzf7PvVWSMzRiN3GVGR6n3qa+hb/XDiUD5l/vCoWkdY1ZvnQL8rY5X2q7EXR0fhe+AjEcyAtGdpHtXfabGzRgglUbkDPSvLNIcQ3sMsjfLL8rY/SvVNCmjlTYx3Oo+XbwCP8a55rU3gzYsyWQ+aOQcfWrHAJ4OKpIX3EMdpPQjvViAlm2scEelQzWwkwUjaOtVLqP8AdAIucDmrrR5JIbkfrUbYGMHGe1UFjnWvX4AOAp6VuWOydcgABh3rF1K3Mc7FV+U9fatvSFHkICfu88daNCntoWPswVn2cbh/kUllB/FyP8a0XXI9BUMS4Z9xyM8UhJjbopCq8Ag9x2qS18p4m8rv1qG/KiDPG4dDisu1vPIl3DP+6O9MajdG2Rt+UjI6GqMypFNlQc9CKrz6nvJywTHOSaoXmrQZBMwyOuOeadgWh1lmxMfORVyPlc4zXJReKbeOJVjgllcjHoKD4nvFXENtGnHVjk0WMnJHVM+CMHmsvU70oxCtg/SuTutd1GRj/pO0+iLiqLS3FzlpppXYn1ptdxqaR2FpdGZwruuO5zir06xSAkSKSP8Aa4rgVtmP3mYH6mnMNvG84HvSsh+1d9j0S1kiRCDJGCe+6pUuLVCS08fv81eaAEgldxHY5qOSKbHQ/nTsg522epLe2nOLiLHu1Qz6hDG37qeNievNeaRWU8pGM4NadtozsByxpaIFJnfxXKTIDvU+2atJJFEufl3HpmuQstHZcHc4/GtFdObAHmScd80ri5joN64wW680wyBQx27j61gS2EqjKzSZ+tVmhvVPEz0XC9zoS/IPc9vSpDyM42/1rmPM1KM/6wH6ig6rfxLmSFGouDZsXJHI6HsfSqefJk3E4J6CsqfXZAMSwYBPOO1QS6tDN1DKcU0rjUu50AuEMeRn1wKqtdpvZd/JPArKS7TYdkvB9aghmTzQ68v70rMqPKdIZSiDc2AahN0pBycDtmsWfURHu6yEDIA5xVUXNzdS7o7SfgDJ8s4FWk7C5ka9673CYToO1UozOZFUsxXp8opLadSctNuwcY6VbW9jHC4zn0quS4Oqo6Fyzg8jLn5fqKdNKGfpk1WY3dw222tpG9yMCrNvpGoTf6zy4j/tNmrjSbMXVW4izBemTjqaf9qG3c5VU96sxeGXkfNxdP8ASOP/ABrQtvC9kpBeKaZh3latFRfUzliF0Oae98xiIEeVs4+Rc0NZajckDbFAvqx3H8hXcxaVaxABbZVP14qZbOFBxBHnNaKjFGMqspHn6+GIZHD3krXTDkq5wn5VPceG7K4ctsSN+zIdp/Su7MUYyPKh/wC+aCi/884gfdauy2sZXfc81l8NXUbBra4WTHQPwcfWoWhv7dSLm1kxnqgz/KvTXjUnlIhzjgVG1vGcny0wfSs5Uos0VSSPLZNQBHlsRGR2PBNNeVSVw64PXFejXel2dymJbdGHQ5XNYl54OsJeYvMtyOmxsfpUex7GyxDOOuLf7VJHtup4toPEZwD9ahTT3Lc395x0G+t+48JXkPNrdLIOyyDBP41m3FjqdoCbixlKr3T5hUuDRXtYvcmsg0UMce9nK8bnOWPuaKzLXUuf9IiNu/Xaxzn26UVNmaqaC4uBuJBxXL65qjRFhCS0zdAOabqepuz+XbqWkb1OAKNN0suzTOC7D5mJP3jWC03JeuxBptsABLdB3mPVsZCj0rYhe2JIQEyeijB/KrqxARlVQRn+83Sq89kdqywnc38WOCaNXsF1Er/YDJ5jlSyYwc9qqX2Y3SNSCwI4POK0ETYdrGRRjqOQKjuvIt1LofnGDgjOfemrod0ZwieR8qqg45ye9RTK5TDyKnOOBxU6qJAXuGyznPHpVW4k2MY0kOG6AjNaImTRTuFMbxncWJyCRyM/0qiWNtKm37r9STwDWowZIm89emG3DgE1nXUUaiRy2W6j/PerMHZEU2YS6qo8onj2btXc+CtV+0Ro0rncPlIPY1wrSBJYmRVXIw6k5H5VoeG7g2Ny4IZoXO5D7+lRUV0XGR7TvV4z5fzZ9fWiLMbj58seornrC8+0RrKs4V0x8g5B9jVttQAkDuYwB05wa50mdUZJnSKisBgcd6oXURjbCH5SehqtHr9nFApDs791UZ/WqV9rbznMNvsXGcu39KpRYnNI0r2JTAHce/NO09hv/u4Hfiubn1K8uV8tpMD0UVAYZpG3NI+T6mq5QdXQ7qbULaAAy3EanGD81UZ/EFgrfL5shxxsFcxBarz5vLe9WViVE5AHsKaijPnZav8AxC7qUitwAehY1hzXl3MxJbb9KstF5jHH3fWnCPYowvP0qtB3kZ8dtLO2ZHJA9TV+DTlVQW5NWFAQdOaeLnAIA5pO/QOV9RBHHEp29f5VBK0knygYU96txIHPYk077OWbABwKm5agitb2g4aQ8CrBKBdqAcdKurYSGPltq/rULWwjHyZJpN3Goozp1b+E806G1aTG4VfgtGdizflWrBZ8ZxSY7GdaWGewx9KvLpqleR0rVt7cBMgDFWmiB6UrlWMy305dw2AcVrWdkQegxU1tBtX5utaEYCrUsVisbYLxxS/Z+asHBOe1TKoK57VCFYoGEdxSNahj92r+wORg0549o69KdxWMl7IHqAKpXFkuDkZxW6+7PTioZEyDVBY5S60wOD8o/GsSfSymePxrvJouM8VQntg4YEVSYrHDtaMgwD0qHEkTcDk+vSumvbM7SVABFZU0DA81omQ4djY8L+JrPSNy3WlxMzcGRR/Ou1i1zTdRgaSO4TcRxH0xXl/k/LyM1X+zMXLRkr9DWsaljGUGdTL4esr/AF+9nXJGFZsHjJFb1ppVpboESNQB3CgVwthqd/p/ETbkzkhutb1j4uhHy30LRn+8ORW8asWYuDOsSKJVwEH1JqZWCr0X8qy7TV9Puh+6uY8+hPNXRIDjlWz6VqnchlnzmAIDYHtSGYnqxqLd3wce9DEkDIBFBNx+/rlvxzRvyBk00EMuMA55o7cHGKBXFyCOAcZ6ikJ46nHWlI4GWJPtRtG7+ZoC4nTFHQdfyNLjkZP60AEjg0WC5HliOvPamP0J/SpWj4+U85pGDc8jHegLlS+Zo7K4kiBaVI2ZAO5A4rk0uF1FLaGbVJfs0Fqbm6uY32He33VJHp6V2NzILW1kuJASkaF2x1wBmudspL2ea4iMGnx/abT7VFEIvlDbvl3n+I0DciXT7WPU9EtJdRgSSV4gWLrgtzwfxFFamlXK6hp9vdBCpljBK9cHoR9OKKXKHMeD2GkTZDyAFz1JHH4VspZzbNrFdvqoxWqjRJ0YM2OlK0jdgAPU15rO+1iibR2wHkYgcYzS3tuQyIrfKEGCPWrBmVTmRx7YqN7sNhVAwe5q43RMkZ72r7SBIRmqs9m7rhm3AdBWs88QHzuOPUUsEZuuUj+Xs3SrjFyZnKSitTnriyLsMsVx/dqCTSJHOVG5uxbpXU3X2exUF8F+yjqayJbm5nk2p+6X261s4RjuZKcpbGY2lXuVxJEAOo5xTZNJtUdfPLyMP4kYCtVbctkux/OneR02j9Kzcl0LUH1OYPh9jcO0bloyc/vB834kVdttAVJC3mSPznGcLW+luTgHIHpVuK1wMckegpcxagZVpZFSVjBHY4Na1tpzdSOfSr9vAkY4A3ntmrCgk4rO5pYpraIrYIH0FOa2LHCKAPU9q0oYtzZH5mpZQqLgcn2pXGlYzorQJyMZ9TSOM/KoxU8hZycjCikjhJAJJyTRsXykW0Jx1z3qOVXcgDgVoG2wMHvTAmBgc/hS5hqIy0tVIx1q59mCnoOlWbWFUjzj5jUdxv6LnJqbl2M25jUA5IHNVoLZnlJ7CtH7K0knzevSrUVs2cAcVfNZWLtYqwwqfkVcEHrW9DZKsSgL8w5NQW1sIpAWXittVBjBFQ3clme8A2e9VvsiswrX2ZbAp/l4HOBgUAZkVqqt0GBVoQgDpTwRu21bjQYGKQxIohgccelTMq7htAx71JwEzimxjcx46UASptOKkYcYp8afL0pzxnHy9aVrhciVOPSnlflwOlPjRsfMDmp/LZVyelHIJysVYk4zU4UlTkZofqNo61NGp2ZbpS5QImUMvA5qpcxFRgCtCQAD6VDMoKcU7AZLhivPaq0qEHrV9zgn1FQ4LNyRTEZbxB8g1n3lkCvBArcnXDnHFVZRxyKdxWfQ5x7crxnNAhCnA71qTIuDnNVY7diSxPHancXL3Kv2cyAqo+YVDJZFwQyDNa8UJByTg1OEBXpk1VzOUTiLmykRyUDKR0Ip9pqN/asBFdSKR2JyK66WBGQ5XrWNeWKA7gMfSqU30I5UyW28UapD/rdky+hGK0rfxrASBdWzoe+KwVjCpg0xrRWOSufetFVkjL2aO4tfEml3I2LchW9G4rUiuYJMGGRJOOMNXlslipycYqIRzWx/czSJ9DWir9yXQXQ9b3ngnj2xTlYnnpXmVrreqWw+W53j0YVei8aXcYIuLZJAepXg1arRM3Rkd/vJH3SDR7n9DXL2XjPT5wBOkkL+pFbdrqljdY+z3KYPYmtFJMz5Wi/ndjJ+ozQQSMEc01QCBjoe4PWnAHOcn1piGXBh8mQzLmLaS64zxjn9K4YS6Yr77fxBdRWwj8gD7OSVjznZvx/9eu3uUee1uIo28tpI2RX/ALpI61hWs97baWuntoFw0yx+V8oUwscY3bvTv60Bcv6NeabNarb6ZKNtugUR4KsB64PP40VR0uwuotR09ZYyFsrMwvcA/wCtY4O0eoX3ooC55yborjChfTuahNy5zvJb/e4qr8xIOen5UhUt1bd9OlcCR6DbYskvXAyKjxK/VtqipRGAMsNx/lVmytnurqOKNMlj17CrjG+hD03F0vS2vJRuz5YPJPetjVJ4tNhWOAL5uMKvp71r3Ii0fSjIR04A6FjXEzSSXEzyzDc7Hqew9K6X+7jZbnPFOq79CB4nmlLyNvc9W9Kmii2/dwKtwxfLxx6gVIUXf26VyuVzrjCxVhQs2R2qdRgnaMtTxFuI9PWrUaRxL05qS+WxWiiLsScgip+gweDUqjYC7HoOMUkSbyGwQD696Q1EEU5yPpmrFspZtvOB1NNAIcx49+Ks267gB1NSy7E+PLi+UA5psURA3vz2q3DCoxnmnTrgcDmpuFioYN5BJ4+lWooUTp6UsTpkDOD6Yp7knORxSY7EUyhjgfjTY4wAcdvWjbtbAOSasLGMhfXrQXaw62iyhJHWpjCpIyv0qzGgWIc/hVbgycn2+lAJXK8kG+UBRx7VdtYsD5uDUtvCNo7AnqaZNuRwoOBQPcdIULgNwMVbtRmP5WOKzNvzks2a0LeZQAAelFgaJ2GN1MCseW5Han7g6jbT4yT9P5UWEV4497Nk7SParNsAgIYZPrSZ2sB3z2qTGTjpVWYNjmYEAY4q3bJ8pytRwIMkkcVah+XOe9TsQ2XrW3Drk9KtJaK2SOSBnFVoJwAADWvZSRlQXwO31q1ZivYzWtW3AjGMU420kuARitB5YkkIHKgUv2yFWUtyaduxN2zJaxkHzYJPpTjCwTkEAdeK0bi/Qg7BjPeiC7jljEbAcevehRRVzCmyxqlI7Bip4xXQzWYKEoOCc1j3EB34xjNDiUpIz2wWyOT71DICHq/5Cg44qKaLJwRUWC6MqcEtnNRt71eeHDZxxTHgLNkDipY7mTOm7OBxUSqVwCK1JoSvtUEkeVz3oQiBVHJb8KcU49KjYNnBBpu9h0BJFMTiS7MrgjFZt2mG+UZFaAct1GKYUG8YXjvzVJ2J5TDuLRnjDqTk9qhtt6tiQED3rplhUYxjFVri2Qk4FUnciyMxlzyOfwqN7dZV5XDVfaHbgLTfKIJI60yDn57OZScZwDUSxMB8/SumKhuCKoXtmFGaNhrXcynsg4+U81UlhkhbCEjHORxWwjBAcjpVa6mVieKEwULkdnrGpWvEVyx29mORW/Z+NLhNovLdZFHdeDXLyoM5HB9qRYncgDp9KpVJImVFM9C/4S+xm0+4MTmGcRsUDDvjise0t7K7eyA1e48u7s2k8/7ScCYYznn3PHtXI3UckMTyFNwUFuO+KzY7S/e3RkjtRE/7wJgkDP8AWtY1+5zyoHtnhuRZdA09ljKr5XQsT69z1z1/GivPNJ8Wavp8UUVx5UyIMFNuAPpRWyqxM/YSMHaWwMYA7CnKmfwqTjdjFSLGzJ90jPpXLsdxCEJOeuO1dt4Y0wW1obmYYkYZ+grG8P6Y9/fpG4ygIZhiul8VXRtbJbaDh5Bj3A7100Y2TmzlrO7UEcnrt4+o3LKABbIx2+59azUiwenT1qdk5weFHQU+KPe2B+dYVJuTudNOCirESnJwM7R6UbSWyBzVthHDEVAB96dAgdR8oDGs2akKwsQTjAHXFSQxGSQZztXrzV+FOABjAHA9KlWFcYQYz+dK4yvIgMeFQbh/KhI2VlD87athfKGGwWPSo2JBY9Ce1A0hotiS2Dz61YtIDk7RmkicbhjrVy1b5/nO3aal7DJYYdgwTUdwoC/KetW1OYye2c1QvZNh4G4UuUEQCQJkjnFMS4kd+DxTXLuuCMKasWsPHGBQ1YtE1qN0nTkVfSMFT8vzVHBCFwehqSRjEw5zUse4hbC4HJqlGxNwVUZ55qxLNg5UA5pisFbIABPNOxS0NOIgKN3X0qOdsgjHPrVVpwGyQc1Zt8yhqLE2KxBxt5xUiclBg1fSJAAGIIomQeYpUdPanYdx6YTG0dRzT4pF5Hb1qLLA4AyDxQY2wAB1pqInoWggYbu/anQIQcEc5qC3WXdwDtXqK1LSPYu6TpVWIbsKVKLuwKSSTCA5qWV025LY9qqTHOenrWbREdw+1hcYJzmrkF8w71jDk1JGxLilsW1c6JbnK57mqlxOM4BqurgR8VXJZiTjIoUmRaxdM+RjPJp9vcFZAAMjvWeGK9qfGxHI6mqT1GdLBdKpBA4PXNMmRZZQy1jJKwX5s5qyl02TggewrW+hDVh15anIIGD7VCIDJy2eKuLMSufve1W7aHzEBZcUrEt2MdoVCdOajEAAxjNbk1sCTx+VU5odgwv3u1S0NMw54RuJqk0YP4VrXClc7qqMAOwrJm8TOaIFj+VRm2G76VcfaHyop0aDGQKQ3oUFi5xTXiUtkjmtJ07jFVzC5bPBFO5BXRPXqKZMMAmrTxsBwKBHuXkU0zNoxJWXkg5xVcSkvgjitW4s4xk4xnms97chiafMNK5Sup3RvlbimLeBwA461PcQk4yODVNoSsmMU7lcpZkt0Zdy/WqFzbqF3dT6Vq2vzDB606WDJxgc0KQr2Ob2Z/hxU9smGHcVbuLVlzhTioQpTA24NDlcpWJpoSbWZoyoZUJXd0zisGztdPNlH/xNJFYjLKJwoDdxjtWtcXVzCVSK0FyGB3ZcLj2wetRp9qfG3QYP++1/wppmNSOow2UbWsRikMqheJC27d7570VtWtr/AKLF5sQhcrzEDkJ7cUVLbBIwYIRI29sBe2O9atpaeY8YVcs52qPeqUEeMHOMdM12/hLTXuStzKMIv3fr611U6bqSSM61RUocxZ0vR5tOgMsKKcj5j3Ncdq939qv5JW652qPQCvUtXuUsNNlkYgALnmvIZA0srykYeQliPTNduJioRSRx4RucnJlc5dm7AdKIyQvOf/rVMImXIHX370nlnJOSD0rgZ6SIAvzc/dNSpnGUJwDzUyQbk3AgD1p4BClTjj9aRSCPJwACW9RWjGpjTd1Y1XgZQgJ5NWDMAozznipZZHGd8pGDnHelK75uOvQ5qVCA6lew5NIA0kpZex5pXEHkkAcAgHqKilcqSCeB0rQZdicfNnsKz7hC7HdwaYRZYtn82MhiRx0qOcNuKnAA5puCiA5wegpArucycn/ZpWGSxoZsA/LU9o4jYAqCc9SajXrtBwy96fEmSwbqOTSepaNDzNgJ6g/lVaaUMMY6+lV3mbgbunamIxPQcmkolImRgCd3akDh8sCCO9QNH855OKIgQzBSMGrsJlzAdc5rQstqDqRgfnWamFOBwT1qbeQQM8HvSsI0vM3uABzVqPpg4zisqHPnfKT9a0lI8vI4osJjWPz45x7VYR3wo2ioYWJBPA+tPLIGxuPFMRZjnKjCgD1960o3R0UjH0rCklTrg7gO1JbXcwcjtQyHG5p3LKuQfXgVUkOW5446UksgfnrjrVd5h05NQ0ESVAMnNRl9knHSm+Z0xwKUAB+R1qbFlhZweDmrUYDDIqgI+c55q9bD5eO1KxEgdSF5xTVYcA8VZVdxzQYgScChEormXaQfvU+PLsGHUVDPhT8vPrRGwBGTg1a1G1dGjBIyuFxya6G3lDKFOAAOtc5BICQMjPrWhDcN5hXGV9aszaNFpVwxUk84qu+0lsjmmHIA2Y96iDZzu+96Chgivdxbhx171nXMJRc9TWxMV65GSKqTjPPBrOSubRdjJeNeu3mowjKWY9BVx2G85Bz6YqF9xBG3HNZl3uQEk4OMU5RyP5VKicEEUgIUn1oIauRsCT0pScMBikViXORSTSCPmi4nEbcKrJk9R0rImQgtwKvM7OMqRVWbLBuR1oGolfy96gEVUntOcirsZ29elTKFYZA/CmNmPFmOXoasM3GSKutCGByuKhaIEFc5OKLkNJmdJMFBPUVVadXblKuPbkk5XioGtsHIWqQ7FSW/sLZ0Fy5Utyvyk/yqxFr2lDj7Qfr5bf4VFcAW1vNLjOxC2PoKxEu9YaWNftFuHlh89F8vj/dz+I5qkk0RK513nx3Fqktu2Y3GVJGOKKo6Xc/a9Ot3dzI7JksRjJ78CipGrFzR9Ma/uI4lX5OrEivTrG2jt4kijUKiDkVm+H9OTTbFCwzKw5PWtiVhBbFm44ya93D0lTjfqeLiK3tZW6HGePbrzfLslbhzuYn0Fcf5e85Xls1pajK97eT3BPysSqeu0VUjwh5btmuLEVOaR34anywKxiJJbH3TULghjs4bGTVt23uy5wKrTIqRjacknPNcp2oapYKB/D1xinHqvGSadGAke7oCcjNRtycgHk9aqwEq8NtBxmrCIChB7VVjVs88j3q9Ep8oMTxUsaJYowyDntQhEcuCP/r1LEVwMAkEdaDHlR8vPT6VA2Tl0CEcZFU51ByWYH2p5UgYyC3Q5phjXysMcH1poVrEJcOhGckjgVPB83yrgcVCI+3TFWYPkUE9R0psZPY27BDjHXvUs0W1SU9eaSOVvOIwT7Cp3DRgh+c81I7tGPJnnd2NGOV67evFLOxeXaB1OafEo28H5hxg1Y0wIyMKOKYjFQVx9akABUAgHHWlaP5gc8UXGOibO3jOetWGB4BGOeKjhUBwByParyQNL9B0ouJi2o43HtxViPJOAcE+tWLK2/egEcEValtVV8449anmFdFe2hHzF+fam3Ee18xdfersIB3BfypZ4iVG7n+lTcV7GLKCrZbrUiOFA/vVLdQ55wTVRFbzGCj86q490Wo3XHpk1CzfO2D+nSgx4GCKIkMvA65xSFZD0Q9asGM/L6CiOMhQGXrVgw7QSTwetQybkCruYbTzV22wpw3WoEVFfIPFWkxkEUCuWFHamuQAc1G74YA81FIShzztNBK3I5j83HAPSohHg5DZzUqOkhAIGaV4izDAx6U0aXsTWsYHOSa04yDGGTj1zWdFuQfMM/SrkRBHP3T2q7mbFMr7yh5FD5VyVFSFEOMCpQnHbPajcLozgZM5IO30pQHPU8elXZEGzuCKcEUrwvBHWkWmrGRJFufeOAPWoWBWQ7jkda2pLc7QxHyjuKxrvdk47VDRcdSpPd7G+XoKqSXW7LKB+FJMhdjSQ2wTJZ+DSsaWSHJdHbyOPWoJ7kuDtGRTZ4hn5DxUaxlTgDilYLIlE2FyBiq6y/OSwOCelSbccnr6UxwD0/GgVkWUiRwCB71IIsD5eKLRgECkc1bRecDGaDN6aFGRGx0qPyT95jV+6VsVF5ZIA9aCSpsU89ahuEVeQK0Wt9p7ZqGWIr1FBBkzxxmJzLgR7Tvz0xjnNc3Lp8MukRXFrHfKsRby9p/eeWTzjP8ADjtXW3iQSxyQSuBvRsjdg7cYJ/CsKOa+gtlgjvNLdVXYtwZsEAdCV9aqJEh2nW8MVjAbM5tigKH296K0LCGK306C3icSIqYDjnd7/nRQyk2epQr50wx90CsPxrqHk2ZijbDyfIAP1rfGLe13fxNXmOt6ib7Wp3Dfu4RsX0z3r6CtPlieJh6fPMryA7AFyMDFQ/ZmkOVB49Kcs3nMcYxWjZg8leR69q8acnc9yKsjLubZo03sflrPGG65x2rp79A8eCOvpXP3MPlt8vA9KSLTuMxuUAGlVT68dzSoRkZPHT6GnOQmAOoOD71YBG2SQvK5xWzZwo0G0/nWVGo27gdp3dK0LSYlG3dM4qJAh6R4mwTlQe1WXjBLFdwU0y3O6XB6+taPlAIxbk9sVI2zHfajbmUegNMiTfKA/Q0+8H8A596SJSuMck8A0weo54tspIwRjIzQFYqRt61IzAjOQcDgVIjBfv5x2NIBtsnzngjHc1LdyMCAoyemamVlJPQ8ce9VpV+fHY0AtTP2YcSMaawCliRyeRV+aE+UCVBHaqjRMW5PWmUizbW4xvbgfzqeeDbggAjFFmpeNoyDgd6S4d0URnoTwaQFdFw+UIye1acE5wFZcY9Kzo4ArMWJBNPkkdduw+1Mq1zbgusSADj61YlkMiklTtrEgkLEZGe1bVsp8tRJnntUktJDraTcwATB7mrLsS2GPWmhFX7vFRsjs3GSKmxDdyC4BDHBqmCUPIzmr88fy5Bye9VR8pBIBqik9AjXzCM1Olrg7lGAPSpIWRU5HWni53OFQgr6CghtiCMg/WnNE2eOneplOTyenQVOwDJgnBqGK5l4weOlWIWAA5z71A4ETFck896CDgYO00FdCZ3G7j1pLhiVIFMDge5FRNMkjYz+VBNrDIkwd3etCNd6qfzqusQY5B4q3GNqkr0pocncesYB61biQFe2KqxuM5PSrQcbcjpVEWZOBsAP60jSJuG1vxqlc3WI2CHNMtiWUE9+1IpQHz3DeaRkAVZtZgwIJ6CoHgDjIHzUkCNGxzgYouVpYtvOQpTtVZ4MqQVLZ70OzAbuD7U2O9ZPlOMHpVJocblG4sjsxGMetQGzbZgDk9jWwh3Ak/kadiOUhMlT1zRYdznfsUjDAUhRSmwaOMsw6V1NvCCSAAQBU8lkk0GdvNJxJ9pZnBSp6daqMjB+eDXV3umbH5WqV5bRqqkDn0pWLU0YsEboS1WLZ3D5yDn1q08YVMgc+lV4Iz5mahorRonc7m+bimn73H3fWpigxluDTVGUI70rELYYJE38t81IxDlhtGKaLTfKW71YEJVc55oJkkjIvYooxLO8UbOkTDc/93uCfSuZijklshcx+HLHYV3hd43FfUDFdbqESvC8Mo3JICrD2Irj11DyV+yR6zGLdf3fnfZmZlHTG/7ue2aqJnKNtTR0m9WbyIJbRLVZIfNgMTbkZO4HoR6UVatdMjimgljn3W8EHlW6AdAeWYnuTRQ7Ak+p23jDVBZ6dKykBsbUHqT0rzKLKxHOCzHLe5rW8Z6l9t1UW0eDHBycd2rJaTK7VGcY6V6uIqczsceDpciuy7p8a5P+ea2oIjuOPuCsfTSC2OuentW3bEINpwcnPFefI7iK65XGeRWVcxFpBwSD0xWxIvXdz71SuRggZ2qBzUpjRmRoDn5QOtMdM7jj2NWZY95Yx9h+dQgcKO46VrELiLtGSQQCO9SxMC2OgxxUTHIJz1GCKfAgUKc59DVWuJMt2rukm85PqKvG4JHJPTtWcHw2BkYPJqRn6DPWs3EdyYgSEHsOKAw8tCASAfypnm7VPTA5wKfBiVGwcHrj2oHckkjCfd2nP6U1JUkGD97oKhabYGBJz2qu0uBwPnHOaLAi4WIGMn2NTptcgg81m+aS4bov9a07F1Kdt2c0noUyyV/c47H9KrmMMAUUcGrD4KAr3qus/lMeM5647VLBEsbsqnYuPeopJMn5xz/KlM6sBwQM9aJBvI29+9AydovMjDY49KoMUEm1icZ/KtB2KxDsQKoSYfqpDZoRUTTtREpDJzWsm1iCG7dqwrMGPjv71qJhVBPX2oZMtS2JlUHPGKlDAj5Tge1ZmSZD3Bq5EQMbuntU3IcUOl2hDn1/GsbUJCuCmQK2JtrHABz2NU7iAMhDDn1ouONkZJvTtxniptLmHmkseD0FZ86gSHA71fsLYHDCrKaVjdTBfIanyTBU3Ee1Ux+7XnJxzVK7vP7oPoRUWM4xuyxdTIXBU5qRZlbGQfasUzAz4BwKvwyg42ngUNFuJNJvcEKcAVQRmE+M9K0gQc4zzUE0YVTxzSQLQuWc6seKvsVOK52FvLkDZwO9asM4Zcqaozkral5sbMLUe5gwUE+9LExGd3NRzyrH8x4zSuEdSZYQeanVBgcHiqVvK5AyeKviTj2oY3cmRlXDEHB/SoJiBISo5I70ofop59qbORwMYNIUUQuxKHGKRI1POMt1pFALH1pS2GwpKjFBpcsRJvQ5wD3pmAnABJHQ06LPDA809AC5yarmIbZPbTHGSo3Vo2M8UjkSyYIHQVkvIojJGM1R89vPGOK0TElc6C5dGWRSgZm6H2rKubJAgbdn2qW1uxI22TqatvGmPm+6eaYLQ5+5hXy/k6ntVWCPB5A4610ZtCxJjTdkVAdOO/kbfWpcS1KyMCVWLZ/hpisVPXiugurEeUSqkYrKktm4wO/pUOIJpojtnVicA5qztG0krxSR2wQnjk+lOETq3OdtKxDjruZuq2guLWeJGCvJGVB9CRXKW92LXT47GTS7r7QkflmFYso5xjO7pg12N5PbwkC6uIYSeVDuFJ/Os17yww4F/a9Dx5y/40JDXqVNEsntdKtoLjHmomGwc4Pp+FFWfDYP/CN6exJYmLJJOc8mik0yLo5CAb5WduZCclj3q1BHskYtwO3FVLZOcd+uM1adyFIX7y849a6pO+oJcqsi9bBUI7En0rTt5V3AdV7NWRE+AuSTu/Sr0R2gbTg1kykWXmCMMc46j2rPuW+Y5+6c0+V9zjB4PJPpVS+IT5gx5pJFWKzy4woJ5/lTvMUpk/exxVQtnrkkcj6U5WGDk8HpWqWhL3JVJzkH3p4YAHsDztNVmdQOTz24pC5YZPI6VVhF4ScnPGR0qVGBHI7VnI5ABPX0qQSn6E0gRcRgcjndjv6UK7RqdvJ9aqCfJA79qd5vzEHqO3pSsWid5BIDvJUjp71XabaeOT3qF5C+OKa33DtPPpQkFydpT9at2UrM2V+lZXmNnB4zU9rN5TYA4qZIE7nV22SmTzUEkZDsQODxWdBqJjzk8Gr0d4koyo/OotYaGt02nHvxT4JVB2sT7Ufw7jjNKFwQSM5pDuW/9YM9AKckK9cfN2qFEbjk49qsI4BI70guCgcEjmnCVm4HfvULBiw5IXFPD4UliB6EdaALKnAGSPepYpQq4/WqqyKygA0M6qCe/tQIvLL75pkswEbEgFvSqIlbGQajlZgpYnNFh2RRuXaWT7vU9q1LPKRjdx7VVj2Bd3pUgnwpUCqG9VYtzXChST0rIup1c4TpU8koMLbuKy9pHzZGM0JCSsSSMVbJHIq1ZzgEg9DWaWZnIHIApoc7sg4NMo6eKYEjkcVJM+epGDXPwSkEZJq5HeLuCnnFRawmi5NEAmf4ait7gwyEN0PQVaEysvbJrLui3nZA47UC33OggnDKCTzTrsCSEnv2Fc/BK8ciuWP0rTW7V4xk80E8tnoS2bH7rVqxP8uDWTBKiydferyy5AJwRUoUmTNnfkUpbJzyaqvMVkz2qTeMZXOaClsOztY8546UoY5B7e9NQDcXYH6U7fySANtAMmR/lHYetMaX5vlP1qBmwozxzToyGDY6ChEtakN1K/OGyKqxtIzDDAkVbnVfLyOMmqsT7JgOAKpOxa2LEckik7+D2xWpYPK8eWfK+lZcrY5xwat20pMR2jGKuLJlsbtncOHO07QK0IoI5lDh9zjqtc3b3LEnDDjtU8N7JFLvGBinch3Z001vFKqxxkLjqDVSTS08vcBwKrfblu0DZ2yA8YPWtBZt8CxAlXHXNPcjVGVNZqGbYv0qrJasg+cYruLeCGS3V4gpcYzmmT2C3e4lQAOhpcpn7ZX1PNL/AE2yunDXVnDOy/KpkUNgelZFxoemq2P7OtR/2zFdP4vmudFMMiad9pt3YI0nmhBGxOBu44HvWPdtrhXDeHiuT1F4uP5UKJfNFkEECQosUaqkSDCqvAA9BRUgtrhraMzw+TM4y8QbdsPpmiosacqZ5u5Zcr/KljIGM56de9SE4XKkEEdahzzhjx2rdiNG2+dSAR5Y9fWp1l3fKQB7Z6VkJIwAXIyORzirLuSFKkbsc4qGikyzPOIznOagaQzsN3QDrSFDMPl7cGmeUQTjkdzSRVyBiASCwAzSRMU4k/Cp1id1wHA9qrujJkE8mquQwByCQCfWkYlAuRx3FR72iX5D15+lI0rSEiQD8KoCQyDHJz700yHGAxBqMggHPzCkHTOABTEWvMLc8DjrThLuXk8daqAgc9T2zTWOc4I57Uh3LBk3v3pwkXIZiOKro45wOPX1pp+YHsfegLk8jAvnORVlI1Kbs5xWcmPvYznirUBwMBiDn9KTRUWX/s6sMr3HSo97RMUyQy06FnV9xbgcirJVJl81eZO+Klosfa3gZMSdqnF2rKQuSScCoEgVh+8XDH0pkipCQRnHoO1SBpxTOBgj/wCtT1lAOWOKoxXGWII696ZI7Rg5O5TSSEzXMwK4DZJqFZGXJOSKyBOTwCQO1Wo7hiu1jkVTiJM0PMIBJIC1ELr94qjkd6iA3L/KnRwjfucUrDuaAIIBHQ1KFRjtJzUUcYC8EmmyPhiVFFrk3C4RV5UYNQI7Lk96HuMEkjjFRtPGo+bA4osx3ZHcMXRgcc1QY4GDkY9adPMrHKnBzUMsxPXBx607BcfbMGYjOM1LIpVsIvNQRsGbI21dhlVyFRTI3+yM0WB1EiKMSM3pipFRwckZqf7JqEp/cafMR6kYpptdWjI3afKR7UcrD2qHK7LhjkYq0su9gOOaqzR3ccQM0EkY/wBodKiglIUsrKwPXHapcGhqalsbC2wc84NNkiEaEMMY6EVDBcMh6nFTtMkuN7c+9JahqVVmKHL549KvW92GcDPBqncqu75MEn0qmjmKQc8dzRYb1R0wkGc+lL5gHIPWsVbwb8DnNW7WbeNvU1LVg2NHz+RUgKsOTyaqIuTkU8cn3pC0CXc7BeRj0qxAoRDvpImBxuAzU+VxjvQJshfaF6ZqmWA3b1xV3aed1QTQZFA4tFX5mxhvl64qxatIwIJIFTeWkSAgduaXcjIAnFUhtk0SLGN2frTZZMMdrYBqJXzwx6dqRlVn61SZFtS1aTkdOnrWxYXxfCyPknjNYEYMeQD8tTWxC8LnrmmmJo6m21CSDeitlD6Ves9UcgKXP41zEcvbOKX7QE57VSdjJwTOuvdX0eOM2utXFkiTIcx3Drh178HqKzLzWvD7zqiatpwhxgYnXiua1yO01Gx/fOkTRESR3DgfumHfnqPUd6s6frGiyTKofSpJMYwqpyfaq3RkqbjK6OhfT7W6tVns5I5o3G5JIyGVh6g0VPpF7AoO1USMfKqgYA9gKKLIblNaHidz4enj/hJArLutMuFGShGO1e4S6YjdhVG40aN85QH8K6PZnJHEvqeIPauD80ZAHegbgw+bHqMV65deG4JM5Qe2RWNd+E0Y/IuM+lQ6ZssUupwYJ2gKxyDxjtU8MvVJgGU9SK6C58LSoCEzisubQ7mEEKp/EVm6bNlWiyqpVCTjcRwOKr3eGG1lIbrzVow3EIIKkED86z5S5c5VvSkotFqUWVZULA7QD60xRtXBqVk5HOPWo2BIIBp2LuM7nk4NKD2xketLHJ5ZbaBjuDTGJJJXjvigBQSxIGPrSheeBuqNie2ATUij5RzyOtUtQBQo47mmthSQfxpzY28U0ngHGakB6DBBB69qdEdp46+9MUlQd3TtUkecEAdu/egZbRy2d35irUUiwgMACKzmQx4DnFTByRk84FJq5SZfF44ySDj19KBOj/eIyOtVYJcqQy89vemyKGyCNmOtLlHcGkYMSDkZ6U8TO4AY8UwqAx5B9qmjHy8CqUSXIAARzwfSrMa7cZBJpkaE4AAz6+lXLePDDce9Vy3M+axNF5m0Hbgd+eas7xswAMevpVy30ue4IMcRZScAkYrXtvCMjIDdy7Qf4UHX8afszN1kc356rgbsfU0omLKSiM30Ga7WDQNPtyA0AY+/NadtZQqQIkRR/u0/ZEuv2R5eLS7uCTHbSkeuMU8aPfng2z49zXp88UYGGbGOwqu1o0pPlK31JpqmkT7dnAR+GLlgC/lqD6mpB4VyuJLgKAeAorulspkGHfg+gqRLJyB8oJHcinZLoS6jfU4RPBkEjDzJJX57HFdt4f0G3tIFhtYYw3qetatnZyDHyKavC1YYYJsI6GlYhzbIU0m5XiVRtxzjikmsFjUb/lPY+laVnq7EtHOu8r/EKr3lwkwYyDPcKtFhKT6nP61bfbLJ7cICSMFyK5yy8IWcPzT7hGoJ4PBNdRe3rwaeFC5JPyADk1BY6Pe3KebfybYupjzgVdlYrmaehxMuk3ss0klnbFrNT8rE81hXjFZSr5Vx1B616td3m6PyLFBHGoxkdK5XVNFguGLOh3nqw65qXRTLjiOV2ZyEczRtuLZBps0m88dDV+70G4i5hbzF9+DWXPDPAcTRsvpxWbpNHTGvGSH8gfK3Iqe0umhcNnr1rP3bjkHkUrHIxk1m4mqmjr7W5RwuGq2Sp5UjPeuPt7p0UDrir9tqTBl3nHasnCw7djpVZP4utPYqFyKyPtiuwA61ajlJUb+KloLFwMpGaceBkVVifa2cfLU0koxxSsJi7hj5uRVaZ1JzCCMVHM7BCFIxVZZn80KRjNWkVEni3eaC3NXgyqeByapqvp1NO80IwBOTQPcvgbqcH8s9gKorOS2c49qkkmDLk8Gghplprnrt5Pc1HLc4jPf1rN83EuBnNTEkD5ulMfKZOtXUC6jYy6jA9xpqK4ZQpdUkOMMyjqMVDqGreHJ7d4ktorgkECOK2O8ntjjg+9Q61c3R1CCzspVgeRGleUruwo4wB681UtNSuIJ5LPUCguChaCdBtWbA6ezD0q0RKOtzqfD15eQaTZW927GdYwHLHJHoCfpiisTQLya40i0nnbfM8e5m9Tk0U2ylHQ92aNSODUZiBGB+tOEgPel3c5rsPnrkJt89gaha1Bzhau7vfFOUjnIFA7mRJYqeoqpNpiMDlQa6DANNMYJ6UD5jkbrQoXBDIMYrLuvDEDLwgBrv3iHoDUTWwPYUrFKozyi88IKclcise78KzR8oD1r2h7QHORnNVptPUjoKXKjaOIkjwu40G4iOdp/AVQnsZl4ZGyPQV7xNpMbDlAfwrMufD0Lk/IPyqeRGscS+p4k8ZXgqR701QexxXq134UikBwmPwrFu/CDAHYMfSk4s1WJi9zhGGOe3p60AAHj0rpLrwxcI5IHNZk2k3MS4aMn0qOWxqqsWUWJA6dOtT27AMCRyajkgkQ8oR+FMZyoGVIIoaNFJF9yrcEDI5FQlmJ+YDPoKovOBICWwcU1r0A+vbikNySLyvgnbnIpwJyDzmq9lFcXUirDC8jHpgHmuq0nwlqNx81yRCnooyaqxk6iMJmAGSwzSwyTyuEtraWZj/dTgfjXolj4XsLM/6nzG7mQ5Na0MIQ7YYUXA7LVKJm6vY88sfD+qXbAzp9mT82rr9F8Pi0KsAjSZ+/JyRW/BZ3c5xt2j6Vdh0aRuZmOCa0SS2MZSvuV4YxFh5Zt7L2HSppb5QmIxuc/kK0I9GiVgAhb8auR6RGDyoHtTM+ZHNBnOGJYk+1Isjhvm3j2Arrhp0CpklRTVsrcnov1NS0P2iOdiJY/u4ck92qwrXg4CAD6VueXBFx1HsKek6ZCrGGz0pWJc7mNDHI5IcEVqRWsZjG/irc8ciqD5agfSskX+658lsFhTDVjvLlinH2Zizf3a1HhcoDcsOn3FqayaHZmNQJOpzVbUr+C3PzZM3bFIZjPaltRTadkbHH1qW6Aj3pFHyOpNVjO13epyVAOSK19TlUMkiqCu3a1BTOa0tonujdXRJWElUTuTWjfXM14oViY4euBxmub0WYma7P3sSnbnoK2FdpCWfnFaITIXjVVAQcVWljGemavYDN0460xo8nOMCncSRlSQKenWq1xaKww6hgexFa7RgH1qN4g3IouO1jlrrw/azZIXYSOq1iXnh65jJ8twwA4yK9BaEdsc1E8IJANJpPcqMpLY8qmguICVkjYY6tSQn5upz2zXpc1gjjDICPTGaybvw/BLyF2N221jKlfY6IYhrc5qOboCMNWzaTl1AYYxVafQLmMkxnzAOgNMXzrYESRsKwlTaN1WUkbAYMT2FQmQq/HIqlHdAjhse1SNJxkGs+WxSkWWJb5sU0xkuGFVkuscH6VJHNz1zRYpMnYuiEscD2qkbn5/lHTpS3c42EGorVA5DHr70WKTNG3y4DVNL83TtUSSBeAMGmyygHp170g3HJ6sOakmUlRio4gzyZJGzFSzHK4HOKEJvUxL/SkvWjd/MWSJso8bbWHqM+hp15oyXtv5d0h2E5GOCD2IPrS6xeGFRDHI8KrGZpnjGX252hUz/ExOM1TuV+xy2xtWvIJ5TtDyTGRA56K6k9D0yOlVqJy8ja0rTorOzhtUZmWJdqlup+tFSaZdC/tIbnbsLrkpn7p6Efnmildi5j0hLoHoamW4G3rWClWVJ29TXpngtG0JuxzUizDoM1kqTkcnpVlCdtSSaAkGelO8wVUQ8UA/NQBcz6daXtiq696cDzSAmGKTaDnAz9aSikA0oGx2qN4QasjpUbdaB3Kj26t1FQSWaMSMVpHpTB3oC7MWbTkbICiqM+iRtnKjB9q6cdTUTfeplKTOJuvDcEg/1YrEvPCMLNnbkZ5r0pgMHiqsoHmdKXKjSNSR5wmgRQcC1j/Fc1padpekrg3VrET6bK6icD5uB0qhcouPur09KTijTnk+pasn02GLZbQJF/ugVa2+acCQZ+tctJxIccfSrNm75X5m/OnYZ1MOmqcE9PY1ajhiiYBQD+FZVrI/l/fb86v2xO9eaRm2zWt4lC5Gfxp0t7DG4iQbpAO1Qyk7V571lab/AMhCT/fpoIxvubct3IqKfLIL8A4qe3t5pkLSOQfbvTbv/WQ/WtSP/VrSuOyRDBZxqvzDce+akaGLcPkGalqNvvD6UkxIpansjgbagJrK0s77csx+cNkD8an1AnbJzVKx+631plWNqeYPjL/Ljsc81iQRot8zED5h1NEB/wBH/E/zoX7340FR3N20jVm3dSB2rD8QTrHMwRQW6A1vQ8WhI9K5XVf9dFSH1IrJTGc9SxyTV/UrwQaXNJJjAXPNVreqvi//AJAb/UUxmN4djP2Qu2f3rl63FODx2rP08YtY8egq7H941RD3Jfp3prMeR6UL941E/egBB15ocBQMd6B0/Cmd6QCEY5FHUcDmlPQUL1FA0NAOTmk2qw6U/saR+tAyJoVK8j6YqtJZxyKd6g/WrlCd6Cjnr/RbdyNihfcVmSaJKikwyE+xrrbjtUI+7UOKZSkzgry1vIF+eLcB3Wsw6lJA+2VWUds16NMM781zesRRlclFJ56ip9mjWNVowH1gMoBANTWmqJnk4+tY2ooqnhQOOwqCLt9KiUUbxnc7NbkMAQRz6VP5isOPmrn9NPFalqTsHPesbFpmjDIA3JIqV5g2dnWs+U8UqUWEUtfid8TxxmUGMwyxK2GZM5DKf7wIyKxGvLid49sl3dSxsGjSWDykDdmc98dcDrXQ3PQ1RJJ6072LUL6l3S3+x2cMSOWWNcEnqT3P50VSTv8ASikOx//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Widespread retiform purpura are present in this patient with disseminated intravascular coagulation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Acral purpura in disseminated intravascular coagulation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple purpuric lesions are present on the hand of this patient with disseminated intravascular coagulation. Several lesions exhibit a retiform shape.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_34_36392=[""].join("\n");
var outline_f35_34_36392=null;
var title_f35_34_36393="Pathophysiology and etiology of edema in adults";
var content_f35_34_36393=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathophysiology and etiology of edema in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/34/36393/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/34/36393/contributors\">",
"     Richard H Sterns, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/34/36393/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/34/36393/contributors\">",
"     Michael Emmett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/34/36393/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/34/36393/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/34/36393/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 29, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Edema is defined as a palpable swelling produced by expansion of the interstitial fluid volume. A variety of clinical conditions are associated with the development of edema, including heart failure, cirrhosis, and the nephrotic syndrome (",
"    <a class=\"graphic graphic_table graphicRef53550 \" href=\"mobipreview.htm?5/3/5181\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Some patients have localized edema. This can be caused by a variety of conditions, including venous obstruction, as occurs with deep vein thrombosis or venous stasis, and allergic reactions (such as laryngeal edema).",
"   </p>",
"   <p>",
"    This topic will review the pathophysiology and etiology of generalized edematous states. The clinical manifestations, diagnosis, and therapy of edema are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/36/34375?source=see_link\">",
"     \"Clinical manifestations and diagnosis of edema in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/50/30503?source=see_link\">",
"     \"General principles of the treatment of edema in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/40/650?source=see_link\">",
"     \"Treatment of refractory edema in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY OF EDEMA FORMATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two basic steps involved in edema formation:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An alteration in capillary hemodynamics that favors the movement of fluid from the vascular space into the interstitium.",
"     </li>",
"     <li>",
"      The retention of dietary or intravenously administered sodium and water by the kidneys.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The importance of the kidneys in the development of edema should not be underestimated. Edema (other than localized edema as with an allergic reaction) does not become clinically apparent until the interstitial volume has increased by at least 2.5 to 3 liters. Since the normal plasma volume is only about 3 liters, it is clear that patients would develop marked hemoconcentration and shock if the edema fluid were derived only from the plasma.",
"   </p>",
"   <p>",
"    Hemoconcentration and shock do not occur because of the following sequence:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The initial movement of fluid from the vascular space into the interstitium reduces the plasma volume and consequently tissue perfusion.",
"     </li>",
"     <li>",
"      In response to these changes, the kidney retains sodium and water.",
"     </li>",
"     <li>",
"      Some of this fluid stays in the vascular space, returning the plasma volume toward normal. However, the alteration in capillary hemodynamics results in most of the retained fluid entering the interstitium and eventually becoming apparent as edema.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The net effect is a marked expansion of the total extracellular volume (as edema) with maintenance of the plasma volume at closer-to-normal levels. This pathophysiologic sequence also illustrates an important point that must be considered when treating a patient with edema. Renal sodium and water retention in most edematous states is an",
"    <strong>",
"     appropriate",
"    </strong>",
"    compensation in that it restores tissue perfusion, even though it also augments the degree of edema. Removing the edema fluid with diuretic therapy will improve symptoms due to edema but may diminish tissue perfusion, occasionally to clinically significant levels. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/50/30503?source=see_link\">",
"     \"General principles of the treatment of edema in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The hemodynamic effects are different when the primary abnormality is",
"    <strong>",
"     inappropriate",
"    </strong>",
"    renal fluid retention. In this setting, both the plasma and interstitial volumes are expanded, and deleterious hemodynamic effects from removal of the excess fluid are much less likely. This is an example of overfilling of the vascular tree which most often occurs with primary renal disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Capillary hemodynamics",
"    </span>",
"    &nbsp;&mdash;&nbsp;The exchange of fluid between the plasma and the interstitium is determined by the hydraulic and oncotic pressures in each compartment. The relationship between these parameters can be expressed by Starling's law [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/34/36393/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    Net filtration &nbsp;= &nbsp; LpS &nbsp; x &nbsp;",
"    <span class=\"nowrap\">",
"     (&Delta;",
"    </span>",
"    hydraulic pressure &nbsp; - &nbsp;",
"    <span class=\"nowrap\">",
"     &Delta;",
"    </span>",
"    oncotic pressure)",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; = &nbsp; LpS &nbsp; x &nbsp; [(Pcap &nbsp;- &nbsp; Pif) &nbsp; - &nbsp; s(&pi;cap &nbsp; - &nbsp; &pi;if)]",
"   </p>",
"   <p>",
"    where Lp is the unit permeability (or porosity) of the capillary wall, S is the surface area available for fluid movement, Pcap and Pif are the capillary and interstitial fluid hydraulic pressures, &pi;cap and &pi;if are the capillary and interstitial fluid oncotic pressures, and s represents the reflection coefficient of proteins across the capillary wall (with values ranging from 0 if completely permeable to 1 if completely impermeable). The interstitial oncotic pressure is derived primarily from plasma proteins that have crossed from the capillary to the interstitium and, to a lesser degree, proteoglycans, which originate in the interstitium. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/12/40133?source=see_link\">",
"     \"Chapter 7B: Exchange of water between plasma and interstitial fluid\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Approximate normal values in the skeletal muscle capillary are shown in this table (",
"    <a class=\"graphic graphic_table graphicRef78801 \" href=\"mobipreview.htm?8/26/8620\">",
"     table 2",
"    </a>",
"    ). As can be seen, the mean capillary hydraulic pressure (17 mmHg), which pushes fluid out of the capillary, and the plasma oncotic pressure (28 mmHg), which pulls fluid back into the capillary, are quantitatively the most important. There is normally a small mean gradient of about 0.3 mmHg favoring filtration out of the vascular space; the fluid that is filtered is then returned to the systemic circulation by the lymphatics so that fluid accumulation in the interstitium is prevented.",
"   </p>",
"   <p>",
"    Starling's forces are substantially different in some other organs, such as the liver [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/34/36393/abstract/3\">",
"     3",
"    </a>",
"    ]. The hepatic sinusoids are highly permeable to proteins; as a result, the capillary and interstitial oncotic pressures are roughly equal, and there is little transcapillary oncotic pressure gradient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/34/36393/abstract/2\">",
"     2",
"    </a>",
"    ]. The net effect is that the hydraulic pressure gradient favoring filtration is essentially unopposed. To some degree, filtration is minimized by a lower capillary hydraulic pressure than in skeletal muscle since approximately two-thirds of hepatic blood flow is derived from the portal vein, a low-pressure system. In addition, ascites does not normally develop because the filtered fluid is removed by the lymphatics.",
"   </p>",
"   <p>",
"    The alveolar capillaries also have a relatively low capillary hydraulic pressure (due to perfusion from the low-pressure system in the right ventricle) and are more permeable than skeletal muscle to proteins. This results in smaller transcapillary hydraulic and oncotic pressure gradients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/34/36393/abstract/4\">",
"     4",
"    </a>",
"    ]. The clinical significance of this difference will be discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Edema formation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development of edema requires an alteration in one or more of the Starling forces in a direction that favors an increase in net filtration and also inadequate removal of the additional filtered fluid by lymphatic drainage. Edema may form in response to an elevation in capillary hydraulic pressure (which increases the",
"    <span class=\"nowrap\">",
"     \"&Delta;",
"    </span>",
"    hydraulic pressure\"), increased capillary permeability (Lp), higher interstitial oncotic pressure, a lower plasma oncotic pressure (which reduces the",
"    <span class=\"nowrap\">",
"     \"&Delta;",
"    </span>",
"    oncotic pressure\"), or a combination of these changes (",
"    <a class=\"graphic graphic_table graphicRef53550 \" href=\"mobipreview.htm?5/3/5181\">",
"     table 1",
"    </a>",
"    ). Edema can also be induced by lymphatic obstruction since the fluid that is normally filtered is not returned to the systemic circulation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Increased capillary hydraulic pressure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Capillary hydraulic pressure, although generated by cardiac contraction, is relatively insensitive to alterations in arterial pressure. This stability is due to autoregulatory changes in resistance at the precapillary sphincter, which determine the extent to which the arterial pressure is transmitted to the capillary. If the arterial pressure is increased, for example, the sphincter constricts, minimizing the elevation in capillary hydraulic pressure and preventing the development of edema.",
"   </p>",
"   <p>",
"    In contrast, the resistance at the venous end of the capillary is not well regulated. Consequently, changes in venous pressure result in parallel alterations in capillary hydraulic pressure. The venous pressure is increased in two settings: (1) when the blood volume is expanded, augmenting the volume in the venous system, and (2) when there is venous obstruction. Examples of edema due to volume expansion include heart failure and renal disease; edema due to effective venous obstruction is commonly seen with cirrhosis of the liver, in which there is a marked increase in hepatic sinusoidal pressure, and with deep venous thrombosis in the lower extremities. Diastolic dysfunction due to decreased compliance of the heart (which results in pulmonary edema) and right heart failure and pericardial disease (which result in peripheral edema) are other causes of effective venous obstruction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Hypoalbuminemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypoalbuminemia due to albumin loss in the urine in the nephrotic syndrome or to decreased hepatic albumin synthesis also contributes to edema formation. However, chronic hypoalbuminemia alone may be insufficient to induce edema (see",
"    <a class=\"local\" href=\"#H9\">",
"     'Compensatory factors'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Increased capillary permeability",
"    </span>",
"    &nbsp;&mdash;&nbsp;An increase in capillary permeability due to vascular injury promotes the development of edema for several reasons. With vascular injury, the unit permeability (porosity, or \"Lp\" in the equation above) of the capillary wall increases, which tends to increase net filtration. In addition, the reflection coefficient of proteins across the capillary wall (\"s\" in the equation above) decreases, and the movement of albumin from the vascular space into the interstitium narrows the difference between the capillary and interstitial oncotic pressures (\"ncap\" and \"nif\"), thereby reducing the oncotic pressure gradient.",
"   </p>",
"   <p>",
"    Increased capillary permeability contributes to edema in the following clinical settings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Burns, in which both histamine and oxygen free radicals can induce microvascular injury in addition to the direct physical action of the injury [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/34/36393/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Therapy with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/33/30231?source=see_link\">",
"       recombinant human interleukin-2",
"      </a>",
"      or vascular endothelial growth factor, which appear to directly increase capillary permeability [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/34/36393/abstract/6,7\">",
"       6,7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Episodic idiopathic",
"      <strong>",
"       capillary leak",
"      </strong>",
"      syndromes, which may be mediated by increased expression of interleukin-2 receptors on circulating mononuclear cells or by increased generation of kinins [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/34/36393/abstract/8-10\">",
"       8-10",
"      </a>",
"      ]. Affected patients often have an associated monoclonal gammopathy and, during episodes, have a massive leak of proteins and fluids out of the vascular space with the hematocrit rising acutely to as high as 70 to 80 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/34/36393/abstract/10\">",
"       10",
"      </a>",
"      ]. The mortality rate is high in this disorder. Preliminary evidence suggests that the combination of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/19/14648?source=see_link\">",
"       aminophylline",
"      </a>",
"      (an inhibitor of phosphodiesterase) and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/55/12151?source=see_link\">",
"       terbutaline",
"      </a>",
"      (a relatively selective beta-2-adrenergic agonist) may prevent episodes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/34/36393/abstract/10,11\">",
"       10,11",
"      </a>",
"      ] and therefore improve survival [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/34/36393/abstract/8,11\">",
"       8,11",
"      </a>",
"      ]. It is not clear, however, why these drugs are effective. The associated monoclonal gammopathy may progress to overt multiple myeloma among those patients with capillary leak syndrome who survive long enough. In one series of 11 patients followed for a mean of 6.4 years, three died&mdash;one during an attack and two from multiple myeloma [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/34/36393/abstract/8\">",
"       8",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/26/426?source=see_link\">",
"       \"Idiopathic systemic capillary leak syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Any of the conditions associated with the adult respiratory distress syndrome. In this disorder, ischemia- or sepsis-induced release of cytokines, such as interleukin-1 or tumor necrosis factor, may play an important role in the increase in pulmonary capillary permeability, at least in part via the recruitment of neutrophils [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/34/36393/abstract/12,13\">",
"       12,13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Capillary permeability is moderately increased in patients with diabetes mellitus [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/34/36393/abstract/14,15\">",
"       14,15",
"      </a>",
"      ]. This abnormality may be mediated in part by hyperglycemia-induced accumulation of advanced glycosylation end products derived from the combination of glucose with circulating proteins [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/34/36393/abstract/16\">",
"       16",
"      </a>",
"      ]. The net effect is to enhance the severity of edema which, in these patients, is usually due to heart failure or the nephrotic syndrome.",
"     </li>",
"     <li>",
"      The malnutrition syndrome, kwashiorkor, may be another example of edema due in part to increased capillary permeability. Although edema has often been ascribed to hypoalbuminemia, increased generation of cysteinyl leukotrienes that increase capillary permeability may be of primary importance in the edema of kwashiorkor [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/34/36393/abstract/17\">",
"       17",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Compensatory factors'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Lymphatic obstruction (lymphedema)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lymphatic obstruction is an unusual cause of edema (called lymphedema). It is most often due to radical lymph node dissection for malignancy (eg, breast cancer). Lymphatic obstruction may also play a pivotal role in the development of \"nephrogenic ascites\" [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/34/36393/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/52/1866?source=see_link\">",
"     \"Clinical manifestations and diagnosis of lymphedema\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/31/20986?source=see_link&amp;anchor=H30#H30\">",
"     \"Gastrointestinal disease in dialysis patients\", section on 'Idiopathic dialysis ascites'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13679763\">",
"    <span class=\"h3\">",
"     Myxedema",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypothyroidism leads to a marked accumulation of interstitial albumin and other proteins [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/34/36393/abstract/20\">",
"     20",
"    </a>",
"    ]. Although this may be due in part to an elevation in capillary protein permeability, the excess interstitial protein and fluid would normally be returned to the systemic circulation by the lymphatics. However, lymphatic flow is low or normal in patients with myxedema [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/34/36393/abstract/20\">",
"     20",
"    </a>",
"    ] and not increased as in other edematous states [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/34/36393/abstract/21\">",
"     21",
"    </a>",
"    ]. This may be due to binding of the filtered proteins to excess interstitial mucopolysaccharides, thereby preventing their removal by the lymphatics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/34/36393/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Compensatory factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since there is normally a small gradient favoring filtration, it might be expected that only a minor change in these hemodynamic forces would lead to edema. However, experimental and clinical observations indicate that there must be at least a",
"    <strong>",
"     15 mmHg",
"    </strong>",
"    increase in the gradient favoring filtration before edema can be detected [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/34/36393/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Three factors contribute to this protective response.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lymphatic flow and contractility increase in the presence of tissue edema and remove some of the excess filtrate [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/34/36393/abstract/22,23\">",
"       22,23",
"      </a>",
"      ]. With pulmonary edema due to heart failure, for example, accumulation of lung liquid at any given elevation in pulmonary capillary pressure is related to the functional capacity of the lymphatics which, in turn, is influenced by both individual factors and the acuteness of the hemodynamic change [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/34/36393/abstract/24\">",
"       24",
"      </a>",
"      ]. With acute rises in pulmonary capillary pressures, the pulmonary lymphatic system does not have an increased capacity to remove fluid; as a result, pulmonary edema occurs at pulmonary artery capillary pressures as low as 18 mmHg. In contrast, patients with chronic heart failure have an increased lymphatic capacity and do not develop pulmonary edema until much higher pulmonary capillary pressures (eg, &gt;25 mmHg) are reached.",
"     </li>",
"     <li>",
"      Fluid entry into the interstitium will eventually raise the interstitial hydraulic pressure, reducing the pressure gradient favoring filtration [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/34/36393/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Fluid entry into the interstitium also lowers the interstitial oncotic pressure, both by dilution and by lymphatic-mediated removal of interstitial proteins. As an example, interstitial oncotic pressure falls to very low levels in heart failure, while the plasma oncotic pressure is relatively normal [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/34/36393/abstract/25\">",
"       25",
"      </a>",
"      ]. The associated increase in the transcapillary oncotic pressure gradient (&pi;cap &nbsp;- &nbsp;&pi;if) counterbalances the rise in capillary hydraulic pressure, thereby minimizing the degree of edema formation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The reduction in interstitial oncotic pressure has important implications for the role of hypoalbuminemia in edema formation and for the tendency of edema to form at different sites. The normal interstitial oncotic pressure in subcutaneous tissue in humans may be as high as 12 to 15 mmHg [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/34/36393/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. As a result, a gradual fall in plasma oncotic pressure in the nephrotic syndrome, for example, will be associated with a parallel decline in the interstitial oncotic pressure due to less entry of albumin into the interstitium. The net effect is that the transcapillary oncotic pressure gradient is initially maintained with little tendency to edema formation. Thus, in the absence of severe hypoalbuminemia, edema in the nephrotic syndrome and renal disease is primarily due to renal sodium retention. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/10/36008?source=see_link\">",
"     \"Pathophysiology and treatment of edema in patients with the nephrotic syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Similar considerations concerning hypoalbuminemia-induced edema apply to the pulmonary circulation. The alveolar capillaries appear to have a greater baseline permeability to albumin and therefore a higher interstitial oncotic pressure of about 18 mmHg [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/34/36393/abstract/2,4\">",
"     2,4",
"    </a>",
"    ]. This leads to a larger protection against edema due to hypoalbuminemia than seen in skeletal muscle since there can be a greater parallel decline in the interstitial oncotic pressure. Thus, in the absence of a concurrent rise in left atrial and pulmonary capillary pressures, pulmonary edema is not usually seen with hypoalbuminemia, even at a plasma albumin concentration acutely low enough to induce peripheral edema [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/34/36393/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The response is appreciably different after the rapid administration of large volumes of saline to patients with marked hypovolemia, a condition in which a low plasma albumin concentration can predictably cause edema. In this setting, there is acute dilutional hypoalbuminemia without time for the interstitial albumin concentration to fall. As a result, the transcapillary oncotic pressure gradient is reduced, and pulmonary edema can occur before the restoration of normal intracardiac filling pressures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Renal sodium retention",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, the retention of fluid by the kidney in edematous states can represent an appropriate compensatory response to reduced effective arterial blood volume (also called effective circulating volume depletion) or an inappropriate manifestation of renal disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/34/36393/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. In most instances, the effective arterial blood volume is directly proportional to the cardiac output. Thus, when the cardiac output is reduced because of underlying cardiac disease, the kidney serves to restore the effective arterial blood volume by retaining sodium and water.",
"   </p>",
"   <p>",
"    However, effective tissue perfusion and the cardiac output are not always related since the former can also be reduced by a decrease in peripheral vascular resistance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/34/36393/abstract/30\">",
"     30",
"    </a>",
"    ]. As an example, experimental creation of an arteriovenous fistula is associated with no initial change in cardiac output, yet tissue perfusion is reduced since the blood flowing through the fistula is bypassing the capillary circulation. In response to this hemodynamic change, the kidney retains sodium and water, thereby increasing the blood volume and cardiac output [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/34/36393/abstract/31\">",
"     31",
"    </a>",
"    ]. The new steady state is characterized by a cardiac output that exceeds the baseline level by an amount equal to the flow rate through the fistula.",
"   </p>",
"   <p>",
"    A common clinical correlate of this experiment occurs in patients with cirrhosis and ascites, who frequently have an elevated cardiac output [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/34/36393/abstract/32\">",
"     32",
"    </a>",
"    ]. Despite this, they behave as if they are volume depleted, as evidenced by avid renal sodium retention and a progressive rise in secretion of the three hypovolemic hormones&mdash;renin, norepinephrine, and antidiuretic hormone (ADH) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/34/36393/abstract/30,33,34\">",
"     30,33,34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/12/17608?source=see_link\">",
"     \"Hyponatremia in patients with cirrhosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The disparity between the high cardiac output and the renal and neurohumoral responses in cirrhosis is due both to splanchnic vasodilatation and to the presence of multiple arteriovenous fistulas throughout the body, such as spider angiomata in the skin. The net effect is a marked fall in systemic vascular resistance and a reduction in systemic blood pressure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/34/36393/abstract/30,35\">",
"     30,35",
"    </a>",
"    ]. Much of the cardiac output is circulating ineffectively, as there is a progressive reduction in renal and eventually musculocutaneous perfusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/34/36393/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The renal sodium and water retention seen in heart failure or cirrhosis results from both a hypovolemia-induced fall in glomerular filtration rate (GFR) and, more importantly, an increase in tubular reabsorption. The latter is mediated by increases in the activity of the renin-angiotensin-aldosterone and sympathetic nervous systems [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/34/36393/abstract/30,37,38\">",
"     30,37,38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     The compensated state",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the renin-angiotensin-aldosterone system undoubtedly contributes to sodium retention in disorders such as heart failure and cirrhosis, the plasma renin activity is normal in some patients with these disorders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/34/36393/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. A partial explanation for this seemingly paradoxical finding is that the patient has entered a compensated state in which the initial fluid retention has increased venous return to the heart, thereby allowing systemic hemodynamics to be stabilized (at least in the resting state) and removing the stimulus for continued renin release [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/34/36393/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. This sequence is depicted in the figure, which shows the changes that occur with chronic thoracic inferior vena cava constriction, an experimental model that simulates the changes seen in heart failure in humans (",
"    <a class=\"graphic graphic_figure graphicRef52302 \" href=\"mobipreview.htm?11/49/12063\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/34/36393/abstract/37\">",
"     37",
"    </a>",
"    ]. The new steady state seen after six to seven days is characterized by plasma volume expansion but normalization of the systemic blood pressure, urinary sodium excretion, and renin and aldosterone release.",
"   </p>",
"   <p>",
"    In many patients, however, stable heart failure is associated with a persistent reduction in cardiac output, and it is not clear why renin levels should be normal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/34/36393/abstract/37\">",
"     37",
"    </a>",
"    ]. One possible explanation is that circulating levels may not reflect the degree of activation of tissue renin-angiotensin systems. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/61/36825?source=see_link\">",
"     \"Actions of angiotensin II on the heart\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common causes of generalized edema seen by the clinician are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Heart failure",
"     </li>",
"     <li>",
"      Cirrhosis",
"     </li>",
"     <li>",
"      Nephrotic syndrome and other forms of renal disease",
"     </li>",
"     <li>",
"      Premenstrual edema and pregnancy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The pathogenesis of edema in heart failure will be reviewed here because it illustrates many of the mechanisms described above [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/34/36393/abstract/40\">",
"     40",
"    </a>",
"    ]; the unusual causes of drug-induced edema and refeeding edema will also be briefly reviewed. However, the pathogenesis of edema in cirrhosis, renal disease, and premenstrual or pregnant women is discussed separately. The pathogenesis of the uncommon condition idiopathic edema, which is generally seen in young women, is also presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/1/21527?source=see_link\">",
"     \"Pathogenesis of ascites in patients with cirrhosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/10/36008?source=see_link\">",
"     \"Pathophysiology and treatment of edema in patients with the nephrotic syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/20/27978?source=see_link\">",
"     \"Preeclampsia: Clinical features and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/31/20981?source=see_link\">",
"     \"Idiopathic edema\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Heart failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Heart failure can be produced by a variety of disorders, including coronary artery disease, hypertension, the cardiomyopathies, valvular disease, and cor pulmonale. The edema in the different causes of heart failure is due to an increase in venous pressure that produces a parallel rise in capillary hydraulic pressure and to renal sodium retention due to reduced perfusion of the kidneys. Despite the similarity in pathogenesis, the",
"    <strong>",
"     site",
"    </strong>",
"    of edema accumulation is variable and is dependent upon the nature of the cardiac disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/34/36393/abstract/41\">",
"     41",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Coronary, hypertensive heart disease, and left-sided valvular disease tend to preferentially impair left ventricular function. As a result, patients with one of these disorders typically present with pulmonary but not peripheral edema.",
"     </li>",
"     <li>",
"      Cor pulmonale, in contrast, is initially associated with pure right ventricular failure, resulting in prominent edema in the lower extremities and perhaps ascites.",
"     </li>",
"     <li>",
"      Cardiomyopathies tend to produce equivalent involvement of both the right and left ventricles, often leading to the simultaneous onset of pulmonary and peripheral edema.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In acute pulmonary edema due to a myocardial infarction or ischemia, the left ventricular disease results in elevations in left ventricular end-diastolic and left atrial pressures, which are transmitted",
"    <strong>",
"     back",
"    </strong>",
"    through the pulmonary veins to the pulmonary capillaries. In general, the pulmonary capillary pressure must exceed 18 to 20 mmHg (normal equals 5 to 12 mmHg) before acute pulmonary edema occurs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/34/36393/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pathogenesis of edema formation is somewhat different in chronic heart failure. In this setting, the increase in capillary pressure is a result of plasma volume expansion, not solely the obstructive effect of a diseased heart. This is called the",
"    <strong>",
"     forward",
"    </strong>",
"    hypothesis of heart failure, in which the primary event is a reduction in cardiac output [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/34/36393/abstract/30,43\">",
"     30,43",
"    </a>",
"    ]. This decrease in tissue perfusion leads to activation of the sympathetic and renin-angiotensin systems, which tend to promote sodium and water retention; they also tend to increase vascular resistance and cardiac inotropy, which maintain the systemic blood pressure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/34/36393/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/44/32455?source=see_link\">",
"     \"Pathophysiology of heart failure: Neurohumoral adaptations\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The net effect in patients with relatively well-preserved cardiac function is an initially mild impairment in sodium-excretory ability. Edema is often absent at this time, unless there is a high level of sodium intake [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/34/36393/abstract/46\">",
"     46",
"    </a>",
"    ]. With more advanced disease, however, forward output can be restored only by plasma volume expansion and intracardiac filling pressures that are high enough to promote edema formation.",
"   </p>",
"   <p>",
"    Similar considerations apply to high-output heart failure due, for example, to hyperthyroidism (where the hypermetabolic state leads to an increase in energy requirements) or to arteriovenous fistulas (where blood flowing through the fistulas is bypassing the capillary circulation). In these conditions, the patients still behave as if they are effectively volume depleted since the cardiac output is inappropriately low in relation to tissue needs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/34/36393/abstract/31,47\">",
"     31,47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The effect of fluid retention on cardiac function is illustrated in the following figure (",
"    <a class=\"graphic graphic_figure graphicRef58693 \" href=\"mobipreview.htm?32/56/33677\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/34/36393/abstract/40\">",
"     40",
"    </a>",
"    ]. The left ventricular end-diastolic pressure (LVEDP) is a function of the plasma and extracellular fluid volumes and is increased or decreased by expanding or reducing those fluid spaces. The upper curve represents the normal Frank-Starling relationship between stroke volume and LVEDP and shows how increasing cardiac stretch enhances cardiac contractility [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/34/36393/abstract/36\">",
"     36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/34/23076?source=see_link\">",
"     \"Pathophysiology of heart failure: Left ventricular pressure-volume relationships\"",
"    </a>",
"    .) The development of mild cardiac failure (middle curve) will, if the sympathetic stimulation of cardiac function is insufficient, lower both stroke volume and cardiac output (line AB). The ensuing renal sodium and water retention can reverse these abnormalities since the increments in plasma volume will increase the LVEDP, and this augments cardiac contractility (line BC).",
"   </p>",
"   <p>",
"    At this point, the patient is in a new steady state of compensated heart failure in which the stroke volume and cardiac output are normal, sodium excretion matches sodium intake, and the activity of the renin-angiotensin-aldosterone system has returned to normal (",
"    <a class=\"graphic graphic_figure graphicRef52302 \" href=\"mobipreview.htm?11/49/12063\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/34/36393/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. The restoration of tissue perfusion in this setting has occurred only after there has been an elevation in the LVEDP, perhaps to a level sufficient to produce pulmonary edema.",
"   </p>",
"   <p>",
"    There are several points that deserve emphasis in this simple example of mild to moderate heart failure:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      It demonstrates again the dual effects of fluid retention in edematous states: a beneficial increment in cardiac output and a potentially harmful elevation in venous pressure.",
"     </li>",
"     <li>",
"      It illustrates that vascular congestion (that is, an elevated LVEDP) and a low cardiac output do not have to occur together in patients with heart disease. At point B, the patient is in a low-output state, but there is no congestion; at point C, the patient is congested but has a normal cardiac output.",
"     </li>",
"     <li>",
"      The Frank-Starling relationship varies with exercise. Patients with moderate heart disease may have a normal cardiac output at rest but may be unable to increase it adequately with even mild exertion [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/34/36393/abstract/48\">",
"       48",
"      </a>",
"      ]. This relative decrease in tissue perfusion can lead sequentially to further neurohumoral activation, renal vasoconstriction and ischemia, sodium retention, and ultimately edema [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/34/36393/abstract/49,50\">",
"       49,50",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients with mild to moderate heart disease may have no edema with dietary sodium restriction but may retain sodium and possibly become edematous if given a sodium load [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/34/36393/abstract/46\">",
"       46",
"      </a>",
"      ]. Suppose points A and C in the figure reflect the hemodynamic state on a low-sodium diet (",
"      <a class=\"graphic graphic_figure graphicRef52302 \" href=\"mobipreview.htm?11/49/12063\">",
"       figure 1",
"      </a>",
"      ). An increase in sodium intake will initially expand the intravascular volume and raise the LVEDP. In the normal subject (point A) who is still on the ascending limb of the Frank-Starling curve, the increase in filling pressure will enhance stroke volume and cardiac output, which will then promote the excretion of the excess sodium. In contrast, a similar elevation in the LVEDP in the patient with heart failure (point C), who is on a flatter part of the curve, will produce less of an increment both in cardiac output and consequently in sodium excretion. Limiting dietary sodium intake in this setting may be sufficient to alleviate the edema.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The situation is somewhat different with severe heart failure (",
"    <a class=\"graphic graphic_figure graphicRef58693 \" href=\"mobipreview.htm?32/56/33677\">",
"     figure 2",
"    </a>",
"    ). At this time, the plateau in stroke volume occurs earlier and at a lower level than in mild heart failure, and increasing the LVEDP cannot normalize the stroke volume. Two factors appear to account for this plateau.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The heart may simply have reached its maximum capacity to increase contractility in response to increasing stretch. In vitro studies suggest that this abnormality may result from decreased calcium affinity for and therefore binding to troponin C and from decreased calcium availability within the myocardial cells [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/34/36393/abstract/51\">",
"       51",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/24/10632?source=see_link\">",
"       \"Excitation-contraction coupling in myocardium\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The Frank-Starling relationship actually applies to left ventricular end-diastolic",
"      <strong>",
"       volume",
"      </strong>",
"      since it is the stretching of cardiac muscle that is responsible for the enhanced contractility. The more easily measured LVEDP is used clinically since, in relatively normal hearts, pressure and volume vary in parallel. However, cardiac compliance may be greatly reduced with severe heart disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/34/36393/abstract/52\">",
"       52",
"      </a>",
"      ]. As a result, a small increase in volume produces a large elevation in LVEDP but no substantial stretching of the cardiac muscle and therefore little change in cardiac output [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/34/36393/abstract/53\">",
"       53",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Drug-induced edema",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain drugs can induce edema by enhancing renal sodium reabsorption (",
"    <a class=\"graphic graphic_table graphicRef53550 \" href=\"mobipreview.htm?5/3/5181\">",
"     table 1",
"    </a>",
"    ). In the past, this was most likely to occur with potent direct vasodilators such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/5/32848?source=see_link\">",
"     minoxidil",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/38/13924?source=see_link\">",
"     diazoxide",
"    </a>",
"    , which are now infrequently used [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/34/36393/abstract/54-56\">",
"     54-56",
"    </a>",
"    ]. Patients treated with minoxidil, for example, often require therapy with high doses of a loop diuretic (such as 160 to 240 mg of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/52/28488?source=see_link\">",
"     furosemide",
"    </a>",
"    ) to prevent edema formation.",
"   </p>",
"   <p>",
"    The mechanism by which these agents stimulate sodium retention is uncertain. The fall in blood pressure itself probably plays an important role both directly and by activating the renin-angiotensin-aldosterone and sympathetic nervous systems, both of which stimulate sodium retention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/34/36393/abstract/54,57\">",
"     54,57",
"    </a>",
"    ]. The ability of sympatholytic agents to directly diminish renin release and of angiotensin-converting enzyme (ACE) inhibitors to diminish angiotensin II production may explain why these drugs do not produce edema even though they lead to an equivalent reduction in blood pressure.",
"   </p>",
"   <p>",
"    Peripheral edema occurs in 4 to 6 percent of diabetic patients treated with a thiazolidinedione such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/28/43463?source=see_link\">",
"     pioglitazone",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/26/2472?source=see_link\">",
"     rosiglitazone",
"    </a>",
"    (compared to 1 to 2 percent with placebo) and in a higher percentage of patients with a history of heart failure or those also treated with insulin. The mechanism is stimulation of sodium reabsorption by the sodium channels in the luminal membrane of collecting tubule cells, which is the same site stimulated by aldosterone. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/50/21290?source=see_link&amp;anchor=H21#H21\">",
"     \"Thiazolidinediones in the treatment of diabetes mellitus\", section on 'Fluid retention/heart failure'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other causes of drug-induced edema include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Calcium channel blockers, particularly the dihydropyridines in which leakage out of the capillary due to dilatation of the precapillary sphincter appears to be of primary importance [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/34/36393/abstract/58\">",
"       58",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/12/32966?source=see_link\">",
"       \"Major side effects and safety of calcium channel blockers\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Nonsteroidal anti-inflammatory drugs inhibit renal prostaglandin synthesis and can exacerbate edema in patients with underlying heart failure or cirrhosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/34/36393/abstract/59\">",
"       59",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/57/38803?source=see_link\">",
"       \"NSAIDs: Electrolyte complications\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/9/21655?source=see_link\">",
"       Fludrocortisone",
"      </a>",
"      , a synthetic mineralocorticoid used in the treatment of hypoaldosteronism and orthostatic hypotension, initially causes fluid retention, but edema is unusual because of the phenomenon of mineralocorticoid escape. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/1/37911?source=see_link\">",
"       \"Clinical features of primary aldosteronism\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Estrogens (alone or in oral contraceptives) may promote sodium retention, primarily in patients with impaired estrogen metabolism due to hepatic disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/34/36393/abstract/60,61\">",
"       60,61",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/19/32055?source=see_link\">",
"       Pramipexole",
"      </a>",
"      , a dopamine-agonist used in the treatment of Parkinson's disease and restless legs syndrome, causes peripheral edema in approximately 5 percent of patients; this effect appears to be dose-related, but the mechanism is uncertain [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/34/36393/abstract/62\">",
"       62",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"       Docetaxel",
"      </a>",
"      , used in the treatment of metastatic breast cancer, produces fluid retention that is cumulative and often dose-limiting [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/34/36393/abstract/63-65\">",
"       63-65",
"      </a>",
"      ]. However, with appropriate premedication (three to five days of oral corticosteroids, beginning 24 hours prior to dosing), higher cumulative doses can be administered before fluid retention occurs [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/34/36393/abstract/65\">",
"       65",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Refeeding edema",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who have fasted for as little as three days retain sodium and may become edematous after refeeding with carbohydrates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/34/36393/abstract/66-71\">",
"     66-71",
"    </a>",
"    ]. Insulin levels, which increase in response to the renewed intake of carbohydrates, result in enhanced reabsorption of sodium, thereby causing edema [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/34/36393/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?31/53/32594?source=see_link\">",
"       \"Patient information: Edema (swelling) (Beyond the Basics)\"",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1172076394\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There are two basic steps involved in edema formation (see",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathophysiology of edema formation'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      An alteration in capillary hemodynamics that favors the movement of fluid from the vascular space into the interstitium.",
"     </li>",
"     <li>",
"      The retention of dietary or intravenously administered sodium and water by the kidneys.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The following sequence occurs (see",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathophysiology of edema formation'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The initial movement of fluid from the vascular space into the interstitium reduces the plasma volume and consequently tissue perfusion.",
"     </li>",
"     <li>",
"      In response to these changes, the kidney retains sodium and water.",
"     </li>",
"     <li>",
"      Some of this fluid stays in the vascular space, returning the plasma volume toward normal. However, the alteration in capillary hemodynamics results in most of the retained fluid entering the interstitium and eventually becoming apparent as edema.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Renal sodium and water retention in most edematous states is an",
"      <strong>",
"       appropriate",
"      </strong>",
"      compensation in that it restores tissue perfusion, even though it also augments the degree of edema. The hemodynamic effects are different when the primary abnormality is",
"      <strong>",
"       inappropriate",
"      </strong>",
"      renal fluid retention. In this setting, both the plasma and interstitial volumes are expanded. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathophysiology of edema formation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The exchange of fluid between the plasma and the interstitium is determined by the hydraulic and oncotic pressures in each compartment. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Capillary hemodynamics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The development of edema requires an alteration in one or more of the Starling forces in a direction that favors an increase in net filtration and also inadequate removal of the additional filtered fluid by lymphatic drainage. This can be produced by (",
"      <a class=\"graphic graphic_table graphicRef53550 \" href=\"mobipreview.htm?5/3/5181\">",
"       table 1",
"      </a>",
"      ) (see",
"      <a class=\"local\" href=\"#H4\">",
"       'Edema formation'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      An elevation in capillary hydraulic pressure",
"     </li>",
"     <li>",
"      Increased capillary permeability",
"     </li>",
"     <li>",
"      Higher interstitial oncotic pressure",
"     </li>",
"     <li>",
"      A lower plasma oncotic pressure",
"     </li>",
"     <li>",
"      Lymphatic obstruction",
"     </li>",
"     <li>",
"      A combination of these changes",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Three factors protect against edema formation; these include (see",
"      <a class=\"local\" href=\"#H9\">",
"       'Compensatory factors'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Lymphatic flow and contractility increase in the presence of tissue edema and remove some of the excess filtrate.",
"     </li>",
"     <li>",
"      Fluid entry into the interstitium will eventually raise the interstitial hydraulic pressure, reducing the pressure gradient favoring filtration.",
"     </li>",
"     <li>",
"      Fluid entry into the interstitium also lowers the interstitial oncotic pressure, both by dilution and by lymphatic-mediated removal of interstitial proteins.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The most common causes of generalized edema seen by the clinician are (see",
"      <a class=\"local\" href=\"#H12\">",
"       'Etiology'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Heart failure (see",
"      <a class=\"local\" href=\"#H13\">",
"       'Heart failure'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Cirrhosis (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/1/21527?source=see_link\">",
"       \"Pathogenesis of ascites in patients with cirrhosis\"",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Nephrotic syndrome and other forms of renal disease (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/10/36008?source=see_link\">",
"       \"Pathophysiology and treatment of edema in patients with the nephrotic syndrome\"",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Premenstrual edema and pregnancy (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/20/27978?source=see_link\">",
"       \"Preeclampsia: Clinical features and diagnosis\"",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Guyton AC. Chapter 16. In: Textbook of Medical Physiology, 8th ed, Saunders, Philadelphia 1991.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36393/abstract/2\">",
"      Taylor AE. Capillary fluid filtration. Starling forces and lymph flow. Circ Res 1981; 49:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36393/abstract/3\">",
"      Renkin EM. B. W. Zweifach Award lecture. Regulation of the microcirculation. Microvasc Res 1985; 30:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36393/abstract/4\">",
"      Crandall ED, Staub NC, Goldberg HS, Effros RM. Recent developments in pulmonary edema. Ann Intern Med 1983; 99:808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36393/abstract/5\">",
"      Deitch EA. The management of burns. N Engl J Med 1990; 323:1249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36393/abstract/6\">",
"      Belldegrun A, Webb DE, Austin HA 3rd, et al. Effects of interleukin-2 on renal function in patients receiving immunotherapy for advanced cancer. Ann Intern Med 1987; 106:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36393/abstract/7\">",
"      Baumgartner I, Rauh G, Pieczek A, et al. Lower-extremity edema associated with gene transfer of naked DNA encoding vascular endothelial growth factor. Ann Intern Med 2000; 132:880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36393/abstract/8\">",
"      Amoura Z, Papo T, Ninet J, et al. Systemic capillary leak syndrome: report on 13 patients with special focus on course and treatment. Am J Med 1997; 103:514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36393/abstract/9\">",
"      Cicardi M, Gardinali M, Bisiani G, et al. The systemic capillary leak syndrome: appearance of interleukin-2-receptor-positive cells during attacks. Ann Intern Med 1990; 113:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36393/abstract/10\">",
"      Droder RM, Kyle RA, Greipp PR. Control of systemic capillary leak syndrome with aminophylline and terbutaline. Am J Med 1992; 92:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36393/abstract/11\">",
"      Tahirkheli NK, Greipp PR. Treatment of the systemic capillary leak syndrome with terbutaline and theophylline. A case series. Ann Intern Med 1999; 130:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36393/abstract/12\">",
"      Ohlsson K, Bj&ouml;rk P, Bergenfeldt M, et al. Interleukin-1 receptor antagonist reduces mortality from endotoxin shock. Nature 1990; 348:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36393/abstract/13\">",
"      Colletti LM, Remick DG, Burtch GD, et al. Role of tumor necrosis factor-alpha in the pathophysiologic alterations after hepatic ischemia/reperfusion injury in the rat. J Clin Invest 1990; 85:1936.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36393/abstract/14\">",
"      Bollinger A, Frey J, J&auml;ger K, et al. Patterns of diffusion through skin capillaries in patients with long-term diabetes. N Engl J Med 1982; 307:1305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36393/abstract/15\">",
"      Hommel E, Mathiesen ER, Aukland K, Parving HH. Pathophysiological aspects of edema formation in diabetic nephropathy. Kidney Int 1990; 38:1187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36393/abstract/16\">",
"      Brownlee M. Lilly Lecture 1993. Glycation and diabetic complications. Diabetes 1994; 43:836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36393/abstract/17\">",
"      Mayatepek E, Becker K, Gana L, et al. Leukotrienes in the pathophysiology of kwashiorkor. Lancet 1993; 342:958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36393/abstract/18\">",
"      Morgan AG, Terry SI. Impaired peritoneal fluid drainage in nephrogenic ascites. Clin Nephrol 1981; 15:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36393/abstract/19\">",
"      Hammond TC, Takiyyuddin MA. Nephrogenic ascites: a poorly understood syndrome. J Am Soc Nephrol 1994; 5:1173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36393/abstract/20\">",
"      Parving HH, Hansen JM, Nielsen SL, et al. Mechanisms of edema formation in myxedema--increased protein extravasation and relatively slow lymphatic drainage. N Engl J Med 1979; 301:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36393/abstract/21\">",
"      HOLLANDER W, REILLY P, BURROWS BA. Lymphatic flow in human subjects as indicated by the disappearance of 1-131-labeled albumin from the subcutaneous tissue. J Clin Invest 1961; 40:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36393/abstract/22\">",
"      Taylor AE. The lymphatic edema safety factor: the role of edema dependent lymphatic factors (EDLF). Lymphology 1990; 23:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36393/abstract/23\">",
"      Br&auml;utigam P, Vanscheidt W, F&ouml;ldi E, et al. [Involvement of the lymphatic system in primary non-lymphogenic edema of the leg. Studies with 2-compartment lymphoscintigraphy]. Hautarzt 1997; 48:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36393/abstract/24\">",
"      Szidon JP. Pathophysiology of the congested lung. Cardiol Clin 1989; 7:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36393/abstract/25\">",
"      Kwan T, Pintea M, Garcia Morino F, et al. Transcapillary oncotic pressure in the edema of congestive heart failure. Nephron 1990; 54:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36393/abstract/26\">",
"      Fauchald P. Transcapillary colloid osmotic gradient and body fluid volumes in renal failure. Kidney Int 1986; 29:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36393/abstract/27\">",
"      Koomans HA, Kortlandt W, Geers AB, Dorhout Mees EJ. Lowered protein content of tissue fluid in patients with the nephrotic syndrome: observations during disease and recovery. Nephron 1985; 40:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36393/abstract/28\">",
"      Zarins CK, Rice CL, Peters RM, Virgilio RW. Lymph and pulmonary response to isobaric reduction in plasma oncotic pressure in baboons. Circ Res 1978; 43:925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36393/abstract/29\">",
"      Schrier RW. Body fluid volume regulation in health and disease: a unifying hypothesis. Ann Intern Med 1990; 113:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36393/abstract/30\">",
"      Schrier RW. An odyssey into the milieu int&eacute;rieur: pondering the enigmas. J Am Soc Nephrol 1992; 2:1549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36393/abstract/31\">",
"      EPSTEIN FH, FERGUSON TB. The effect of the formation of an arteriovenous fistula upon blood volume. J Clin Invest 1955; 34:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36393/abstract/32\">",
"      KOWALSKI HJ, ABELMANN WH. The cardiac output at rest in Laennec's cirrhosis. J Clin Invest 1953; 32:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36393/abstract/33\">",
"      P&eacute;rez-Ayuso RM, Arroyo V, Camps J, et al. Evidence that renal prostaglandins are involved in renal water metabolism in cirrhosis. Kidney Int 1984; 26:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36393/abstract/34\">",
"      Henriksen JH, Bendtsen F, Gerbes AL, et al. Estimated central blood volume in cirrhosis: relationship to sympathetic nervous activity, beta-adrenergic blockade and atrial natriuretic factor. Hepatology 1992; 16:1163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36393/abstract/35\">",
"      Fernandez-Seara J, Prieto J, Quiroga J, et al. Systemic and regional hemodynamics in patients with liver cirrhosis and ascites with and without functional renal failure. Gastroenterology 1989; 97:1304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36393/abstract/36\">",
"      Cohn JN. Blood pressure and cardiac performance. Am J Med 1973; 55:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36393/abstract/37\">",
"      Watkins L Jr, Burton JA, Haber E, et al. The renin-angiotensin-aldosterone system in congestive failure in conscious dogs. J Clin Invest 1976; 57:1606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36393/abstract/38\">",
"      Dzau VJ, Colucci WS, Hollenberg NK, Williams GH. Relation of the renin-angiotensin-aldosterone system to clinical state in congestive heart failure. Circulation 1981; 63:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36393/abstract/39\">",
"      Chonko AM, Bay WH, Stein JH, Ferris TF. The role of renin and aldosterone in the salt retention of edema. Am J Med 1977; 63:881.",
"     </a>",
"    </li>",
"    <li>",
"     Rose BD, Post TW. Chapter 16. In: Clinical Physiology of Acid-Base and Electrolyte Disorders, McGraw-Hill, New York 2001.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36393/abstract/41\">",
"      Blankfield RP, Finkelhor RS, Alexander JJ, et al. Etiology and diagnosis of bilateral leg edema in primary care. Am J Med 1998; 105:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36393/abstract/42\">",
"      McHugh TJ, Forrester JS, Adler L, et al. Pulmonary vascular congestion in acute myocardial infarction: hemodynamic and radiologic correlations. Ann Intern Med 1972; 76:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36393/abstract/43\">",
"      Warren JV, Stead EA. Fluid dynamics in chronic congestive heart failure: An interpretation of the mechanisms producing the edema, increased plasma volume, and elevated venous pressure in certain patients with prolonged congestive failure. Arch Intern Med 1944; 73:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36393/abstract/44\">",
"      Dzau VJ. Renal and circulatory mechanisms in congestive heart failure. Kidney Int 1987; 31:1402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36393/abstract/45\">",
"      Packer M. Neurohormonal interactions and adaptations in congestive heart failure. Circulation 1988; 77:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36393/abstract/46\">",
"      BRAUNWALD E, PLAUTH WH Jr, MORROW AG. A METHOD FOR THE DETECTION AND QUANTIFICATION OF IMPAIRED SODIUM EXCRETION. RESULTS OF AN ORAL SODIUM TOLERANCE TEST IN NORMAL SUBJECTS AND IN PATIENTS WITH HEART DISEASE. Circulation 1965; 32:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36393/abstract/47\">",
"      Winaver J, Hoffman A, Burnett JC Jr, Haramati A. Hormonal determinants of sodium excretion in rats with experimental high-output heart failure. Am J Physiol 1988; 254:R776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36393/abstract/48\">",
"      Reddy HK, Weber KT, Janicki JS, McElroy PA. Hemodynamic, ventilatory and metabolic effects of light isometric exercise in patients with chronic heart failure. J Am Coll Cardiol 1988; 12:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36393/abstract/49\">",
"      Higgins CB, Vatner SF, Franklin D, Braunwald E. Effects of experimentally produced heart failure on the peripheral vascular response to severe exercise in conscious dogs. Circ Res 1972; 31:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36393/abstract/50\">",
"      Millard RW, Higgins CB, Franklin D, Vatner SF. Regulation of the renal circulation during severe exercise in normal dogs and dogs with experimental heart failure. Circ Res 1972; 31:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36393/abstract/51\">",
"      Schwinger RH, B&ouml;hm M, Koch A, et al. The failing human heart is unable to use the Frank-Starling mechanism. Circ Res 1994; 74:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36393/abstract/52\">",
"      Gault JH, Covell JW, Braunwald E, Ross J Jr. Left ventricular performance following correction of free aortic regurgitation. Circulation 1970; 42:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36393/abstract/53\">",
"      Komamura K, Shannon RP, Ihara T, et al. Exhaustion of Frank-Starling mechanism in conscious dogs with heart failure. Am J Physiol 1993; 265:H1119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36393/abstract/54\">",
"      Markham RV Jr, Gilmore A, Pettinger WA, et al. Central and regional hemodynamic effects and neurohumoral consequences of minoxidil in severe congestive heart failure and comparison to hydralazine and nitroprusside. Am J Cardiol 1983; 52:774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36393/abstract/55\">",
"      Diazoxide therapy: use and risks. Ann Intern Med 1976; 85:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36393/abstract/56\">",
"      Pohl JE, Thurston H, Swales JD. The dntidiuretic action of diazoxide. Clin Sci 1972; 42:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36393/abstract/57\">",
"      Pettinger WA, Keeton K. Altered renin release and propranolol potentiation of vasodilatory drug hypotension. J Clin Invest 1975; 55:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36393/abstract/58\">",
"      Russell RP. Side effects of calcium channel blockers. Hypertension 1988; 11:II42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36393/abstract/59\">",
"      Clive DM, Stoff JS. Renal syndromes associated with nonsteroidal antiinflammatory drugs. N Engl J Med 1984; 310:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36393/abstract/60\">",
"      Christy NP, Shaver JC. Estrogens and the kidney. Kidney Int 1974; 6:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36393/abstract/61\">",
"      PREEDY JR, AITKEN EH. The effect of estrogen on water and electrolyte metabolism. II. Hepatic disease. J Clin Invest 1956; 35:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36393/abstract/62\">",
"      Tan EK, Ondo W. Clinical characteristics of pramipexole-induced peripheral edema. Arch Neurol 2000; 57:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36393/abstract/63\">",
"      Hudis CA, Seidman AD, Crown JP, et al. Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer. J Clin Oncol 1996; 14:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36393/abstract/64\">",
"      Trudeau ME, Eisenhauer EA, Higgins BP, et al. Docetaxel in patients with metastatic breast cancer: a phase II study of the National Cancer Institute of Canada-Clinical Trials Group. J Clin Oncol 1996; 14:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36393/abstract/65\">",
"      Piccart MJ, Klijn J, Paridaens R, et al. Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: final results of a randomized study of the European Organization for Research and Treatment of Cancer Investigational Drug Branch for Breast Cancer. J Clin Oncol 1997; 15:3149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36393/abstract/66\">",
"      Veverbrants E, Arky RA. Effects of fasting and refeeding. I. Studies on sodium, potassium and water excretion on a constant electrolyte and fluid intake. J Clin Endocrinol Metab 1969; 29:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36393/abstract/67\">",
"      Saudek CD, Boulter PR, Knopp RH, Arky RA. Sodium retention accompanying insulin treatment of diabetes mellitus. Diabetes 1974; 23:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36393/abstract/68\">",
"      Hopkins DF, Cotton SJ, Williams G. Effective treatment of insulin-induced edema using ephedrine. Diabetes Care 1993; 16:1026.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36393/abstract/69\">",
"      DeFronzo RA, Cooke CR, Andres R, et al. The effect of insulin on renal handling of sodium, potassium, calcium, and phosphate in man. J Clin Invest 1975; 55:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36393/abstract/70\">",
"      Baum M. Insulin stimulates volume absorption in the rabbit proximal convoluted tubule. J Clin Invest 1987; 79:1104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36393/abstract/71\">",
"      Nakamura R, Emmanouel DS, Katz AI. Insulin binding sites in various segments of the rabbit nephron. J Clin Invest 1983; 72:388.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2309 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-221.179.173.170-189A616C48-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_34_36393=[""].join("\n");
var outline_f35_34_36393=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1172076394\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOPHYSIOLOGY OF EDEMA FORMATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Capillary hemodynamics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Edema formation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Increased capillary hydraulic pressure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Hypoalbuminemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Increased capillary permeability",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Lymphatic obstruction (lymphedema)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13679763\">",
"      - Myxedema",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Compensatory factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Renal sodium retention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      The compensated state",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Heart failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Drug-induced edema",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Refeeding edema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1172076394\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/2309\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/2309|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?11/49/12063\" title=\"figure 1\">",
"      Renin in HF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?32/56/33677\" title=\"figure 2\">",
"      Frank Starling curves in HF",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/2309|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?5/3/5181\" title=\"table 1\">",
"      Major causes of edema by primary mechanism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?8/26/8620\" title=\"table 2\">",
"      Different Starlings forces",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/61/36825?source=related_link\">",
"      Actions of angiotensin II on the heart",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/12/40133?source=related_link\">",
"      Chapter 7B: Exchange of water between plasma and interstitial fluid",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/1/37911?source=related_link\">",
"      Clinical features of primary aldosteronism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/36/34375?source=related_link\">",
"      Clinical manifestations and diagnosis of edema in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/52/1866?source=related_link\">",
"      Clinical manifestations and diagnosis of lymphedema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/24/10632?source=related_link\">",
"      Excitation-contraction coupling in myocardium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/31/20986?source=related_link\">",
"      Gastrointestinal disease in dialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/50/30503?source=related_link\">",
"      General principles of the treatment of edema in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/12/17608?source=related_link\">",
"      Hyponatremia in patients with cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/31/20981?source=related_link\">",
"      Idiopathic edema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/26/426?source=related_link\">",
"      Idiopathic systemic capillary leak syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/12/32966?source=related_link\">",
"      Major side effects and safety of calcium channel blockers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/57/38803?source=related_link\">",
"      NSAIDs: Electrolyte complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/1/21527?source=related_link\">",
"      Pathogenesis of ascites in patients with cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/10/36008?source=related_link\">",
"      Pathophysiology and treatment of edema in patients with the nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/34/23076?source=related_link\">",
"      Pathophysiology of heart failure: Left ventricular pressure-volume relationships",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/44/32455?source=related_link\">",
"      Pathophysiology of heart failure: Neurohumoral adaptations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?31/53/32594?source=related_link\">",
"      Patient information: Edema (swelling) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/20/27978?source=related_link\">",
"      Preeclampsia: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/50/21290?source=related_link\">",
"      Thiazolidinediones in the treatment of diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/40/650?source=related_link\">",
"      Treatment of refractory edema in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_34_36394="Overview of the approach to the adult survivor of classical Hodgkin lymphoma";
var content_f35_34_36394=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of the approach to the adult survivor of classical Hodgkin lymphoma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/34/36394/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/34/36394/contributors\">",
"     Andrea K Ng, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/34/36394/contributors\">",
"     Ann S LaCasce, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/34/36394/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/34/36394/contributors\">",
"     Larissa Nekhlyudov, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/34/36394/contributors\">",
"     Kenneth D Miller, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/34/36394/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/34/36394/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/34/36394/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 29, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H105459014\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hodgkin lymphoma (HL), formerly called Hodgkin's disease, accounts for approximately 10 percent of all lymphomas diagnosed in the developed world annually [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/34/36394/abstract/1\">",
"     1",
"    </a>",
"    ]. This amounts to approximately 8830 new cases of HL in the United States annually [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/34/36394/abstract/2\">",
"     2",
"    </a>",
"    ]. Over the past century, HL has been converted from a uniformly fatal disease to one that is curable in greater than 75 percent of patients worldwide. As a result, there are more than 30,000 long-term survivors of HL in the United States alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/34/36394/abstract/3\">",
"     3",
"    </a>",
"    ], and many more throughout the world, a substantial percentage of whom will have the majority of their care delivered by primary care providers. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/12/13512?source=see_link\">",
"     \"Overview of the treatment of classical Hodgkin lymphoma in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    HL is separated from the other lymphomas based on its unique clinical and pathologic features, and can be divided into two major types:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Classical HL &mdash; Subtypes include nodular sclerosis HL, mixed cellularity HL, lymphocyte rich HL, and lymphocyte depleted HL. These constitute the vast majority of HL and will be discussed here.",
"     </li>",
"     <li>",
"      Nodular lymphocyte predominant HL &mdash; This is a less common and more indolent disease than classical HL and is therefore managed uniquely. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/41/33432?source=see_link\">",
"       \"Clinical manifestations, pathologic features, and diagnosis of nodular lymphocyte-predominant Hodgkin lymphoma\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    HL survivors are at risk of developing therapy-related complications that may present years after treatment (eg, second malignancies, cardiac disease, radiation-induced hypothyroidism). These complications have surfaced as significant causes of increased mortality among HL survivors. Screening for some of these entities is advised in the hope that early detection may lead to better management.",
"   </p>",
"   <p>",
"    This topic review will provide an overview to the care of the classical HL survivor, focusing on issues that require attention at approximately one year from the completion of treatment onwards. The treatment of newly diagnosed or relapsed HL and monitoring for disease recurrence are discussed elsewhere as is a more in depth discussion of secondary malignancies after HL therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/19/30007?source=see_link\">",
"     \"Monitoring of the patient with classical Hodgkin lymphoma during and after treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/26/35242?source=see_link\">",
"     \"Second malignancies after treatment of classical Hodgkin lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H105459483\">",
"    <span class=\"h1\">",
"     TERMINOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The long term management of HL survivors requires a basic understanding of staging and treatment nomenclature, described below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1060969\">",
"    <span class=\"h2\">",
"     Staging",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of patients with HL is primarily guided by the stage of disease as determined by the Ann Arbor staging system with Cotswolds modifications (",
"    <a class=\"graphic graphic_table graphicRef66651 \" href=\"mobipreview.htm?19/23/19836\">",
"     table 1",
"    </a>",
"    ). Pathologic staging used laparotomy and splenectomy to characterize abdominal involvement. In contrast, clinical staging uses imaging studies to define extent of disease. Patients with stage I or stage II disease are considered to have &ldquo;early stage&rdquo; HL. &ldquo;Advanced stage&rdquo; HL often refers to stage III and IV disease, although many experts and clinical trials include patients with stage II plus bulky nodal disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/37/14935?source=see_link\">",
"     \"Staging and prognosis of Hodgkin lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among patients with early stage HL, there is subsequent stratification into favorable and unfavorable prognosis disease based upon the presence or absence of certain clinical features, such as age, B symptoms, and large mediastinal adenopathy. Cooperative research groups have used varying definitions of favorable and unfavorable prognosis disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/29/10711?source=see_link\">",
"     \"Definition of favorable and unfavorable prognosis early (stage I-II) classical Hodgkin lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1060976\">",
"    <span class=\"h2\">",
"     Chemotherapy regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous combination chemotherapy regimens have been used to treat HL, including (",
"    <a class=\"graphic graphic_table graphicRef74186 \" href=\"mobipreview.htm?7/60/8142\">",
"     table 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      MOPP (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/57/40853?source=see_link\">",
"       mechlorethamine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/45/24279?source=see_link\">",
"       procarbazine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      ) was the first chemotherapy regimen to establish the curability of patients with advanced stage HL.",
"     </li>",
"     <li>",
"      ABVD (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/15/39159?source=see_link\">",
"       bleomycin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/3/4152?source=see_link\">",
"       vinblastine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/49/4887?source=see_link\">",
"       dacarbazine",
"      </a>",
"      ) has been the standard regimen used for advanced HL for several decades. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/54/39786?source=see_link&amp;anchor=H7#H7\">",
"       \"Initial treatment of advanced (stage III-IV) classical Hodgkin lymphoma\", section on 'ABVD chemotherapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Stanford V (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/3/4152?source=see_link\">",
"       vinblastine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/57/40853?source=see_link\">",
"       mechlorethamine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/15/39159?source=see_link\">",
"       bleomycin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      ) is a combined modality treatment that incorporates radiation therapy for the great majority of patients. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/54/39786?source=see_link&amp;anchor=H14#H14\">",
"       \"Initial treatment of advanced (stage III-IV) classical Hodgkin lymphoma\", section on 'Stanford V'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/54/39786?source=see_link&amp;anchor=H19#H19\">",
"       \"Initial treatment of advanced (stage III-IV) classical Hodgkin lymphoma\", section on 'Is there a role for radiation?'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Escalated or standard BEACOPP (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/15/39159?source=see_link\">",
"       bleomycin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/45/24279?source=see_link\">",
"       procarbazine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      ) is increasingly being used worldwide. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/54/39786?source=see_link&amp;anchor=H10#H10\">",
"       \"Initial treatment of advanced (stage III-IV) classical Hodgkin lymphoma\", section on 'BEACOPP chemotherapy'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1060983\">",
"    <span class=\"h2\">",
"     Radiation fields",
"    </span>",
"    &nbsp;&mdash;&nbsp;Over time there has been a movement to decrease the field of radiation used for HL in order to limit acute and long-term toxicities while maintaining survival rates. Various definitions have been applied. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/31/11770?source=see_link&amp;anchor=H20474631#H20474631\">",
"     \"Treatment of favorable prognosis early (stage I-II) classical Hodgkin lymphoma\", section on 'Radiation field size'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Extended-field radiation &mdash; Radiation treatment volume includes not only the clinically involved nodes, but also the adjacent, clinically uninvolved sites (eg, mantle field or inverted-Y field).",
"     </li>",
"     <li>",
"      Involved-field radiation &mdash; Radiation treatment volume encompasses all of the clinically involved regions (eg, mediastinal plus low bilateral supraclavicular field which covers the entire mediastinum) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/34/36394/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Involved-node radiation &mdash; Radiation treatment volume includes pre- and post-chemotherapy nodal volumes plus a margin of healthy tissue &le;5 cm [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/34/36394/abstract/5-7\">",
"       5-7",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11941348\">",
"    <span class=\"h1\">",
"     EVOLUTION OF \"STANDARD\" TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The preferred management of patients with HL has evolved over time. Initial efforts were focused on cure, while subsequent efforts focused on decreasing short- and long-term toxicity while maintaining efficacy. The following described general trends in HL treatment:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      1960&rsquo;s and early 1970&rsquo;s &mdash; Patients underwent pathologic staging with laparotomy and splenectomy. Early stage HL was treated with extended-field radiation therapy (mantle, para-aortic with or without pelvis) to doses of 40 to 44 Gy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/34/36394/abstract/8\">",
"       8",
"      </a>",
"      ]. Advanced stage HL was treated with MOPP chemotherapy (",
"      <a class=\"graphic graphic_table graphicRef74186 \" href=\"mobipreview.htm?7/60/8142\">",
"       table 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/34/36394/abstract/9,10\">",
"       9,10",
"      </a>",
"      ]. ABVD chemotherapy was introduced in the late 1970&rsquo;s as a less toxic alternative to MOPP [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/34/36394/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      1980&rsquo;s &mdash; While some patients still underwent pathologic staging, there was an increasing trend towards clinical staging with imaging studies. Pathologically early stage HL was treated with extended-field radiation therapy. There was a transition to using ABVD chemotherapy for advanced stage HL after randomized trials showed significantly superior treatment outcome and lower toxicity with ABVD compared to MOPP [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/34/36394/abstract/12,13\">",
"       12,13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      1990&rsquo;s &mdash; Patients underwent clinical staging with imaging studies. With more effective and less toxic chemotherapy and with increasing documentation of serious late complications associated with extended-field radiation therapy, efforts were made to cut back on radiation therapy for HL. Combined modality therapy with ABVD-based chemotherapy, which eliminates the need for staging laparotomy, and allows the use of more limited radiation treatment volumes and lower radiation doses, was shown to be associated with an improved disease-free and overall survival compared to extended-field radiation therapy alone in early stage patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/34/36394/abstract/12,13\">",
"       12,13",
"      </a>",
"      ]. Advanced stage HL was treated with ABVD or Stanford V. High dose chemotherapy followed by stem cell support (ie, autologous hematopoietic cell transplantation) became available for the treatment of patients with relapsed disease.",
"     </li>",
"     <li>",
"      2000&rsquo;s &mdash; Patients were clinically staged with imaging studies. There was a shift towards decreasing radiation dose and field. Most patients were treated with ABVD chemotherapy with or without limited-field radiation therapy as consolidation to doses ranging from 20 to 36 Gy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/34/36394/abstract/14\">",
"       14",
"      </a>",
"      ].",
"      <strong>",
"      </strong>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/12/13512?source=see_link\">",
"       \"Overview of the treatment of classical Hodgkin lymphoma in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The treatment of HL continues to evolve and issues surrounding treatment decisions are discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/12/13512?source=see_link\">",
"     \"Overview of the treatment of classical Hodgkin lymphoma in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11941356\">",
"    <span class=\"h1\">",
"     PROGNOSIS AND NATURAL HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The relative survival of patients affected by HL has steadily improved in the last several decades as a result of improved staging [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/34/36394/abstract/15-17\">",
"     15-17",
"    </a>",
"    ], more effective and less toxic chemotherapy, advances in radiation therapy technique and delivery, and availability of prognostic factors allowing tailored therapy in patients. With modern therapy, HL is curable in greater than 75 percent of patients. The relapse-free survival (RFS) and overall survival (OS) rates are dependent upon disease stage and treatment received. The following are estimated RFS and OS at five years following initial treatment with combination chemotherapy with or without adjuvant radiation therapy:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Favorable-prognosis, early-stage HL &mdash; RFS &gt;90 percent and OS &gt;95 percent at five years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/34/36394/abstract/18-20\">",
"       18-20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Unfavorable-prognosis, early-stage HL &mdash; RFS &gt;85 percent and OS &gt;90 percent at five years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/34/36394/abstract/19-21\">",
"       19-21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Advanced-stage HL &mdash; RFS 60 to 85 percent and OS 85 to 90 percent at five years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/34/36394/abstract/22-24\">",
"       22-24",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For patients with advanced-stage HL, when compared with ABVD, dose-escalated BEACOPP appears to result in superior RFS, but at the expense of increased toxicity with no clear OS benefit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/34/36394/abstract/23,25\">",
"     23,25",
"    </a>",
"    ]. Stanford V does not appear to be superior to ABVD. The optimal systemic regimen for advanced-stage HL is currently in evolution while awaiting long-term results from randomized trials comparing the different regimens. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/54/39786?source=see_link\">",
"     \"Initial treatment of advanced (stage III-IV) classical Hodgkin lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11941364\">",
"    <span class=\"h1\">",
"     OVERVIEW OF TREATMENT COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As described above, the management of HL has evolved dramatically since the 1960s. Treatments have included staging laparotomy with splenectomy, limited or extensive field radiation, combination chemotherapy of varying types, or a combination of these. A subset of patients has been treated with high dose chemotherapy followed by stem cell support (ie, autologous hematopoietic cell transplantation). These therapies place HL survivors at risk for the development of a diverse array of long-term sequelae, with the potential to negatively impact both their quality of life and ultimately their survival.",
"   </p>",
"   <p>",
"    The following sections describe the most common long-term complications associated with treatment. Specific details regarding the long-term complications of autologous hematopoietic cell transplantation are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/44/35530?source=see_link\">",
"     \"The approach to hematopoietic cell transplantation survivorship\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, further details regarding the long-term complications of specific chemotherapy regimens are presented in more detail separately:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      MOPP &mdash; MOPP, the historical standard systemic therapy for HL, is associated with risks of infertility [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/34/36394/abstract/26\">",
"       26",
"      </a>",
"      ] and secondary malignancies, including leukemia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/34/36394/abstract/27\">",
"       27",
"      </a>",
"      ], lung cancer [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/34/36394/abstract/28-30\">",
"       28-30",
"      </a>",
"      ], and gastric cancer [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/34/36394/abstract/31\">",
"       31",
"      </a>",
"      ]. The risks of leukemia and lung cancer are related to alkylating agent chemotherapy in a dose-dependent manner [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/34/36394/abstract/29,30,32,33\">",
"       29,30,32,33",
"      </a>",
"      ] and typically manifests between several years and a decade after chemotherapy.",
"     </li>",
"     <li>",
"      ABVD &mdash; ABVD, the current standard regimen for HL, is associated with risks of peripheral neuropathy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/34/36394/abstract/34\">",
"       34",
"      </a>",
"      ],",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/15/39159?source=see_link\">",
"       bleomycin",
"      </a>",
"      lung toxicity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/34/36394/abstract/35-37\">",
"       35-37",
"      </a>",
"      ], and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      -associated cardiotoxicity, which can manifest after a latency period [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/34/36394/abstract/38-40\">",
"       38-40",
"      </a>",
"      ]. There does not appear to be an increased rate of myelodysplasia or secondary leukemia, and fertility is preserved in the majority of patients. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/54/39786?source=see_link&amp;anchor=H9#H9\">",
"       \"Initial treatment of advanced (stage III-IV) classical Hodgkin lymphoma\", section on 'ABVD toxicity'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Dose-escalated or standard BEACOPP &mdash; There are limited data on the long term complications of BEACOPP. The main long term toxicities appear to be secondary malignancies and sterility. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/54/39786?source=see_link&amp;anchor=H13#H13\">",
"       \"Initial treatment of advanced (stage III-IV) classical Hodgkin lymphoma\", section on 'BEACOPP toxicities'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Stanford V &mdash; There are limited data on the long term complications of Stanford V. No cases of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/15/39159?source=see_link\">",
"       bleomycin",
"      </a>",
"      lung toxicity, radiation pneumonitis, secondary leukemia or lymphoma have been reported. Fertility appears to be preserved. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/54/39786?source=see_link&amp;anchor=H14#H14\">",
"       \"Initial treatment of advanced (stage III-IV) classical Hodgkin lymphoma\", section on 'Stanford V'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The key late effects of radiotherapy for HL include second malignancy and cardiac disease. Other delayed complications that have been associated with radiation therapy include thyroid dysfunction, pulmonary fibrosis, non-coronary atherosclerotic disease and muscle atrophy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11941388\">",
"    <span class=\"h2\">",
"     Second malignancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Second malignancy is the leading cause of death in long-term survivors of HL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/34/36394/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. Risk factors depend on the type of secondary malignancy being considered, and include radiation dose and field, chemotherapy agents and doses administered, patient age at treatment, patient sex, and smoking history. Solid tumors account for the majority of second cancers in HL survivors with breast, lung, and colon cancer being the most frequent (",
"    <a class=\"graphic graphic_table graphicRef57099 \" href=\"mobipreview.htm?1/22/1391\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/34/36394/abstract/43-45\">",
"     43-45",
"    </a>",
"    ]. Leukemia and non-Hodgkin lymphoma (NHL) are less common, but occur much more frequently in this population when compared with the general population. This is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/26/35242?source=see_link\">",
"     \"Second malignancies after treatment of classical Hodgkin lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The exact rates of secondary malignancy with the radiation techniques used today is unknown, but predicted to be lower than that observed with more extensive radiation of the past [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/34/36394/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. The risk of acute leukemia peaks at five to nine years, while the solid tumor risk is less increased initially but progressively increases after 10 years. Acute leukemia is primarily a complication of chemotherapy, non-Hodgkin lymphoma appears to be unrelated to the type of therapy, and both lung cancer and breast cancer are primarily related to radiation therapy, particularly mantle irradiation for breast cancer. Lung cancer rates are similar after radiation therapy alone or MOPP chemotherapy alone. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/26/35242?source=see_link\">",
"     \"Second malignancies after treatment of classical Hodgkin lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <strong>",
"       Breast cancer",
"      </strong>",
"      &mdash; Breast cancer is one of the most common second malignancies among female survivors of HL. The raised risk of breast cancer occurs late, typically 10 or more years after first treatment. The three major risk factors for breast cancer are the age at treatment for HL, the use (and amount) of mantle radiotherapy, and the effect of alkylating and other agents on ovarian function. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/26/35242?source=see_link&amp;anchor=H25#H25\">",
"       \"Second malignancies after treatment of classical Hodgkin lymphoma\", section on 'Breast cancer'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/0/3079?source=see_link&amp;anchor=H1167672651#H1167672651\">",
"       \"Long-term follow-up of the patient with classical Hodgkin lymphoma\", section on 'Routine testing'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <strong>",
"       Lung cancer",
"      </strong>",
"      &mdash; Lung cancer is one of the most common second malignancies among HL survivors. The raised risk of lung cancer is seen from five to more than twenty years after initial treatment, with cases following chemotherapy usually occurring earlier than those following radiation. The risk is highest in patients treated with both chemotherapy (eg, alkylating agents) and radiation, especially among those patients who smoke. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/26/35242?source=see_link&amp;anchor=H22#H22\">",
"       \"Second malignancies after treatment of classical Hodgkin lymphoma\", section on 'Lung cancer'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/0/3079?source=see_link&amp;anchor=H1167672651#H1167672651\">",
"       \"Long-term follow-up of the patient with classical Hodgkin lymphoma\", section on 'Routine testing'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <strong>",
"       Acute leukemia",
"      </strong>",
"      &mdash; Acute leukemia was the first secondary malignancy to be noted in patients treated for HL because of its relatively early appearance following treatment, as well as the rarity of acute leukemia in the general population. The highest risks and the greatest number of cases occur between 5 and 10 years after initiation of treatment, usually with alkylating agents such as those used in MOPP and BEACOPP. This increased risk persists after 10 years, although at lower levels. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/26/35242?source=see_link&amp;anchor=H7#H7\">",
"       \"Second malignancies after treatment of classical Hodgkin lymphoma\", section on 'Acute leukemia'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <strong>",
"       Non-Hodgkin lymphoma",
"      </strong>",
"      &mdash; While the relative risk (compared with the general population) of NHL is increased among HL survivors, the absolute number of cases is low due to the low incidence in the general population. There is little agreement on definitive risk factors for NHL in patients treated for HL. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/26/35242?source=see_link&amp;anchor=H15#H15\">",
"       \"Second malignancies after treatment of classical Hodgkin lymphoma\", section on 'Non-Hodgkin lymphoma'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <strong>",
"       Other",
"      </strong>",
"      &mdash; Other solid tumors that have an increased incidence among HL survivors include gastrointestinal cancers, bone and soft tissue tumors, thyroid cancers, malignant melanoma, and malignant mesothelioma. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/26/35242?source=see_link\">",
"       \"Second malignancies after treatment of classical Hodgkin lymphoma\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The best screening programs have yet to be defined and clinical practice varies. Our approach is described below. (See",
"    <a class=\"local\" href=\"#H1065733\">",
"     'Cancer screening'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11941396\">",
"    <span class=\"h2\">",
"     Cardiovascular disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiovascular disease is the most common non-malignant cause of death in long term survivors of HL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/34/36394/abstract/41,42,48\">",
"     41,42,48",
"    </a>",
"    ]. Survivors of HL are at risk for long term cardiovascular complications related to the chemotherapy they have received (eg, anthracyclines)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    radiation. Chemotherapy can lead to delayed nonischemic heart failure, and chest radiation has been associated with accelerated atherosclerosis and other cardiotoxicity. Traditional cardiac risk factors, including hyperlipidemia, hypertension, diabetes mellitus and smoking, further contribute to the risk of treatment-related cardiac disease after HL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/34/36394/abstract/40,49,50\">",
"     40,49,50",
"    </a>",
"    ]. These findings underscore the importance of screening for cardiac risk factors and aggressive management of these risk factors in survivors of HL. HL patients with preexisting cardiac disease are at especially high risk of cardiac morbidity requiring hospitalization after mediastinal irradiation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/34/36394/abstract/51\">",
"     51",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/21/34137?source=see_link&amp;anchor=H12#H12\">",
"     \"Cardiotoxicity of radiation therapy for malignancy\", section on 'Hodgkin lymphoma'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Radiotherapy-related cardiac complications include pericardial disease, valvular dysfunction, arrhythmias, cardiomyopathy, and coronary artery disease (CAD) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/34/36394/abstract/52\">",
"     52",
"    </a>",
"    ]. Of these, CAD represents the most life-threatening form of cardiac complication. Compared to the normal population, HL survivors have demonstrated a three- to fivefold increased risk of CAD, with significant excesses first observed 10 years after treatment and persisting beyond 25 years after treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/34/36394/abstract/40,49\">",
"     40,49",
"    </a>",
"    ]. The risk of CAD increases with increased radiation dose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/34/36394/abstract/50,53\">",
"     50,53",
"    </a>",
"    ]. A high prevalence of valvular disease has also been observed, especially beyond 10 years after irradiation. As an example, in a prospective screening study on asymptomatic long-term survivors of HL, echocardiogram detected mild or greater aortic regurgitation in 4.5, 22 and 60 percent of patients 2 to 10, 11 to 20, and &gt;20 years after radiation therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/34/36394/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most of the data on cardiac disease after HL relate to patients who have received mediastinal radiation therapy. The addition of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    -based chemotherapy (eg, ABVD) to radiation therapy further contributes to the risk of cardiac complications. A Canadian study examining cardiac hospitalization found an additive effect of chemotherapy to radiation on cardiac risks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/34/36394/abstract/40\">",
"     40",
"    </a>",
"    ]. Initial studies also suggest an increased risk of cardiac mortality associated with doxorubicin-based therapy for HL in the absence of mediastinal irradiation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/34/36394/abstract/38,39,51\">",
"     38,39,51",
"    </a>",
"    ]. However, studies to date are limited by small numbers of patients, short follow-up time, and competing lymphoma mortality, since patients given chemotherapy alone are more likely to have advanced-stage disease. As an example, a British study reported that, compared with the normal population, patients treated with ABVD without mediastinal radiation a 7.8-fold increased risk of cardiac mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/34/36394/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Monitoring for cardiovascular disease is discussed below. Acute and chronic cardiotoxicity associated with chemotherapy agents and radiation is discussed in more detail separately. (See",
"    <a class=\"local\" href=\"#H1065750\">",
"     'Cardiovascular health'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/46/41706?source=see_link\">",
"     \"Cardiotoxicity of anthracycline-like chemotherapy agents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/12/40138?source=see_link\">",
"     \"Cardiotoxicity of nonanthracycline cancer chemotherapy agents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/21/34137?source=see_link\">",
"     \"Cardiotoxicity of radiation therapy for malignancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11941404\">",
"    <span class=\"h2\">",
"     Non-coronary atherosclerotic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiation therapy to the neck increases the risk of developing carotid atherosclerosis. A 2.2 to 5.6-fold increased risk of stroke has been demonstrated in long-term HL survivors after neck irradiation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/34/36394/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]. The absolute excess risk, however, is low, estimated at 0.1 percent per person per year, such that routine screening with Doppler is likely to be of low yield. In asymptomatic patients, there are no data to suggest that screening would be of benefit. However, careful auscultation for bruits as part of physical examination with low threshold for referral for carotid ultrasound may be of benefit. Of note, the risk of non-coronary atherosclerotic disease after HL therapy is further increased in the presence of other traditional cardiac risk factors, again emphasizing the importance of life style modifications in these patients to reduce the risk of late effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/34/36394/abstract/50,56\">",
"     50,56",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/21/34137?source=see_link&amp;anchor=H12#H12\">",
"     \"Cardiotoxicity of radiation therapy for malignancy\", section on 'Hodgkin lymphoma'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11941412\">",
"    <span class=\"h2\">",
"     Pulmonary dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the acute and subacute setting, patients with HL can develop radiation pneumonitis and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    lung toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/34/36394/abstract/35-37\">",
"     35-37",
"    </a>",
"    ]. Long-term survivors of HL are also at risk for late pulmonary complications that range from pulmonary fibrosis, bronchiectasis, chronic pleural effusions, and recurrent pneumonia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/34/36394/abstract/57-60\">",
"     57-60",
"    </a>",
"    ]. Although rarely immediately life-threatening, the reduced pulmonary function can affect daily function and patients' quality of life. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/33/24090?source=see_link\">",
"     \"Radiation-induced lung injury\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/31/12794?source=see_link\">",
"     \"Bleomycin-induced lung injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One study demonstrated that diminished lung function correlated directly with fatigue levels in HL survivors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/34/36394/abstract/61\">",
"     61",
"    </a>",
"    ]. In this study, gas transfer impairment was the most prevalent pulmonary dysfunction, and patients with gas transfer impairment were significantly more likely to report chronic fatigue, compared with patients without pulmonary dysfunction (48 versus 17 percent). In another prospective study on pulmonary function of HL patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    -based chemotherapy with or without mediastinal irradiation, smoking was associated with a persistently reduced percentage of predicted carbon monoxide-diffusing capacity at one year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/34/36394/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is a lack of data on interventional approaches for patients with chronic pulmonary dysfunction as a result of prior HL therapy. For patients with pulmonary symptoms, pulmonary function tests with diffusion capacity and referral to a pulmonologist may be indicated. Current efforts of limiting radiation dose and fields and chemotherapy doses will hopefully reduce the risk of long-term lung complications in future survivors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/34/36394/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11941420\">",
"    <span class=\"h2\">",
"     Infertility and endocrine dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;HL survivors are at risk for developing endocrine abnormalities such as gonadal dysfunction and hypothyroidism. Less is known about other endocrinopathies resulting from treatment of HL. A small subgroup of HL patients undergoing hematopoietic cell transplantation with total body irradiation (TBI) conditioning may suffer from growth hormone deficiency, hypogonadism, insulin resistance, and dyslipidemia. Further details regarding pregnancy in HL survivors are presented below. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/44/35530?source=see_link&amp;anchor=H94492389#H94492389\">",
"     \"The approach to hematopoietic cell transplantation survivorship\", section on 'Endocrine'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H23221326\">",
"     'Pregnancy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1063826\">",
"    <span class=\"h3\">",
"     Gonadal dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Counseling regarding infertility risks associated with HL therapy is important for patients of childbearing age. The risk is mostly related to exposure to alkylating chemotherapy (eg, MOPP, BEACOPP), but in rare cases of infradiaphragmatic HL, the use pelvic irradiation can lead to gonadal dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/34/36394/abstract/63-66\">",
"     63-66",
"    </a>",
"    ]. Fertility is mostly preserved with ABVD. Although ABVD can lead to transient azoospermia, the majority of men show spermatogenesis recovery following treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/34/36394/abstract/67\">",
"     67",
"    </a>",
"    ]. Female gonadal function also appears to be preserved after ABVD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/34/36394/abstract/68\">",
"     68",
"    </a>",
"    ]. However, the more intense chemotherapy regimens including dose-escalated BEACOPP and its variant regimens have been associated with prolonged azoospermia and amenorrhea in men and women, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/34/36394/abstract/69,70\">",
"     69,70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The impact of alkylating chemotherapy and ovarian radiation on gonadal dysfunction can be illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one series of 86 women who had been treated during childhood for HL, 87 percent overall had normal menstrual function [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/34/36394/abstract/71\">",
"       71",
"      </a>",
"      ]. However, none of those who underwent pelvic radiation without oophoropexy retained this function [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/34/36394/abstract/71\">",
"       71",
"      </a>",
"      ]. Among the girls treated with MOPP, the degree of ovarian injury was related to both the number of cycles and the ovarian radiation dose. Among the boys treated with six cycles of MOPP, 10 of 12 developed absolute azoospermia that persisted as long as 11 years after therapy.",
"     </li>",
"     <li>",
"      A cohort study of 1700 women treated for HL between 1964 and 2004 analyzed the risk of premature ovarian failure (POF) and fertility among 460 women treated between ages 15 and 40 years and not using hormonal contraceptives [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/34/36394/abstract/72\">",
"       72",
"      </a>",
"      ]. At a median follow-up of 16 years, the cumulative risk of POF was significantly higher after alkylating chemotherapy than after nonalkylating chemotherapy (60 versus 3 percent). For women treated with nonalkylating chemotherapy, the cumulative risk of POF was similar among women younger and older than age 32 years (3 and 9 percent). POF risk increased by 23 percent per year of age at treatment. Fewer women who developed POF had one or more children after treatment (22 versus 41 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Early involvement of reproductive endocrinology for fertility preservation options may be prudent in patients of child-bearing age. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/50/7977?source=see_link\">",
"     \"Overview of fertility and pregnancy in cancer survivors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1063870\">",
"    <span class=\"h3\">",
"     Thyroid dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Between 30 to 60 percent of HL survivors will experience thyroid dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/34/36394/abstract/73,74\">",
"     73,74",
"    </a>",
"    ], with hypothyroidism being the most common after neck irradiation. While most cases take place within the first five years after treatment, its occurrence can be delayed beyond 10 years. Higher doses of radiation therapy are associated with an increased risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/34/36394/abstract/74,75\">",
"     74,75",
"    </a>",
"    ]. Routine thyroid function tests as part of follow-up can help detect subclinical hypothyroidism so that thyroid hormone replacement can be initiated prior to emergence of symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1062242\">",
"    <span class=\"h2\">",
"     Neurologic, muscular, and psychosocial complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;HL survivors are also at risk for neurologic, muscular, and psychiatric complications following the completion of treatment. These include vinca alkaloid-associated neuropathy, cervicoscapular muscular atrophy, and mental health issues.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/3/4152?source=see_link\">",
"     Vinblastine",
"    </a>",
"    in the ABVD regimen is responsible for the development of peripheral neuropathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/34/36394/abstract/76\">",
"     76",
"    </a>",
"    ]. The classical presentation is numbness and tingling of the extremities, which usually improves slowly several months after treatment completion. The other complications are discussed in more detail below. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/32/43530?source=see_link&amp;anchor=H20#H20\">",
"     \"Neurologic complications of non-platinum cancer chemotherapy\", section on 'Vincristine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1064448\">",
"    <span class=\"h3\">",
"     Cervicoscapular muscular atrophy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Small case series and case reports have reported development of muscle atrophy in the neck and upper chest wall muscles occurring decades after irradiation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/34/36394/abstract/77-79\">",
"     77-79",
"    </a>",
"    ]. This condition is known as \"dropped-head syndrome\" because of difficulty of affected patients keeping an upright head position. It was thought to be both myogenic and neurogenic in origin. Although it appears to be an irreversible process, early referral to physical therapy for postural recommendation and fitting of braces for support may be of some help in affected patients.",
"   </p>",
"   <p>",
"    A cohort study of 20 patients treated with mantle field radiotherapy and followed for a median of 23 years reported that 17 (83 percent) experienced neck muscle weakness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/34/36394/abstract/80\">",
"     80",
"    </a>",
"    ]. Further testing of 12 patients found that eight patients had severe atrophy of the sternocleidomastoid on physical examination and that muscle ultrasound was abnormal in three. Almost all patients demonstrated myogenic changes on electromyography of the neck muscles and patterns of neurogenic damage in the deltoid, biceps,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    antebrachial flexor muscles. These results suggest that the muscle damage may be due to long-term effects on the vasculature rather than damage to the nerves themselves. If this is the case, HL survivors may benefit from exercises designed to strengthen the neck muscles. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1064190\">",
"    <span class=\"h3\">",
"     Psychosocial issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oncologists and primary care physicians should be aware of the high prevalence of mental health issues faced by HL survivors. The early identification of patients with mental health issues can facilitate referral to mental health professionals to initiate treatment. Such interventions can aid greatly in patients&rsquo; ability to return as closely as possible to the quality of life they enjoyed before their HL diagnosis and treatment. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/6/32873?source=see_link&amp;anchor=H418032811#H418032811\">",
"     \"Overview of cancer survivorship care for primary care and oncology providers\", section on 'Psychosocial well being'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Studies have demonstrated that, when compared with the normal population, long-term HL survivors have poorer health-related quality of life (HR-QOL), primarily due to impairments in physical health [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/34/36394/abstract/81,82\">",
"     81,82",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A longitudinal survey study on the HR-QOL of 935 patients treated for early-stage HL and followed for a median of 92 months reported significant improvement in most HR-QOL domains within 18 months of the end of treatment [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/34/36394/abstract/83\">",
"       83",
"      </a>",
"      ]. Improvements were not seen in cognitive functioning or motivation. Factors associated with significantly impaired HR-QOL were older age and female sex. Persistent fatigue more than two years after",
"      <strong>",
"      </strong>",
"      therapy was observed in half of the patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Another study comparing the QOL of HL survivors with that of the general population found that HL survivors reported lower QOL [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/34/36394/abstract/84\">",
"       84",
"      </a>",
"      ]. This was particularly apparent in patients reporting chronic fatigue.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Several studies have shown persistent fatigue over time in HL survivors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/34/36394/abstract/81,85-88\">",
"     81,85-88",
"    </a>",
"    ]. In addition to adversely affecting QOL, fatigue may be a manifestation of physical abnormalities such as anemia, hypothyroidism, or underlying cardiopulmonary dysfunction. Some studies have shown a correlation between fatigue level and cardiac disease, pulmonary dysfunction, and other late effects in HL survivors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/34/36394/abstract/61,85,88,89\">",
"     61,85,88,89",
"    </a>",
"    ]. These findings suggest that in an otherwise healthy survivor, complaints of fatigue should initiate an investigation for potential underlying cardiopulmonary abnormalities.",
"   </p>",
"   <p>",
"    Initial studies suggest that long-term survivors of childhood HL are at increased risk for neurocognitive impairment. In one study, neurocognitive testing was used to evaluate a cohort of 62 adult survivors of childhood HL randomly selected from a larger cohort of patients treated with either high dose thoracic radiation or lower dose thoracic radiation plus an anthracycline [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/34/36394/abstract/90\">",
"     90",
"    </a>",
"    ]. HL survivors demonstrated impairment in measures of sustained attention, short- and long-term recall, memory, and cognitive fluency. The pathophysiology driving these suspected neurocognitive changes in this population is unclear, but may be related to cerebrovascular pathology related to impaired cardiopulmonary function.",
"   </p>",
"   <p>",
"    HL survivors may also suffer from job discrimination, difficulty in obtaining health and life insurance, marital problems, and decreased sexual functioning [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/34/36394/abstract/91,92\">",
"     91,92",
"    </a>",
"    ]. Some of these difficulties may be related to treatment-associated long-term cosmetic changes (eg, scarring and permanent local hair loss) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/34/36394/abstract/91\">",
"     91",
"    </a>",
"    ]. A study comparing long-term HL survivors and their siblings, however, found no significant difference in sexual function and satisfaction between the two groups [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/34/36394/abstract/93\">",
"     93",
"    </a>",
"    ]. In another large study, patients with early stage disease achieved a normal level of sexual quality of life, while patients with advanced disease reported sexual quality of life measures below that expected for healthy controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/34/36394/abstract/94\">",
"     94",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11941468\">",
"    <span class=\"h1\">",
"     POSTTREATMENT SURVEILLANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following the completion of therapy, patients are followed longitudinally for signs of relapse or treatment-related complications. The majority of relapses after modern therapy for HL occur within the first five years following treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/34/36394/abstract/38,95-98\">",
"     38,95-98",
"    </a>",
"    ]. In contrast, many of the late complications after HL are associated with latency periods of 10 years or longer. In general, in the first five years, the focus is on managing acute and subacute side effects of treatment and on detecting HL recurrences so that subsequent therapy can be instituted in a timely manner. Beyond five years, the attention shifts to monitoring for and managing late effects of treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1064528\">",
"    <span class=\"h2\">",
"     Monitoring for relapse",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following the completion of therapy, restaging, and documentation of complete remission, patients are seen at periodic intervals to be monitored and assessed for possible relapse. In the absence of empiric data, the frequency and extent of these visits depends upon the comfort of both the patient and physician. Our approach to monitoring for recurrent disease is discussed separately. Relapsed disease can be suggested by changes on imaging studies but can only be confirmed by biopsy. As such, a biopsy should be obtained to document relapsed disease before proceeding to subsequent therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/0/3079?source=see_link&amp;anchor=H1167672602#H1167672602\">",
"     \"Long-term follow-up of the patient with classical Hodgkin lymphoma\", section on 'Follow-up for relapse'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1064552\">",
"    <span class=\"h2\">",
"     Monitoring for complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;As described above, HL survivors are at risk of developing therapy-related complications that may present years after treatment (eg, second malignancies, cardiac disease, radiation-induced hypothyroidism). Screening for some of these entities is advised in the hope that early detection may lead to better management. As such, HL survivors should be assessed periodically to monitor for these potential complications (",
"    <a class=\"graphic graphic_table graphicRef85763 \" href=\"mobipreview.htm?4/47/4861\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1065733\">",
"    <span class=\"h3\">",
"     Cancer screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;While HL survivors are at increased risk of developing secondary malignancies, the ideal screening program has not been defined. Our approach is generally consistent with those proposed by the American Cancer Society [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/34/36394/abstract/99,100\">",
"     99,100",
"    </a>",
"    ], the Children&rsquo;s Oncology Group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/34/36394/abstract/101\">",
"     101",
"    </a>",
"    ], and the National Comprehensive Cancer Network (NCCN) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/34/36394/abstract/14\">",
"     14",
"    </a>",
"    ]. HL survivors should be encouraged to participate in routine age-appropriate cancer surveillance with the following notable exceptions (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/4/37962?source=see_link&amp;anchor=H9#H9\">",
"     \"Overview of preventive medicine in adults\", section on 'Cancer morbidity and mortality'",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Risk awareness counseling annually",
"      </strong>",
"      &mdash; HL survivors should be advised of their increased risk of developing a malignancy following treatment and encouraged to report any concerning symptoms to their physician. Smoking cessation should be recommended, and patients should be counseled to limit unprotected sun exposure. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/3/23609?source=see_link\">",
"       \"Overview of smoking cessation management in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Screening clinical assessment annually",
"      </strong>",
"      &mdash; In addition to a routine physical examination, HL survivors should undergo an at least annual complete skin examination to monitor for the development of skin cancers, especially within prior radiation treatment fields. &nbsp;",
"     </li>",
"     <li>",
"      <strong>",
"       Breast cancer screening",
"      </strong>",
"      &mdash; Female HL survivors should undergo screening for breast cancer beginning no later than age 40 years. For patients who have received total body or chest irradiation, breast cancer screening should begin eight years after radiation or at age 25 years, whichever occurs later. The type or combinations of types of screening modalities and time schedule may need to be tailored to individual patients depending on type of treatment, age at treatment, current age, and other breast cancer risk factors. Mammography can be used to screen most women for breast cancers, but women who received radiation to the chest during childhood, adolescence, or young adulthood (eg, age of 10 and 35 years) should be considered for screening with both annual breast magnetic resonance imaging (MRI) and mammography. There are no data on the role of chemoprevention specific to female Hodgkin lymphoma survivors. However, selected female HL survivors may benefit from a consultation with a high-risk breast specialist to discuss chemoprevention options. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?43/13/44246?source=see_link&amp;anchor=H9621357#H9621357\">",
"       \"Selective estrogen receptor modulators and aromatase inhibitors for breast cancer prevention\", section on 'Patient Selection'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/0/3079?source=see_link&amp;anchor=H1167672651#H1167672651\">",
"       \"Long-term follow-up of the patient with classical Hodgkin lymphoma\", section on 'Routine testing'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Lung cancer screening",
"      </strong>",
"      &mdash; The role of early detection using chest computed tomography (CT) or low-dose chest CT screening is a rapidly evolving field. For patients with a significant smoking history, clinicians should consider performing an annual low-dose spiral computed tomography scan for lung cancer screening, starting five years after the diagnosis of HL. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/58/28586?source=see_link\">",
"       \"Screening for lung cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Colon cancer screening",
"      </strong>",
"      &mdash; The absolute risk of colorectal cancer in a 40-year-old patient treated for HL as a child, adolescent, or young adult is similar or greater than the risk of colorectal cancer in 50- to 54-year-old adults, the age at which routine colorectal screening is recommended. Accordingly, clinicians should consider starting colorectal screening in such long-term HL survivors at least 10 years earlier than would be recommended for the general population. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/0/3079?source=see_link&amp;anchor=H1167672665#H1167672665\">",
"       \"Long-term follow-up of the patient with classical Hodgkin lymphoma\", section on 'Screening for colorectal cancer'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Skin cancer screening",
"      </strong>",
"      &mdash; Survivors of HL are at increased risk for developing secondary skin cancers. As an example, in the Childhood Cancer Survivor Study, which included 1927 survivors of pediatric HL followed for a median of 23 years, HL survivors had an estimated cumulative incidence of nonmelanoma skin cancers of approximately 20 percent at 30 years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/34/36394/abstract/102\">",
"       102",
"      </a>",
"      ]. All patients should be encouraged to minimize life-long sun exposure and to use ultraviolet light-blocking agents. They should be counseled about self-skin examination and advised to examine their skin regularly and notify their physicians if moles change. In addition, they should have a regular full body skin examination by a clinician with skin expertise.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1065750\">",
"    <span class=\"h3\">",
"     Cardiovascular health",
"    </span>",
"    &nbsp;&mdash;&nbsp;Screening and counseling techniques similar to those used for other high risk populations are applied to HL survivors with the goal of decreasing mortality from cardiovascular disease. Our approach is generally consistent with those proposed by the National Comprehensive Cancer Network (NCCN) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/34/36394/abstract/14\">",
"     14",
"    </a>",
"    ] and the Children&rsquo;s Oncology Group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/34/36394/abstract/101\">",
"     101",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cardiac risk factors should be minimized (eg, smoking, obesity, hyperlipidemia, hypertension). Routine care should incorporate regular measurement and control of blood pressure, auscultation of the carotids for bruits, heart murmurs, nutritional counseling and obesity control, counseling for smoking cessation, and control of diabetes and lipids. For this at-risk population, an LDL of 100 or lower is typically targeted.",
"     </li>",
"     <li>",
"      In addition, we commonly refer HL survivors to a cardiologist for baseline evaluation after the completion of treatment and determination of the necessity and frequency of additional screening or diagnostic studies (eg, resting and stress echocardiogram). Cardiac evaluation is especially important for patients who have received radiation therapy, particularly once 10 years have passed since the radiation therapy.",
"     </li>",
"     <li>",
"      At a minimum, patients should be instructed not to ignore persistent troubling symptoms and to bring them to the attention of their physician without delay. Physicians must be aware of HL survivors&rsquo; treatment history; additional testing should be pursued if suspicion of a late complication arises.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The largest prospective cardiac screening study was conducted by the Stanford group using resting echocardiography, stress echocardiography, and nuclear scintigraphy on 294 asymptomatic HL survivors with history of chest irradiation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/34/36394/abstract/54\">",
"     54",
"    </a>",
"    ]. Echocardiography detected mild or greater aortic regurgitation in 4.5, 22, and 60 percent of patients 2 to 10, 11 to 20, and &gt;20 years after therapy. Further, only 6.3 percent of cases were detectable by auscultation. There was a two- to threefold risk of diastolic dysfunction after 10 years, which was significantly associated with subclinical coronary disease and to subsequently develop cardiac events [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/34/36394/abstract/103\">",
"     103",
"    </a>",
"    ]. As a result of the screening, 40 of the 294 screened patients underwent angiography, 16 of whom were found to have &gt;70 percent coronary disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/34/36394/abstract/104\">",
"     104",
"    </a>",
"    ]. A total of nine patients required either PTCA or coronary artery bypass graft based on angiography findings. These results support the use of diagnostic studies to screen HL survivors beginning 10 years after the completion of chest irradiation. The role of these screening tests in patients who have not received radiation is not clear. (See",
"    <a class=\"local\" href=\"#H11941396\">",
"     'Cardiovascular disease'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H11941404\">",
"     'Non-coronary atherosclerotic disease'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1065758\">",
"    <span class=\"h3\">",
"     Endocrine assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;HL survivors whose treatment included radiation to the neck or mediastinum should have an assay of thyroid stimulating hormone (TSH) measured one year after the completion of therapy and then annually. If the serum TSH concentration is elevated, the TSH measurement should be repeated along with a serum free T4 to make the diagnosis of hypothyroidism. Assays can be performed earlier if clinical suspicion exists, but the clinician must be aware of the possibility of acquired transient central hypothyroidism (the sick-euthyroid syndrome) early after radiation treatment. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/7/26744?source=see_link\">",
"     \"Diagnosis of and screening for hypothyroidism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/39/44663?source=see_link\">",
"     \"Thyroid function in nonthyroidal illness\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1064521\">",
"    <span class=\"h2\">",
"     Lifestyle modifications",
"    </span>",
"    &nbsp;&mdash;&nbsp;At each visit, HL survivors should be encouraged to incorporate healthy practices into their lifestyle in order to decrease the risk of developing complications. Increased efforts may be needed to reach out to and educate survivors of lower socioeconomic status. This was suggested in a questionnaire study on long-term HL survivors that reported that a lower socioeconomic status was associated with poorer adherence to routine health care and a higher likelihood of engaging in unhealthy habits including physical inactivity, smoking, and",
"    <span class=\"nowrap\">",
"     moderate/heavy",
"    </span>",
"    alcohol use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/34/36394/abstract/105\">",
"     105",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The cardiovascular sequelae of HL treatment can be mitigated through active lifestyle modifications. Reducing or eliminating comorbid conditions, such as diabetes, hypertension, hyperlipidemia, and obesity, is important. Smokers should be encouraged to quit, both to reduce the risk of cardiac disease, improve lung function, and decrease the risk of lung cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/34/36394/abstract/30,49,62\">",
"     30,49,62",
"    </a>",
"    ]. Resources should be provided to HL survivors who smoke to educate them about the behavioral and pharmacologic interventions that can assist with smoking cessation efforts. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/3/23609?source=see_link\">",
"     \"Overview of smoking cessation management in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Engaging in regular physical activity may be particularly critical in helping HL survivors to be healthy. Physical inactivity is designated by the American Heart Association as one of the major risk factors for coronary heart disease. In addition to reducing risk of heart disease, exercise may potentially help with fatigue, a common long-term problem in HL survivors. In a pilot study assessing the feasibility of an exercise-program in HL survivors with chronic fatigue, it was noted that the fatigue, physical functioning, and maximal aerobic capacity were significantly improved after a home-based exercise intervention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/34/36394/abstract/106\">",
"     106",
"    </a>",
"    ]. Therefore, all HL survivors should be encouraged to participate in at least some exercise, with patients informed that the more exercise they get, the better chance they have of improving their quality of life. Consultation with exercise physiologists and nutritionists may be appropriate in select patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23221326\">",
"    <span class=\"h1\">",
"     PREGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pregnancy rate among premenopausal HL survivors approaches that of the normal female population (85 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/34/36394/abstract/71\">",
"     71",
"    </a>",
"    ]. Among the factors that have contributed to the preservation of fertility are pelvic shielding with primary irradiation, oophoropexy for those requiring pelvic radiotherapy, and a shift towards combination chemotherapy with ABVD. As described above, MOPP and BEACOPP are associated with significant risks of long term infertility. (See",
"    <a class=\"local\" href=\"#H1063826\">",
"     'Gonadal dysfunction'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23221333\">",
"    <span class=\"h2\">",
"     Pregnancy outcome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women previously treated for HL are generally able to have favorable outcomes with future pregnancies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/34/36394/abstract/107-112\">",
"     107-112",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A Danish cohort study that included 192 children of female HL survivors reported no substantially increased risk of preterm birth, low birth weight, or stillbirth or congenital anomalies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/34/36394/abstract/108\">",
"       108",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another study compared the outcome of 93 pregnancies in 48 HL survivors to 228 pregnancies in 69 sibling controls [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/34/36394/abstract/109\">",
"       109",
"      </a>",
"      ]. No significant differences in spontaneous abortions or abnormal offspring were noted in the 35 patients who had been treated with irradiation alone. However, the likelihood of abnormal offspring was higher in the women who had received both irradiation and chemotherapy. Interestingly, wives of male patients who had been treated with both approaches had a higher incidence of spontaneous abortion than wives of male controls.",
"     </li>",
"     <li>",
"      A questionnaire survey of 453 HL survivors with a median time from last treatment of 15 years evaluated the attempt and achievement of successful pregnancy with or without the use of infertility therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/34/36394/abstract/113\">",
"       113",
"      </a>",
"      ]. By the time of the survey, 120 (45 percent) men and 91 (50 percent) women had attempted to have children. Of these, the majority (63 percent of males and 75 percent of females) had children successfully without infertility therapy. In addition, 10 men and one woman had children with infertility treatment. Factors associated with successful reproduction included treatment with radiation therapy alone, chemotherapy with low gonadotoxicity (eg, ABVD), and younger age (&lt;30 years) at diagnosis. Ten-year probabilities of successful pregnancy outcomes were 82, 55, 51, and 27 percent for patients who received radiation alone, low, medium, and highly gonadal-toxic chemotherapy, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Similar observations have been made in large series that have evaluated survivors of childhood cancer. The offspring of these survivors, compared with controls, do not have an increase in either genetic abnormalities (3.4 versus 3.1 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/34/36394/abstract/114\">",
"     114",
"    </a>",
"    ] or nonhereditary cancer (standardized incidence ratio of 1.3) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/34/36394/abstract/115\">",
"     115",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A more general discussion of fertility and pregnancy issues in cancer survivors is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/50/7977?source=see_link\">",
"     \"Overview of fertility and pregnancy in cancer survivors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/7/38010?source=see_link\">",
"     \"Fertility preservation in patients undergoing gonadotoxic treatment or gonadal resection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/26/1447?source=see_link\">",
"     \"Ovarian failure due to anticancer drugs and radiation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23221340\">",
"    <span class=\"h2\">",
"     Counseling",
"    </span>",
"    &nbsp;&mdash;&nbsp;Our general guidelines for planning subsequent pregnancy after treatment for HL are empirically derived and based upon the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most HL relapses occur within two to three years of definitive therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/34/36394/abstract/116,117\">",
"       116,117",
"      </a>",
"      ]. In one series of 249 patients who had been in remission for two years, only 10 percent subsequently relapsed at a median follow-up of 10.5 years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/34/36394/abstract/117\">",
"       117",
"      </a>",
"      ]. As a result, follow-up imaging diminishes in frequency after two to three years and can be safely delayed in the pregnant patient.",
"     </li>",
"     <li>",
"      Chemotherapy-induced menstrual irregularity using ABVD is often transient, resolving within one to two years.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For these reasons, it is generally recommended that women delay pregnancy for at least two years after treatment has been completed. Follow-up imaging should be performed before conception but not during pregnancy unless indicated by physical findings or symptoms. The patient should be evaluated for infertility if she does not become pregnant within one year. For women older than age 35, fertility work up is indicated if pregnancy does not occur within six months. If pregnancy does occur, a physical examination specifically focused to evaluate for signs and symptoms of recurrent HL should be performed at least once during pregnancy. The management of HL during pregnancy is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/56/17287?source=see_link\">",
"     \"Overview of infertility\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/31/12793?source=see_link\">",
"     \"Management of classical Hodgkin lymphoma during pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An important issue to recognize is that women need more thyroid hormone during pregnancy and unlike normal women, those with hypothyroidism (eg, due to prior mantle irradiation) are unable to increase thyroidal T4 and T3 secretion. On average, hypothyroid women need 45 percent more T4 during pregnancy to maintain normal TSH secretion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/34/36394/abstract/118\">",
"     118",
"    </a>",
"    ]. Failure to appropriately regulate thyroid status can have adverse effects on both the mother and fetus. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/53/43865?source=see_link&amp;anchor=H19#H19\">",
"     \"Treatment of hypothyroidism\", section on 'Hypothyroidism during pregnancy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11941484\">",
"    <span class=\"h1\">",
"     COORDINATION OF CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;HL is an uncommon diagnosis. Most patients enjoy a high cure rate and the serious complications are often much delayed, occurring decades after treatment. Typically, the medical oncologist follows the patient closely for several years after finishing therapy, and subsequently the patient transitions back to the primary care physician (PCP) as his or her main provider. This transition period can be fraught with miscommunication between even the most well-meaning providers. Establishing a survivorship care plan is one way to facilitate communication and allocation of responsibility during this time period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/34/36394/abstract/119\">",
"     119",
"    </a>",
"    ]. Regular communications between PCPs and oncologists regarding follow-up and screening recommendations and management of late complications that arise over time would further promote optimal care for HL survivors. The patient&rsquo;s attendance of a survivorship clinic, where available, can also aid in promoting well-coordinated care. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/6/32873?source=see_link&amp;anchor=H418030689#H418030689\">",
"     \"Overview of cancer survivorship care for primary care and oncology providers\", section on 'Coordination of care'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    With the young median age at diagnosis, patients with HL tend to be highly mobile. It can be logistically difficult for survivors who no longer live locally to return to their oncology center for regular follow up visits. Long-term survivors of HL, many of whom are relatively young and asymptomatic, may also be less motivated to maintain contact with their oncologists. Studies have suggested a benefit for long-term survivors to receive follow-up care from oncologists. Such clinicians would be expected to have more experience in addressing late effects of cancer therapy and be more familiar with key health issues in this population. In a study conducted by the childhood cancer survivor study (CCSS) group on young adult survivors of pediatric cancers, 87 percent of the survivors reported general medical contact, but only 19 percent reported visits to a cancer center [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/34/36394/abstract/55\">",
"     55",
"    </a>",
"    ]. In a subsequent analysis from the same group, survivors who received care in a cancer",
"    <sup>",
"    </sup>",
"    center were more likely than those who received their care elsewhere",
"    <sup>",
"    </sup>",
"    to report an indicated echocardiogram (53 versus 22 percent) or mammogram",
"    <sup>",
"    </sup>",
"    (62 versus 35 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/34/36394/abstract/120\">",
"     120",
"    </a>",
"    ]. In another study, HL survivors who had received information from an oncologist were significantly more likely to correctly assess their breast cancer risk than those who received information from other sources [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/34/36394/abstract/89\">",
"     89",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, continued follow-up care at cancer centers can be challenging as survivors move to new places, and it can also be restricted by limited oncology clinic schedule and space. Survivors can be encouraged to take a more active role in their follow-up care, and this can be facilitated by providing patients with information of their treatment history and educating patients regarding the potential late complications and the importance of adherence to screening practice and risk-reducing behavioral modification.",
"   </p>",
"   <p>",
"    Through a deepened understanding of late treatment effects, we can begin to more effectively counsel our patients on the risks they face and the lifestyle modifications and other interventions that can reduce the ill effects of these complications. Effectively managing these consequences of therapy may improve the quality of life of HL survivors and has the potential to prolong their survival.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H105459257\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There are a growing number of long-term survivors of Hodgkin lymphoma (HL). These patients must be monitored periodically not only for disease recurrence, but also for long term complications related to the disease and its treatment (",
"      <a class=\"graphic graphic_table graphicRef85763 \" href=\"mobipreview.htm?4/47/4861\">",
"       table 4",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11941468\">",
"       'Posttreatment surveillance'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      The risk of developing both hematologic and solid tumor second malignancies is increased in long term survivors of HL, and likely differs depending upon the age at treatment and the treatment received. Solid tumors account for the majority of second cancers in HL survivors with breast, lung, and colon cancer being the most frequent (",
"      <a class=\"graphic graphic_table graphicRef57099 \" href=\"mobipreview.htm?1/22/1391\">",
"       table 3",
"      </a>",
"      ). Female HL survivors should undergo screening for breast cancer beginning no later than age 40 years. For patients who have received total body or chest irradiation, breast cancer screening should begin eight years after radiation or at age 25 years, whichever occurs later. Mammography can be used to screen most women for breast cancers, but women who received radiation to the chest during childhood, adolescence, or young adulthood (eg, age of 10 and 35 years) should be considered for screening with both annual breast magnetic resonance imaging (MRI) and mammography. (See",
"      <a class=\"local\" href=\"#H11941388\">",
"       'Second malignancy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1065733\">",
"       'Cancer screening'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Survivors of HL are at risk for long term cardiovascular complications (eg, congestive heart failure, stroke) related to the chemotherapy they have received (eg, anthracyclines)",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      radiation. Risk factors include preexisting hypertension, young age at HL diagnosis, and the amount of radiotherapy received. (See",
"      <a class=\"local\" href=\"#H11941396\">",
"       'Cardiovascular disease'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11941404\">",
"       'Non-coronary atherosclerotic disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cytotoxic agents and radiation therapy can produce gonadal dysfunction in both male and female survivors of HL. Infertility is relatively uncommon among younger patients treated with ABVD. Infertility rates are higher among older patients and those receiving BEACOPP or high dose chemotherapy followed by autologous hematopoietic cell transplantation. Survivors who received neck",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      mediastinal radiation are at risk for developing hypothyroidism. (See",
"      <a class=\"local\" href=\"#H11941420\">",
"       'Infertility and endocrine dysfunction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The pregnancy rate among premenopausal HL survivors approaches that of the normal female population. It is generally recommended that women delay pregnancy for at least two years after treatment has been completed. HL survivors who become pregnant should have a physical examination specifically focused to evaluate for signs and symptoms of recurrent HL at least once during pregnancy. (See",
"      <a class=\"local\" href=\"#H23221340\">",
"       'Counseling'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      Lifestyle modification including regular exercise, smoking cessation, and a healthy diet are all important in minimizing the severity of late treatment sequelae. (See",
"      <a class=\"local\" href=\"#H1064521\">",
"       'Lifestyle modifications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Coordination of care among the medical oncologist, primary care physician, and other healthcare professionals is critical and can be facilitated by the patient&rsquo;s participation in a survivorship clinic, where available. (See",
"      <a class=\"local\" href=\"#H11941484\">",
"       'Coordination of care'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36394/abstract/1\">",
"      Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin 2009; 59:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36394/abstract/2\">",
"      Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36394/abstract/3\">",
"      Mariotto AB, Rowland JH, Yabroff KR, et al. Long-term survivors of childhood cancers in the United States. Cancer Epidemiol Biomarkers Prev 2009; 18:1033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36394/abstract/4\">",
"      Yahalom J, Mauch P. The involved field is back: issues in delineating the radiation field in Hodgkin's disease. Ann Oncol 2002; 13 Suppl 1:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36394/abstract/5\">",
"      Campbell BA, Voss N, Pickles T, et al. Involved-nodal radiation therapy as a component of combination therapy for limited-stage Hodgkin's lymphoma: a question of field size. J Clin Oncol 2008; 26:5170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36394/abstract/6\">",
"      Girinsky T, van der Maazen R, Specht L, et al. Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: concepts and guidelines. Radiother Oncol 2006; 79:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36394/abstract/7\">",
"      Paumier A, Ghalibafian M, Beaudre A, et al. Involved-node radiotherapy and modern radiation treatment techniques in patients with Hodgkin lymphoma. Int J Radiat Oncol Biol Phys 2011; 80:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36394/abstract/8\">",
"      Kaplan HS, Rosenberg SA. The treatment of Hodgkin's disease. Med Clin North Am 1966; 50:1591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36394/abstract/9\">",
"      DeVita VT Jr, Simon RM, Hubbard SM, et al. Curability of advanced Hodgkin's disease with chemotherapy. Long-term follow-up of MOPP-treated patients at the National Cancer Institute. Ann Intern Med 1980; 92:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36394/abstract/10\">",
"      Devita VT Jr, Serpick AA, Carbone PP. Combination chemotherapy in the treatment of advanced Hodgkin's disease. Ann Intern Med 1970; 73:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36394/abstract/11\">",
"      Bonadonna G, Zucali R, Monfardini S, et al. Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer 1975; 36:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36394/abstract/12\">",
"      Santoro A, Bonadonna G, Valagussa P, et al. Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin's disease: superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy. J Clin Oncol 1987; 5:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36394/abstract/13\">",
"      Canellos GP, Anderson JR, Propert KJ, et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 1992; 327:1478.",
"     </a>",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) guidelines available online at  www.nccn.org.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36394/abstract/15\">",
"      Brenner H, Gondos A, Pulte D. Survival expectations of patients diagnosed with Hodgkin's lymphoma in 2006-2010. Oncologist 2009; 14:806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36394/abstract/16\">",
"      Storm HH, Klint A, Tryggvad&oacute;ttir L, et al. Trends in the survival of patients diagnosed with malignant neoplasms of lymphoid, haematopoietic, and related tissue in the Nordic countries 1964-2003 followed up to the end of 2006. Acta Oncol 2010; 49:694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36394/abstract/17\">",
"      Bessell EM, Bouliotis G, Armstrong S, et al. Long-term survival after treatment for Hodgkin's disease (1973-2002): improved survival with successive 10-year cohorts. Br J Cancer 2012; 107:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36394/abstract/18\">",
"      Engert A, Pl&uuml;tschow A, Eich HT, et al. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med 2010; 363:640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36394/abstract/19\">",
"      Ferm&eacute; C, Eghbali H, Meerwaldt JH, et al. Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease. N Engl J Med 2007; 357:1916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36394/abstract/20\">",
"      Sj&ouml;berg J, Halthur C, Kristinsson SY, et al. Progress in Hodgkin lymphoma: a population-based study on patients diagnosed in Sweden from 1973-2009. Blood 2012; 119:990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36394/abstract/21\">",
"      Eich HT, Diehl V, G&ouml;rgen H, et al. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. J Clin Oncol 2010; 28:4199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36394/abstract/22\">",
"      Aleman BM, Raemaekers JM, Tirelli U, et al. Involved-field radiotherapy for advanced Hodgkin's lymphoma. N Engl J Med 2003; 348:2396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36394/abstract/23\">",
"      Diehl V, Franklin J, Pfreundschuh M, et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 2003; 348:2386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36394/abstract/24\">",
"      Federico M, Luminari S, Iannitto E, et al. ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. J Clin Oncol 2009; 27:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36394/abstract/25\">",
"      Diehl V, Haverkamp H, Mueller R, et al. Eight cycles of BEACOPP escalated compared with 4 cycles of BEACOPP escalated followed by 4 cycles of BEACOPP baseline with or without radiotherapy in patients in advanced stage Hodgkin lymphoma (HL): Final analysis of the HD12 trial of the German Hodgkin Study Group (GHSG). J Clin Oncol 2009; 27:15s.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36394/abstract/26\">",
"      Viviani S, Santoro A, Ragni G, et al. Gonadal toxicity after combination chemotherapy for Hodgkin's disease. Comparative results of MOPP vs ABVD. Eur J Cancer Clin Oncol 1985; 21:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36394/abstract/27\">",
"      Kaldor JM, Day NE, Clarke EA, et al. Leukemia following Hodgkin's disease. N Engl J Med 1990; 322:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36394/abstract/28\">",
"      Kaldor JM, Day NE, Bell J, et al. Lung cancer following Hodgkin's disease: a case-control study. Int J Cancer 1992; 52:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36394/abstract/29\">",
"      Swerdlow AJ, Schoemaker MJ, Allerton R, et al. Lung cancer after Hodgkin's disease: a nested case-control study of the relation to treatment. J Clin Oncol 2001; 19:1610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36394/abstract/30\">",
"      Travis LB, Gospodarowicz M, Curtis RE, et al. Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease. J Natl Cancer Inst 2002; 94:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36394/abstract/31\">",
"      van den Belt-Dusebout AW, Aleman BM, Besseling G, et al. Roles of radiation dose and chemotherapy in the etiology of stomach cancer as a second malignancy. Int J Radiat Oncol Biol Phys 2009; 75:1420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36394/abstract/32\">",
"      Valagussa P, Santoro A, Fossati-Bellani F, et al. Second acute leukemia and other malignancies following treatment for Hodgkin's disease. J Clin Oncol 1986; 4:830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36394/abstract/33\">",
"      van Leeuwen FE, Chorus AM, van den Belt-Dusebout AW, et al. Leukemia risk following Hodgkin's disease: relation to cumulative dose of alkylating agents, treatment with teniposide combinations, number of episodes of chemotherapy, and bone marrow damage. J Clin Oncol 1994; 12:1063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36394/abstract/34\">",
"      Cil T, Altintas A, Tamam Y, et al. Low dose vincristine-induced severe polyneuropathy in a Hodgkin lymphoma patient: a case report (vincristine-induced severe polyneuropathy). J Pediatr Hematol Oncol 2009; 31:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36394/abstract/35\">",
"      Sleijfer S. Bleomycin-induced pneumonitis. Chest 2001; 120:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36394/abstract/36\">",
"      Martin WG, Ristow KM, Habermann TM, et al. Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma. J Clin Oncol 2005; 23:7614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36394/abstract/37\">",
"      Hirsch A, Vander Els N, Straus DJ, et al. Effect of ABVD chemotherapy with and without mantle or mediastinal irradiation on pulmonary function and symptoms in early-stage Hodgkin's disease. J Clin Oncol 1996; 14:1297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36394/abstract/38\">",
"      Swerdlow AJ, Higgins CD, Smith P, et al. Myocardial infarction mortality risk after treatment for Hodgkin disease: a collaborative British cohort study. J Natl Cancer Inst 2007; 99:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36394/abstract/39\">",
"      Avil&eacute;s A, Neri N, Nambo JM, et al. Late cardiac toxicity secondary to treatment in Hodgkin's disease. A study comparing doxorubicin, epirubicin and mitoxantrone in combined therapy. Leuk Lymphoma 2005; 46:1023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36394/abstract/40\">",
"      Myrehaug S, Pintilie M, Tsang R, et al. Cardiac morbidity following modern treatment for Hodgkin lymphoma: supra-additive cardiotoxicity of doxorubicin and radiation therapy. Leuk Lymphoma 2008; 49:1486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36394/abstract/41\">",
"      Ng AK, Bernardo MP, Weller E, et al. Long-term survival and competing causes of death in patients with early-stage Hodgkin's disease treated at age 50 or younger. J Clin Oncol 2002; 20:2101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36394/abstract/42\">",
"      Aleman BM, van den Belt-Dusebout AW, Klokman WJ, et al. Long-term cause-specific mortality of patients treated for Hodgkin's disease. J Clin Oncol 2003; 21:3431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36394/abstract/43\">",
"      Dores GM, Metayer C, Curtis RE, et al. Second malignant neoplasms among long-term survivors of Hodgkin's disease: a population-based evaluation over 25 years. J Clin Oncol 2002; 20:3484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36394/abstract/44\">",
"      Ng AK, Bernardo MV, Weller E, et al. Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors. Blood 2002; 100:1989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36394/abstract/45\">",
"      Hodgson DC, Gilbert ES, Dores GM, et al. Long-term solid cancer risk among 5-year survivors of Hodgkin's lymphoma. J Clin Oncol 2007; 25:1489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36394/abstract/46\">",
"      Hodgson DC, Koh ES, Tran TH, et al. Individualized estimates of second cancer risks after contemporary radiation therapy for Hodgkin lymphoma. Cancer 2007; 110:2576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36394/abstract/47\">",
"      De Bruin ML, Sparidans J, van't Veer MB, et al. Breast cancer risk in female survivors of Hodgkin's lymphoma: lower risk after smaller radiation volumes. J Clin Oncol 2009; 27:4239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36394/abstract/48\">",
"      Ng AK. Review of the cardiac long-term effects of therapy for Hodgkin lymphoma. Br J Haematol 2011; 154:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36394/abstract/49\">",
"      Aleman BM, van den Belt-Dusebout AW, De Bruin ML, et al. Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood 2007; 109:1878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36394/abstract/50\">",
"      Hull MC, Morris CG, Pepine CJ, Mendenhall NP. Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of hodgkin lymphoma treated with radiation therapy. JAMA 2003; 290:2831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36394/abstract/51\">",
"      Myrehaug S, Pintilie M, Yun L, et al. A population-based study of cardiac morbidity among Hodgkin lymphoma patients with preexisting heart disease. Blood 2010; 116:2237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36394/abstract/52\">",
"      Galper SL, Yu JB, Mauch PM, et al. Clinically significant cardiac disease in patients with Hodgkin lymphoma treated with mediastinal irradiation. Blood 2011; 117:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36394/abstract/53\">",
"      K&uuml;peli S, Hazirolan T, Varan A, et al. Evaluation of coronary artery disease by computed tomography angiography in patients treated for childhood Hodgkin's lymphoma. J Clin Oncol 2010; 28:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36394/abstract/54\">",
"      Heidenreich PA, Hancock SL, Lee BK, et al. Asymptomatic cardiac disease following mediastinal irradiation. J Am Coll Cardiol 2003; 42:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36394/abstract/55\">",
"      Bowers DC, McNeil DE, Liu Y, et al. Stroke as a late treatment effect of Hodgkin's Disease: a report from the Childhood Cancer Survivor Study. J Clin Oncol 2005; 23:6508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36394/abstract/56\">",
"      De Bruin ML, Dorresteijn LD, van't Veer MB, et al. Increased risk of stroke and transient ischemic attack in 5-year survivors of Hodgkin lymphoma. J Natl Cancer Inst 2009; 101:928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36394/abstract/57\">",
"      Abratt RP, Morgan GW, Silvestri G, Willcox P. Pulmonary complications of radiation therapy. Clin Chest Med 2004; 25:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36394/abstract/58\">",
"      Gustavsson A, Eskilsson J, Landberg T, et al. Long-term effects on pulmonary function of mantle radiotherapy in patients with Hodgkin's disease. Ann Oncol 1992; 3:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36394/abstract/59\">",
"      Lund MB, Kongerud J, Nome O, et al. Lung function impairment in long-term survivors of Hodgkin's disease. Ann Oncol 1995; 6:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36394/abstract/60\">",
"      Ng AK, Abramson JS, Digumarthy SR, et al. Case records of the Massachusetts General Hospital. Case 24-2010. A 56-year-old woman with a history of Hodgkin's lymphoma and sudden onset of dyspnea and shock. N Engl J Med 2010; 363:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36394/abstract/61\">",
"      Knobel H, H&aring;vard Loge J, Lund MB, et al. Late medical complications and fatigue in Hodgkin's disease survivors. J Clin Oncol 2001; 19:3226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36394/abstract/62\">",
"      Ng AK, Li S, Neuberg D, et al. A prospective study of pulmonary function in Hodgkin's lymphoma patients. Ann Oncol 2008; 19:1754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36394/abstract/63\">",
"      Longo DL, Young RC, Wesley M, et al. Twenty years of MOPP therapy for Hodgkin's disease. J Clin Oncol 1986; 4:1295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36394/abstract/64\">",
"      Chapman RM, Sutcliffe SB, Rees LH, et al. Cyclical combination chemotherapy and gonadal function. Retrospective study in males. Lancet 1979; 1:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36394/abstract/65\">",
"      Viviani S, Ragni G, Santoro A, et al. Testicular dysfunction in Hodgkin's disease before and after treatment. Eur J Cancer 1991; 27:1389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36394/abstract/66\">",
"      De Bruin ML, Huisbrink J, Hauptmann M, et al. Treatment-related risk factors for premature menopause following Hodgkin lymphoma. Blood 2008; 111:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36394/abstract/67\">",
"      Anselmo AP, Cartoni C, Bellantuono P, et al. Risk of infertility in patients with Hodgkin's disease treated with ABVD vs MOPP vs ABVD/MOPP. Haematologica 1990; 75:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36394/abstract/68\">",
"      Hodgson DC, Pintilie M, Gitterman L, et al. Fertility among female hodgkin lymphoma survivors attempting pregnancy following ABVD chemotherapy. Hematol Oncol 2007; 25:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36394/abstract/69\">",
"      Behringer K, Breuer K, Reineke T, et al. Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group. J Clin Oncol 2005; 23:7555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36394/abstract/70\">",
"      Sieniawski M, Reineke T, Nogova L, et al. Fertility in male patients with advanced Hodgkin lymphoma treated with BEACOPP: a report of the German Hodgkin Study Group (GHSG). Blood 2008; 111:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36394/abstract/71\">",
"      Ortin TT, Shostak CA, Donaldson SS. Gonadal status and reproductive function following treatment for Hodgkin's disease in childhood: the Stanford experience. Int J Radiat Oncol Biol Phys 1990; 19:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36394/abstract/72\">",
"      van der Kaaij MA, Heutte N, Meijnders P, et al. Premature ovarian failure and fertility in long-term survivors of Hodgkin's lymphoma: a European Organisation for Research and Treatment of Cancer Lymphoma Group and Groupe d'Etude des Lymphomes de l'Adulte Cohort Study. J Clin Oncol 2012; 30:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36394/abstract/73\">",
"      Hancock SL, Cox RS, McDougall IR. Thyroid diseases after treatment of Hodgkin's disease. N Engl J Med 1991; 325:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36394/abstract/74\">",
"      Sklar C, Whitton J, Mertens A, et al. Abnormalities of the thyroid in survivors of Hodgkin's disease: data from the Childhood Cancer Survivor Study. J Clin Endocrinol Metab 2000; 85:3227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36394/abstract/75\">",
"      Constine LS, Donaldson SS, McDougall IR, et al. Thyroid dysfunction after radiotherapy in children with Hodgkin's disease. Cancer 1984; 53:878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36394/abstract/76\">",
"      Pace A, Bove L, Nistic&ograve; C, et al. Vinorelbine neurotoxicity: clinical and neurophysiological findings in 23 patients. J Neurol Neurosurg Psychiatry 1996; 61:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36394/abstract/77\">",
"      Malow BA, Dawson DM. Neuralgic amyotrophy in association with radiation therapy for Hodgkin's disease. Neurology 1991; 41:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36394/abstract/78\">",
"      Furby A, B&eacute;hin A, Lefaucheur JP, et al. Late-onset cervicoscapular muscle atrophy and weakness after radiotherapy for Hodgkin disease: a case series. J Neurol Neurosurg Psychiatry 2010; 81:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36394/abstract/79\">",
"      Rowin J, Cheng G, Lewis SL, Meriggioli MN. Late appearance of dropped head syndrome after radiotherapy for Hodgkin's disease. Muscle Nerve 2006; 34:666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36394/abstract/80\">",
"      van Leeuwen-Segarceanu EM, Dorresteijn LD, Pillen S, et al. Progressive muscle atrophy and weakness after treatment by mantle field radiotherapy in Hodgkin lymphoma survivors. Int J Radiat Oncol Biol Phys 2012; 82:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36394/abstract/81\">",
"      Loge JH, Abrahamsen AF, Ekeberg O, Kaasa S. Hodgkin's disease survivors more fatigued than the general population. J Clin Oncol 1999; 17:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36394/abstract/82\">",
"      Arden-Close E, Pacey A, Eiser C. Health-related quality of life in survivors of lymphoma: a systematic review and methodological critique. Leuk Lymphoma 2010; 51:628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36394/abstract/83\">",
"      Heutte N, Flechtner HH, Mounier N, et al. Quality of life after successful treatment of early-stage Hodgkin's lymphoma: 10-year follow-up of the EORTC-GELA H8 randomised controlled trial. Lancet Oncol 2009; 10:1160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36394/abstract/84\">",
"      Hjermstad MJ, Oldervoll L, Foss&aring; SD, et al. Quality of life in long-term Hodgkin's disease survivors with chronic fatigue. Eur J Cancer 2006; 42:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36394/abstract/85\">",
"      Ng AK, Li S, Recklitis C, et al. A comparison between long-term survivors of Hodgkin's disease and their siblings on fatigue level and factors predicting for increased fatigue. Ann Oncol 2005; 16:1949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36394/abstract/86\">",
"      R&uuml;ffer JU, Flechtner H, Tralls P, et al. Fatigue in long-term survivors of Hodgkin's lymphoma; a report from the German Hodgkin Lymphoma Study Group (GHSG). Eur J Cancer 2003; 39:2179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36394/abstract/87\">",
"      Loge JH, Abrahamsen AF, Kaasa S. Fatigue and psychiatric morbidity among Hodgkin's disease survivors. J Pain Symptom Manage 2000; 19:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36394/abstract/88\">",
"      Milt&eacute;nyi Z, Magyari F, Simon Z, Ill&eacute;s A. Quality of life and fatigue in Hodgkin's lymphoma patients. Tumori 2010; 96:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36394/abstract/89\">",
"      Adams MJ, Lipsitz SR, Colan SD, et al. Cardiovascular status in long-term survivors of Hodgkin's disease treated with chest radiotherapy. J Clin Oncol 2004; 22:3139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36394/abstract/90\">",
"      Krull KR, Sabin ND, Reddick WE, et al. Neurocognitive function and CNS integrity in adult survivors of childhood hodgkin lymphoma. J Clin Oncol 2012; 30:3618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36394/abstract/91\">",
"      Chen A, Feng Y, Neuberg D, et al. Employment and insurance status in Hodgkin lymphoma survivors. Int J Radiat Oncol Biol Phys 2008; 72:S138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36394/abstract/92\">",
"      Hannah M, Gritz E, Wellisch D, et al. Changes in marital and sexual functioning in long-term survivors and their spouses: Testicular cancer versus hodgkin's disease. Psychooncology 1992; 1:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36394/abstract/93\">",
"      Recklitis CJ, Sanchez Varela V, Ng A, et al. Sexual functioning in long-term survivors of Hodgkin's lymphoma. Psychooncology 2010; 19:1229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36394/abstract/94\">",
"      Behringer K, M&uuml;ller H, G&ouml;rgen H, et al. Sexual quality of life in Hodgkin Lymphoma: a longitudinal analysis by the German Hodgkin Study Group. Br J Cancer 2013; 108:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36394/abstract/95\">",
"      Dryver ET, Jernstr&ouml;m H, Tompkins K, et al. Follow-up of patients with Hodgkin's disease following curative treatment: the routine CT scan is of little value. Br J Cancer 2003; 89:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36394/abstract/96\">",
"      Jerusalem G, Beguin Y, Fassotte MF, et al. Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin's disease. Ann Oncol 2003; 14:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36394/abstract/97\">",
"      Torrey MJ, Poen JC, Hoppe RT. Detection of relapse in early-stage Hodgkin's disease: role of routine follow-up studies. J Clin Oncol 1997; 15:1123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36394/abstract/98\">",
"      Zinzani PL, Stefoni V, Tani M, et al. Role of [18F]fluorodeoxyglucose positron emission tomography scan in the follow-up of lymphoma. J Clin Oncol 2009; 27:1781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36394/abstract/99\">",
"      Kriege M, Brekelmans CT, Boetes C, et al. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med 2004; 351:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36394/abstract/100\">",
"      Saslow D, Boetes C, Burke W, et al. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 2007; 57:75.",
"     </a>",
"    </li>",
"    <li>",
"     Long-term follow-up guidelines for survivors of childhood, adolescent and young adult cancers. www.survivorshipguidelines.org.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36394/abstract/102\">",
"      Friedman DL, Whitton J, Leisenring W, et al. Subsequent neoplasms in 5-year survivors of childhood cancer: the Childhood Cancer Survivor Study. J Natl Cancer Inst 2010; 102:1083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36394/abstract/103\">",
"      Heidenreich PA, Hancock SL, Vagelos RH, et al. Diastolic dysfunction after mediastinal irradiation. Am Heart J 2005; 150:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36394/abstract/104\">",
"      Heidenreich PA, Schnittger I, Strauss HW, et al. Screening for coronary artery disease after mediastinal irradiation for Hodgkin's disease. J Clin Oncol 2007; 25:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36394/abstract/105\">",
"      Ng AK, Li S, Recklitis C, et al. Health practice in long-term survivors of Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys 2008; 71:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36394/abstract/106\">",
"      Oldervoll LM, Kaasa S, Knobel H, Loge JH. Exercise reduces fatigue in chronic fatigued Hodgkins disease survivors--results from a pilot study. Eur J Cancer 2003; 39:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36394/abstract/107\">",
"      Horning SJ, Hoppe RT, Kaplan HS, Rosenberg SA. Female reproductive potential after treatment for Hodgkin's disease. N Engl J Med 1981; 304:1377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36394/abstract/108\">",
"      Langagergaard V, Horvath-Puho E, N&oslash;rgaard M, et al. Hodgkin's disease and birth outcome: a Danish nationwide cohort study. Br J Cancer 2008; 98:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36394/abstract/109\">",
"      Holmes GE, Holmes FF. Pregnancy outcome of patients treated for Hodgkin's disease: a controlled study. Cancer 1978; 41:1317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36394/abstract/110\">",
"      Green DM, Hall B. Pregnancy outcome following treatment during childhood or adolescence for Hodgkin's disease. Pediatr Hematol Oncol 1988; 5:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36394/abstract/111\">",
"      De Sanctis V, Filippone FR, Alf&ograve; M, et al. Impact of different treatment approaches on pregnancy outcomes in 99 women treated for Hodgkin lymphoma. Int J Radiat Oncol Biol Phys 2012; 84:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36394/abstract/112\">",
"      van der Kaaij MA, Heutte N, Meijnders P, et al. Parenthood in survivors of Hodgkin lymphoma: an EORTC-GELA general population case-control study. J Clin Oncol 2012; 30:3854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36394/abstract/113\">",
"      Kiserud CE, Foss&aring; A, Holte H, Foss&aring; SD. Post-treatment parenthood in Hodgkin's lymphoma survivors. Br J Cancer 2007; 96:1442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36394/abstract/114\">",
"      Byrne J, Rasmussen SA, Steinhorn SC, et al. Genetic disease in offspring of long-term survivors of childhood and adolescent cancer. Am J Hum Genet 1998; 62:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36394/abstract/115\">",
"      Sankila R, Olsen JH, Anderson H, et al. Risk of cancer among offspring of childhood-cancer survivors. Association of the Nordic Cancer Registries and the Nordic Society of Paediatric Haematology and Oncology. N Engl J Med 1998; 338:1339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36394/abstract/116\">",
"      Bodis S, Henry-Amar M, Bosq J, et al. Late relapse in early-stage Hodgkin's disease patients enrolled on European Organization for Research and Treatment of Cancer protocols. J Clin Oncol 1993; 11:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36394/abstract/117\">",
"      Garcia-Carbonero R, Paz-Ares L, Arcediano A, et al. Favorable prognosis after late relapse of Hodgkin's disease. Cancer 1998; 83:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36394/abstract/118\">",
"      Mandel SJ, Larsen PR, Seely EW, Brent GA. Increased need for thyroxine during pregnancy in women with primary hypothyroidism. N Engl J Med 1990; 323:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36394/abstract/119\">",
"      Grunfeld E, Earle CC. The interface between primary and oncology specialty care: treatment through survivorship. J Natl Cancer Inst Monogr 2010; 2010:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/34/36394/abstract/120\">",
"      Nathan PC, Greenberg ML, Ness KK, et al. Medical care in long-term survivors of childhood cancer: a report from the childhood cancer survivor study. J Clin Oncol 2008; 26:4401.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14232 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-2D9DC08A38-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_34_36394=[""].join("\n");
var outline_f35_34_36394=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H105459257\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H105459014\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H105459483\">",
"      TERMINOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1060969\">",
"      Staging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1060976\">",
"      Chemotherapy regimens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1060983\">",
"      Radiation fields",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11941348\">",
"      EVOLUTION OF \"STANDARD\" TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11941356\">",
"      PROGNOSIS AND NATURAL HISTORY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11941364\">",
"      OVERVIEW OF TREATMENT COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11941388\">",
"      Second malignancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11941396\">",
"      Cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11941404\">",
"      Non-coronary atherosclerotic disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11941412\">",
"      Pulmonary dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11941420\">",
"      Infertility and endocrine dysfunction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1063826\">",
"      - Gonadal dysfunction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1063870\">",
"      - Thyroid dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1062242\">",
"      Neurologic, muscular, and psychosocial complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1064448\">",
"      - Cervicoscapular muscular atrophy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1064190\">",
"      - Psychosocial issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11941468\">",
"      POSTTREATMENT SURVEILLANCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1064528\">",
"      Monitoring for relapse",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1064552\">",
"      Monitoring for complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1065733\">",
"      - Cancer screening",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1065750\">",
"      - Cardiovascular health",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1065758\">",
"      - Endocrine assessment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1064521\">",
"      Lifestyle modifications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23221326\">",
"      PREGNANCY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23221333\">",
"      Pregnancy outcome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23221340\">",
"      Counseling",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11941484\">",
"      COORDINATION OF CARE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H105459257\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/14232\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/14232|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?19/23/19836\" title=\"table 1\">",
"      Cotswolds system in HL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?7/60/8142\" title=\"table 2\">",
"      Comb chemo reg HL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?1/22/1391\" title=\"table 3\">",
"      Second CA after treatment HL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?4/47/4861\" title=\"table 4\">",
"      Monitoring the HL survivor for long-term complications",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/31/12794?source=related_link\">",
"      Bleomycin-induced lung injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/46/41706?source=related_link\">",
"      Cardiotoxicity of anthracycline-like chemotherapy agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/12/40138?source=related_link\">",
"      Cardiotoxicity of nonanthracycline cancer chemotherapy agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/21/34137?source=related_link\">",
"      Cardiotoxicity of radiation therapy for malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/41/33432?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of nodular lymphocyte-predominant Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/29/10711?source=related_link\">",
"      Definition of favorable and unfavorable prognosis early (stage I-II) classical Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/7/26744?source=related_link\">",
"      Diagnosis of and screening for hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/7/38010?source=related_link\">",
"      Fertility preservation in patients undergoing gonadotoxic treatment or gonadal resection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/54/39786?source=related_link\">",
"      Initial treatment of advanced (stage III-IV) classical Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/0/3079?source=related_link\">",
"      Long-term follow-up of the patient with classical Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/31/12793?source=related_link\">",
"      Management of classical Hodgkin lymphoma during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/19/30007?source=related_link\">",
"      Monitoring of the patient with classical Hodgkin lymphoma during and after treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/32/43530?source=related_link\">",
"      Neurologic complications of non-platinum cancer chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/26/1447?source=related_link\">",
"      Ovarian failure due to anticancer drugs and radiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/6/32873?source=related_link\">",
"      Overview of cancer survivorship care for primary care and oncology providers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/50/7977?source=related_link\">",
"      Overview of fertility and pregnancy in cancer survivors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/56/17287?source=related_link\">",
"      Overview of infertility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/4/37962?source=related_link\">",
"      Overview of preventive medicine in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/3/23609?source=related_link\">",
"      Overview of smoking cessation management in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/12/13512?source=related_link\">",
"      Overview of the treatment of classical Hodgkin lymphoma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/33/24090?source=related_link\">",
"      Radiation-induced lung injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/58/28586?source=related_link\">",
"      Screening for lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/26/35242?source=related_link\">",
"      Second malignancies after treatment of classical Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/13/44246?source=related_link\">",
"      Selective estrogen receptor modulators and aromatase inhibitors for breast cancer prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/37/14935?source=related_link\">",
"      Staging and prognosis of Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/44/35530?source=related_link\">",
"      The approach to hematopoietic cell transplantation survivorship",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/39/44663?source=related_link\">",
"      Thyroid function in nonthyroidal illness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/31/11770?source=related_link\">",
"      Treatment of favorable prognosis early (stage I-II) classical Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/53/43865?source=related_link\">",
"      Treatment of hypothyroidism",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_34_36395="Distinctive and overlapping symptoms of depression and anxiety";
var content_f35_34_36395=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PSYCH%2F87209&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PSYCH%2F87209&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Distinctive and overlapping symptoms of depression and anxiety",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"3\" width=\"33%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Symptoms specific to depression",
"       </td>",
"       <td class=\"subtitle1\">",
"        Symptoms common to anxiety and depression",
"       </td>",
"       <td class=\"subtitle1\">",
"        Symptoms specific to anxiety",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Depressed or hopeless",
"       </td>",
"       <td>",
"        Irritability",
"       </td>",
"       <td>",
"        Excessive worry",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Loss of interest",
"       </td>",
"       <td>",
"        Agitation/restlessness",
"       </td>",
"       <td>",
"        Autonomic hyperactivity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Weight change",
"       </td>",
"       <td>",
"        Concentration difficulties",
"       </td>",
"       <td>",
"        Exaggerated startle response",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Poor appetite",
"       </td>",
"       <td>",
"        Insomnia",
"       </td>",
"       <td>",
"        Muscle tension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Motor retardation",
"       </td>",
"       <td>",
"        Fatigue",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Guilt/worthlessness",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thoughts of death",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Kendall PC, Watson D. Anxiety and Depression: distinctive and overlapping features, Academic Press, San Diego, CA 1989. Table used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_34_36395=[""].join("\n");
var outline_f35_34_36395=null;
var title_f35_34_36396="Antigen expression in AML";
var content_f35_34_36396=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F62499&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F62499&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Antigen expression in acute myeloid leukemia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Antigen",
"       </td>",
"       <td class=\"subtitle1\">",
"        Expressed at diagnosis, percent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Expressed at relapse, percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CD2",
"       </td>",
"       <td>",
"        11",
"       </td>",
"       <td>",
"        22",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CD3",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         CD4dim",
"        </strong>",
"       </td>",
"       <td>",
"        72",
"       </td>",
"       <td>",
"        78",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CD7",
"       </td>",
"       <td>",
"        22",
"       </td>",
"       <td>",
"        30",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CD8",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CD11b",
"       </td>",
"       <td>",
"        41",
"       </td>",
"       <td>",
"        37",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         CD13",
"        </strong>",
"       </td>",
"       <td>",
"        98",
"       </td>",
"       <td>",
"        97",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CD14",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         CD15",
"        </strong>",
"       </td>",
"       <td>",
"        82",
"       </td>",
"       <td>",
"        78",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CD16",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CD19",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         CD32",
"        </strong>",
"       </td>",
"       <td>",
"        76",
"       </td>",
"       <td>",
"        74",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         CD33",
"        </strong>",
"       </td>",
"       <td>",
"        75",
"       </td>",
"       <td>",
"        78",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         CD34",
"        </strong>",
"       </td>",
"       <td>",
"        64",
"       </td>",
"       <td>",
"        74",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         CD38",
"        </strong>",
"       </td>",
"       <td>",
"        96",
"       </td>",
"       <td>",
"        94",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CD56",
"       </td>",
"       <td>",
"        17",
"       </td>",
"       <td>",
"        21",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CD64",
"       </td>",
"       <td>",
"        50",
"       </td>",
"       <td>",
"        45",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         HLADr",
"        </strong>",
"       </td>",
"       <td>",
"        76",
"       </td>",
"       <td>",
"        74",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    This table indicates the frequencies of antigen expression at diagnosis and at relapse in 153 adult patients with de novo acute myeloid leukemia enrolled in CALGB 8361. Testing was performed by multiparameter flow cytometry in a single reference laboratory. Those antigens present in the majority of the cases are shown in bold type.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Baer, MR, et al. Blood 2001; 97:3574.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_34_36396=[""].join("\n");
var outline_f35_34_36396=null;
var title_f35_34_36397="NHANES Normal pediatric lipid values";
var content_f35_34_36397=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F59427&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F59427&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Lipid and lipoprotein distributions in subjects aged 5 to 19 years",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"3\">",
"        Males",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"3\">",
"        Females",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        5-9 years",
"       </td>",
"       <td class=\"subtitle2\">",
"        10-14 years",
"       </td>",
"       <td class=\"subtitle2\">",
"        15-19 years",
"       </td>",
"       <td class=\"subtitle2\">",
"        5-9 years",
"       </td>",
"       <td class=\"subtitle2\">",
"        10-14 years",
"       </td>",
"       <td class=\"subtitle2\">",
"        15-19 years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"7\">",
"        Total cholesterol, mg/dL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        50th percentile",
"       </td>",
"       <td>",
"        153",
"       </td>",
"       <td>",
"        161",
"       </td>",
"       <td>",
"        152",
"       </td>",
"       <td>",
"        164",
"       </td>",
"       <td>",
"        159",
"       </td>",
"       <td>",
"        157",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        75th percentile",
"       </td>",
"       <td>",
"        168",
"       </td>",
"       <td>",
"        173",
"       </td>",
"       <td>",
"        168",
"       </td>",
"       <td>",
"        177",
"       </td>",
"       <td>",
"        171",
"       </td>",
"       <td>",
"        176",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        90th percentile",
"       </td>",
"       <td>",
"        183",
"       </td>",
"       <td>",
"        191",
"       </td>",
"       <td>",
"        183",
"       </td>",
"       <td>",
"        189",
"       </td>",
"       <td>",
"        191",
"       </td>",
"       <td>",
"        198",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        95th percentile",
"       </td>",
"       <td>",
"        186",
"       </td>",
"       <td>",
"        201",
"       </td>",
"       <td>",
"        191",
"       </td>",
"       <td>",
"        197",
"       </td>",
"       <td>",
"        205",
"       </td>",
"       <td>",
"        208",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"7\">",
"        Triglyceride, mg/dL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        50th percentile",
"       </td>",
"       <td>",
"        48",
"       </td>",
"       <td>",
"        58",
"       </td>",
"       <td>",
"        68",
"       </td>",
"       <td>",
"        57",
"       </td>",
"       <td>",
"        68",
"       </td>",
"       <td>",
"        64",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        75th percentile",
"       </td>",
"       <td>",
"        58",
"       </td>",
"       <td>",
"        74",
"       </td>",
"       <td>",
"        88",
"       </td>",
"       <td>",
"        74",
"       </td>",
"       <td>",
"        85",
"       </td>",
"       <td>",
"        85",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        90th percentile",
"       </td>",
"       <td>",
"        70",
"       </td>",
"       <td>",
"        94",
"       </td>",
"       <td>",
"        125",
"       </td>",
"       <td>",
"        103",
"       </td>",
"       <td>",
"        104",
"       </td>",
"       <td>",
"        112",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        95th percentile",
"       </td>",
"       <td>",
"        85",
"       </td>",
"       <td>",
"        111",
"       </td>",
"       <td>",
"        143",
"       </td>",
"       <td>",
"        120",
"       </td>",
"       <td>",
"        120",
"       </td>",
"       <td>",
"        126",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"7\">",
"        LDL, mg/dL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        50th percentile",
"       </td>",
"       <td>",
"        90",
"       </td>",
"       <td>",
"        94",
"       </td>",
"       <td>",
"        93",
"       </td>",
"       <td>",
"        98",
"       </td>",
"       <td>",
"        94",
"       </td>",
"       <td>",
"        93",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        75th percentile",
"       </td>",
"       <td>",
"        103",
"       </td>",
"       <td>",
"        109",
"       </td>",
"       <td>",
"        109",
"       </td>",
"       <td>",
"        115",
"       </td>",
"       <td>",
"        110",
"       </td>",
"       <td>",
"        110",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        90th percentile",
"       </td>",
"       <td>",
"        117",
"       </td>",
"       <td>",
"        123",
"       </td>",
"       <td>",
"        123",
"       </td>",
"       <td>",
"        125",
"       </td>",
"       <td>",
"        126",
"       </td>",
"       <td>",
"        129",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        95th percentile",
"       </td>",
"       <td>",
"        129",
"       </td>",
"       <td>",
"        133",
"       </td>",
"       <td>",
"        130",
"       </td>",
"       <td>",
"        140",
"       </td>",
"       <td>",
"        136",
"       </td>",
"       <td>",
"        137",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"7\">",
"        HDL, mg/dL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        5th percentile",
"       </td>",
"       <td>",
"        38",
"       </td>",
"       <td>",
"        37",
"       </td>",
"       <td>",
"        30",
"       </td>",
"       <td>",
"        36",
"       </td>",
"       <td>",
"        37",
"       </td>",
"       <td>",
"        35",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        10th percentile",
"       </td>",
"       <td>",
"        43",
"       </td>",
"       <td>",
"        40",
"       </td>",
"       <td>",
"        34",
"       </td>",
"       <td>",
"        38",
"       </td>",
"       <td>",
"        40",
"       </td>",
"       <td>",
"        38",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        25th percentile",
"       </td>",
"       <td>",
"        49",
"       </td>",
"       <td>",
"        46",
"       </td>",
"       <td>",
"        39",
"       </td>",
"       <td>",
"        48",
"       </td>",
"       <td>",
"        45",
"       </td>",
"       <td>",
"        43",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        50th percentile",
"       </td>",
"       <td>",
"        55",
"       </td>",
"       <td>",
"        55",
"       </td>",
"       <td>",
"        46",
"       </td>",
"       <td>",
"        52",
"       </td>",
"       <td>",
"        52",
"       </td>",
"       <td>",
"        51",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Normal fasting lipoprotein profiles from the United States National Health and Nutrition Examination Surveys.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Daniels SR, Greer FR, Committee on Nutrition. Lipid screening and cardiovascular health in childhood. Pediatrics 2008; 122:198. Copyright &copy; 2008 by the AAP.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_34_36397=[""].join("\n");
var outline_f35_34_36397=null;
var title_f35_34_36398="Contents: Soft tissue and bone tumors";
var content_f35_34_36398=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"mobipreview.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"mobipreview.htm?3/43/3774\">",
"       Oncology",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Soft tissue and bone tumors",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"mobipreview.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Soft tissue and bone tumors",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Bone tumors",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?41/10/42150\">",
"           Antineoplastic therapy for miscellaneous benign diseases affecting soft tissue and bone",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?36/51/37690\">",
"           Bone sarcomas: Preoperative evaluation, histologic classification, and principles of surgical management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?34/53/35673\">",
"           Bone tumors: Diagnosis and biopsy techniques",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?38/8/39050\">",
"           Chemotherapy and radiation therapy in the management of osteosarcoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?34/39/35450\">",
"           Chondrosarcoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?36/56/37769\">",
"           Clinical presentation, staging, and prognostic factors of the Ewing sarcoma family of tumors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?7/37/7770\">",
"           Epidemiology, pathology, and molecular genetics of the Ewing sarcoma family of tumors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?5/33/5658\">",
"           Giant cell tumor of bone",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/50/32551\">",
"           Langerhans cell histiocytosis (eosinophilic granuloma) of bone in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?20/22/20842\">",
"           Osteosarcoma: Epidemiology, pathogenesis, clinical presentation, diagnosis, and histology",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/53/32599\">",
"           Primary lymphoma of bone",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?24/47/25338\">",
"           Radiation therapy for Ewing sarcoma family of tumors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/55/33658\">",
"           Therapeutic use and toxicity of high-dose methotrexate",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/50/14122\">",
"           Treatment of the Ewing sarcoma family of tumors",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Other tumors",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?41/10/42150\">",
"           Antineoplastic therapy for miscellaneous benign diseases affecting soft tissue and bone",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?37/8/38025\">",
"           Classic Kaposi's sarcoma: Clinical features, staging, diagnosis, and treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?5/35/5688\">",
"           Classic Kaposi's sarcoma: Epidemiology, risk factors, pathology, and molecular pathogenesis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?30/11/30906\">",
"           Desmoid tumors: Epidemiology, risk factors, molecular pathogenesis, clinical presentation, diagnosis, and local therapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?11/38/11881\">",
"           Desmoid tumors: Systemic therapy",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Soft tissue sarcoma",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/11/14521\">",
"           Adjuvant and neoadjuvant chemotherapy for soft tissue sarcoma of the extremities",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/34/33321\">",
"           Adjuvant and neoadjuvant imatinib for gastrointestinal stromal tumors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/23/33146\">",
"           Clinical features, evaluation, and treatment of retroperitoneal soft tissue sarcoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?30/43/31418\">",
"           Clinical presentation, histopathology, diagnostic evaluation, and staging of soft tissue sarcoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/50/13098\">",
"           Dermatofibrosarcoma protuberans",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/13/1242\">",
"           Endoscopic ultrasound for the characterization of subepithelial lesions of the upper gastrointestinal tract",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?34/35/35386\">",
"           Epidemiology, classification, clinical presentation, prognostic features, and diagnostic work-up of gastrointestinal mesenchymal neoplasms including GIST",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?33/50/34602\">",
"           Head and neck sarcomas",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/1/28694\">",
"           Intradural nerve sheath tumors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?34/7/34938\">",
"           Local treatment for gastrointestinal stromal tumors, leiomyomas, and leiomyosarcomas of the gastrointestinal tract",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?37/47/38650\">",
"           Local treatment for primary soft tissue sarcoma of the extremities and chest wall",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/18/32042\">",
"           Pathogenetic factors in soft tissue and bone sarcomas",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?23/24/23946\">",
"           Peripheral nerve tumors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?2/12/2249\">",
"           Presentation, diagnosis, and staging of Wilms tumor",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?17/57/18327\">",
"           Rhabdomyosarcoma and undifferentiated sarcoma in childhood and adolescence: Clinical presentation, diagnostic evaluation, and staging",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/63/16377\">",
"           Rhabdomyosarcoma and undifferentiated sarcoma in childhood and adolescence: Epidemiology, pathology, and molecular pathogenesis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?33/49/34586\">",
"           Rhabdomyosarcoma and undifferentiated sarcoma in childhood and adolescence: Treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?43/40/44680\">",
"           Surgical treatment and other localized therapy for metastatic soft tissue sarcoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/11/41146\">",
"           Systemic treatment of metastatic soft tissue sarcoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/45/27354\">",
"           Treatment of locally recurrent and unresectable, locally advanced soft tissue sarcoma of the extremities",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?33/58/34730\">",
"           Tyrosine kinase inhibitor therapy for advanced gastrointestinal stromal tumors",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-CC5DC06FE7-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f35_34_36398=[""].join("\n");
var outline_f35_34_36398=null;
var title_f35_34_36399="Stenosis subclavian vein";
var content_f35_34_36399=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F74325&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F74325&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Stenosis subclavian vein",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 223px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Stenosis of the subclavian vein is shown on the left. The appearance of the lesion after treatment with angioplasty is shown on the right.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Gerald Beathard, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_34_36399=[""].join("\n");
var outline_f35_34_36399=null;
